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ABSTRACT 
This Thesis provides an evidence for a direct stimulation of the CYP11A1-dependent side-chain 
cleavage activity by the sex hormones estrone and estradiol in a reconstituted in vitro system and 
demonstrates for the first time a novel activity for this enzyme to perform hydroxylation reactions on 
four steroid hormones 11-deoxycorticosterone (DOC), androstenedione, testosterone and 
dehydroepiandrosterone (DHEA). These new hydroxylated products might be useful to generate 
pharmaceutically interesting compounds. 
Furthermore, another important steroid modification was performed in this study by the 
establishment of a novel and efficient Escherichia coli based biocatalyst using chloramphenicol 
acetyltransferase I (CATI) as a steroid acetyltransferase. The results clearly revealed the important role 
of bacterial CATI in a new strategy for 21-hydroxysteroid acetylation. 
Moreover, it was investigated that pregnenolone sulfate (PregS) represents a starting material for a 
steroidogenic pathway of sulfonated steroids. The results in this work clearly proved the role of 
bovine CYP17 in the catalysis of PregS conversion to its corresponding hydroxylated product, 17-
hydroxy-pregnenolone sulfate (17-hydroxy-PregS) and showed that cytochrome b5 has no influence on 
17,20-lyase activity of CYP17 dependent PregS conversion. For this, the expression and purification 
processes of three necessary proteins, bovine cytochrome P450 reductase (CPR), cytochrome b5 and 
CYP17 were developed for the in vitro substrate characterizations. 
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ZUSAMMENFASSUNG 
Die vorliegende Arbeit liefert Aufschluss über die direkte Stimulation der CYP11A1-katalysierten 
Seitenkettenspaltung von Cholesterol durch die Sexualhormone Estron und Estradiol in einem 
rekonstituierten in vitro System. Die Aktivität von CYP11A1 bei der Hydroxylierung der vier 
Steroidhormone 11-Deoxycorticosteron (DOC), Androstenedion, Testosteron und 
Dehydroepiandrosteron (DHEA) konnte zum ersten Mal gezeigt werden. Die hydroxylierten Produkte 
könnten Vorläufer für interessante Pharmazeutika sein. 
Eine weitere wichtige Derivatisierungsreaktion von Steroiden wurde mit Hilfe der 
Chloramphenicolacetyltransferase I (CATI) etabliert. Dabei wirkt das Enzym in einem Escherichia coli 
basierten Ganzzellkatalysator als Steroidacetyltransferase. Die Ergebnisse zeigen, dass die bakterielle 
CATI eine zentrale Rolle bei einem neuen Ansatz zur Acetylierung von 21-Hydroxysteroiden einnimmt. 
Darüber hinaus wurde Pregnenolonsulfat (PregS) als Ausgangsstoff der Biosynthese sulfonierter 
Steroide identifiziert. Die Ergebnisse dieser Arbeit zeigen, dass das bovine CYP17 die Hydroxylierung 
von PregS zu 17-Hydroxy-pregnenolonsulfat (17-hydroxy-PregS) katalysiert. Cytochrom b5 hat keinen 
Einfluss auf die 17,20-Lyaseaktivität beim Umsatz von PregS durch CYP17. Für die 
Substratcharakterisierung in vitro wurde die Expression und Reinigung der notwendigen Proteine, 
bovine Cytochrom P450 Reduktase (CPR), Cytochrom b5 und CYP17, etabliert. 
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1- GENERAL INTRODUCTION 
1.1- CYTOCHROME P450 
1.1.1- GENERAL FEATURES OF CYTOCHROME P450 
The researchers, Garfinkel [1] and Klingenberg [2] first discovered cytochromes P450 (P450) during 
investigating steroid hormone metabolism in the liver microsomes from rats and pigs. The microsomal 
carbon monoxide-binding pigment with an absorption maximum at 450 nm was later demonstrated to 
contain an iron-protoporphyrin IX [3]. This iron (III) ion is equatorially bound to the four nitrogen 
atoms of the protoporphyrin ring. In contrast to most heme proteins, the fifth ligand is a thiolate 
anion of a cysteine, which characteristic leads to a specific maximum absorption at 450 nm in the 
reduced and CO-bound state [4]. 
Cytochromes P450 (EC 1.14.14.1; P450s) are one of most widely characterized and used 
monooxygenases with a molecular weight of approximately 50 kDa. More than 21,039 P450 genes 
have been found in all classes of living organisms (http://drnelson.uthsc.edu/P450.statsfile.html, 
August, 2013) [5-7]. They have been found in mammals, plants, archaea, fungi, bacteria, fish, yeasts, 
and insects. In mammals, they could not only be found in the liver but also in other organs, including 
lung, kidney, gastrointestinal tract, brain, gonads, skin and heart [8,9]. 
The most common reaction catalyzed by cytochromes P450 is the hydroxylation of C-H bond of 
organic compounds [5], however, P450s have become very versatile and developed a broad field of 
chemical activity to perform a number of difficult oxidative reactions [10]. This includes 
isomerizations, dehydratations, N-oxidation, N-, S-, and O-dealkylation, sulfoxidation, epoxidation of 
double bonds, peroxidation, deamination, desulfuration, dehalogenation and N-oxide reduction of 
numerous endogenous and exogenous compounds [11-13]. Furthermore, P450s are involved in the 
metabolism of a variety of xenobiotic chemical compounds, including drugs, alkaloids and carcinogens 
and other xenobiotics as well as the synthesis of important endogenous compounds like steroid 
hormones, bile acids or prostaglandins [14]. 
Noteworthy, the P450s are also of great interest in drug metabolism. They are often involved in the 
oxidation of drugs resulting in the generation of metabolites that are more easily excreted [15]. It was 
demonstrated that human genome encodes for 57 functional P450s and among these 57 P450s genes 
in human, 15 P450s are involved in the metabolism of clinically used drugs, 14 are primarily involved 
in the steroid metabolism, 6 are involved in vitamin metabolism and 9 P450s are involved in the 
metabolism of fatty acids and eicosanoids, whereas the remaining 13 human P450s are considered as 
orphans and their biological functions remain to be firmly established [16,17]. 
Due to the catalytic diversity and broad substrate range of P450s, they are attractive biocatalyst 
candidates for the production of fine chemicals, including pharmaceuticals [14,18]. In fact, the 
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remarkable ability of P450s to catalyze the hydroxylation of non-activated carbon atoms in a regio- 
and stereoselective manner makes P450 proteins very interesting for the production of these 
compounds, avoiding the use of protecting groups and several time-consuming chemical steps since 
the hydroxylation of non activated carbon bonds is often difficult to achieve by classical organic 
synthesis [19]. Therefore, researches focusing on steroid hydroxylation by P450s have attracted the 
interest of scientists for several decades. Nowadays, about 300 approved steroid drugs are known and 
are ranked among the most commercialized medical products representing the second largest 
category next to antibiotics [20]. The industrial applications of P450s comprise the synthesis of new 
anticancer drugs. Since these drugs are naturally only available in limited quantities from their 
biological sources, synthetic routes are required [14,21,22]. 
1.1.2- NOMENCLATURE OF CYTOCHROME P450 
In order to assess the large number of currently known cytochrome P450s, these are not classified 
according to their function, but based on the sequence similarity of their amino acid chain. A regular 
classification of P450 enzymes according to their sequence similarity into families, subfamilies and 
finally into the individual species was established. Species belonging to the same family usually 
possess a sequence similarity of > 40% whereas members of the same subfamilies are > 55% identical. 
This classification resulted in a new nomenclature for all cytochrome P450 members in which CYP 
stands for cytochrome P450 followed by the number denoting the enzymes family. Further, a letter 
behind the family number designates the subfamily and an additional number represents the 
individual enzyme within the subfamily [23,24]. Accordingly, the cytochrome CYP11A1 (Figure 1), 
belongs to the family 11 and the subfamily A. The last number represents the individual enzyme. 
CYP11A1 
    Cytochrome P450 
   Family 
    Subfamily 
                                       Individual enzyme   
Figure 1: Nomenclature of the cytochromes P450 CYP11A1. 
 
1.1.3- CYTOCHROME P450 CLASSIFICATION AND ELECTRON TRANSFER SYSTEM 
P450s are oxidoreductases and in further classification they belong to external monooxygenases 
(Figure 2), in which the external electron donor is used to cleave the oxygen atoms [14]. In the 
reactions catalyzed by the cytochrome P450, an oxygen atom is transferred to the substrate, while the 
other one is reduced to water; they are, therefore, considered to be monooxygenases [25,26]. In 
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mammals, these monooxygenases can be divided into two broad classes based on their intracellular 
localization and requirement for redox partners, which provide electrons for the monooxygenase 
reaction: microsomal and mitochondrial P450s [9,27]. 
 
Figure 2: Classification of cytochrome P450 enzyme in groups. The members of this protein family belong to the 
dark gray sub-groups [26]. 
These cytochrome P450 classes obtain the required electrons from NADPH via two different electron 
transfer systems. In the mitochondrial P450s, which are arranged at the inner mitochondrial 
membrane, the high potential electron is transferred from NADPH to the flavoprotein, adrenodoxin 
reductase (AdR), and subsequently to a non heme iron- sulphur protein, adrenodoxin (Adx). Finally, 
Adx is able to reduce the cytochrome P450 (Figure 3A). In the microsomal system, the electrons are 
transferred from NADPH to the NADPH-cytochrome P450 reductase (CPR) and then to the microsomal 
cytochromes P450, which are abundantly present in the endoplasmic reticulum (ER) (Figure 3B) 
[26,28,29]. 
 
 
Figure 3: Schematic representation of the electron transfer system for P450s enzyme. A) class I, mitochondrial 
electron transfer system; B) class II, microsomal electron transfer system [26]. 
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1.1.4- CYTOCHROME P450 CATALYZED REACTION AND CATALYTIC MECHANISM 
In general, P450 enzymes are proficient at highly regio-specific hydroxylation reactions. The usefulness 
of the P450s consists in the importance of their bioconversion activities of water insoluble chemicals 
into soluble ones by the introduction of single oxygen via a hydroxylation reaction, which is unique for 
P450 to insert hydroxyl groups into even non activated carbon bonds. Most P450s catalyze two-
electron oxidation reactions of organic substrates. Dioxygen and the substrate (RH) bind at the heme 
active site and electrons from NADPH act to cleave the O-O bond leaving a high valent oxo-heme 
moiety that is capable of O-insertion into an otherwise inert C-H bond on the corresponding substrate. 
Thereby an oxygen molecule is transferred to the substrate and the other one is used to form a water 
molecule [14,30,31]. The reactions of all cytochrome P450s are similar (Scheme 1) and can be 
summarized as following:  
 
Scheme 1: Reaction catalyzed by cytochrome P450. The RH represents a substrate and ROH the corresponding 
hydroxylated product. 
The detailed catalytic cycle (Scheme 2) for substrate hydroxylation by P450s is described as follows: 
In the absence of substrate, the ferric iron atom is six-coordinated, complexed with a water molecule. 
The binding of the substrate molecule to cytochrome P450 (1) partially or completely displaces the 
water molecule from the sixth coordination site of the heme iron and causes a shift from a hexa-
coordinated low-spin complex to a penta-coordinated high spin ferric state (2). A single electron from 
the NADPH or NADH obtained from redox partners reduces the iron to the ferrous state (II), which 
allows subsequently the binding of oxygen to the ferrous iron. Binding of molecular oxygen to the 
ferrous protein (3) generates the ferrous oxygenated (oxy-ferrous) state (4), a key intermediate in 
P450 catalysis. The availability of a second electron to the oxy-ferrous intermediate from the redox 
partner yields the peroxo anion state (5a). Proton transfer to the distal oxygen atom orchestrated by 
the active site acid-alcohol pair and bound water molecules results in formation of the hydroperoxo 
state (5b). Each of these peroxo states (compound 0 (Cpd 0)) may undergo a non-productive release of 
peroxide, regenerating the ferric form of the enzyme (depicted as gray lines in the Scheme 2). 
Alternatively, a second protonation of the distal oxygen may occur, which reduces the O-O bond order 
resulting in cleavage and release of water molecule and the generation of a higher valent metal-oxo 
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species referred to as compound 1 (Cpd 1) (6), which then generates the hydroxylated substrate and 
the enzyme is further regenerated into its native ferric form [4,32-34]. 
 
Scheme 2: Proposed scheme for the mechanism action of cytochrome P450s [34]. 
1.2- STEROID HORMONES AND CYTOCHROMES P450 
1.2.1- STEROIDOGENIC P450s 
The biosynthesis of all steroid hormones starts from cholesterol in which two distinct groups of 
enzymes are involved: the cytochromes P450 and the hydroxysteroid dehydrogenases (HSD) [24]. The 
adrenal steroid hormones are produced in multi enzymatic steps in which different cytochromes P450 
and hydroxysteroid dehydrogenases are involved. The P450s involved in the steroidogenic pathway 
include the following ones: CYP11A1 (side-chain cleavage enzyme), CYP17 (17-hydroxylase and 17,20-
lyase), CYP21 (steroid 21-hydroxylase), CYP11B1 (steroid 11β-hydroxylase), CYP11B2 (aldosterone 
synthase) and CYP19 (aromatase) [9,11,35,36]. These P450s are expressed in steroidogenic tissues 
such as the adrenal gland (glucocorticoids, mineralocorticoids and androgens), testis, ovary, placenta 
(progestogens, androgens and oestrogens), and the skin (vitamin D metabolites). Further, they were 
also found in the brain [37-39]. 
1.2.2- STEROID HORMONE BIOSYNTHESIS 
Steroid compounds are widespread in different living systems and represent an essential component 
for life and reproduction [40]. In mammals, steroids are mainly produced in the adrenals and gonads 
in a series of enzymatic steps in the mitochondria and the cytosol of steroidogenic tissues. They are 
known to play a key role in the management of human fertility, menopause, osteoporosis, and blood 
pressure regulation, also are of importance for cholesterol level regulation and cardiovascular and 
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neuroprotective functions. They are also involved in tissue differentiation, cell proliferation, regulation 
of signal transduction pathways and quorum sensing cell-to-cell communication processes [40-42]. 
The steroidogenesis is the process in which biologically active steroid hormones are synthesized from 
cholesterol. To initiate the production of any steroid hormone, the cholesterol must be transported 
from the outer to the inner mitochondrial membrane. This step is the rate-limiting step in 
steroidogenesis. The translocator protein and the steroidogenic acute regulatory protein (StAR) are 
the two major components of the mitochondrial cholesterol transport machinery [43]. These proteins 
deliver cholesterol to CYP11A1 in the inner mitochondrial membrane. The biosynthesis of all steroid 
hormones (Figure 4) is initiated by the mitochondrial steroid hydroxylase CYP11A1 with the side-chain 
cleavage of cholesterol yielding pregnenolone, the precursor of all other steroid hormones [44,45]. 
The formed pregnenolone is transformed into different steroid products through enzymatic reactions 
in a tissue-specific manner [27,43].  
To ensure further steps in pregnenolone metabolism, the pregnenolone produced in the mitochondria 
moves into the cytosol where it serves as substrate for either CYP17 or 3β-HSD to produce either 17-
hydroxy-pregnenolone or progesterone, respectively [46,47]. The formed 17-hydroxy-pregnenolone 
can then serve as substrate for the lyase activity of CYP17 to produce DHEA. DHEA and 17-hydroxy-
pregnenolone also act as substrates for 3β-HSD. Pregnenolone, 17-hydroxy-pregnenolone and DHEA 
are all dehydrogenated at C3 by 3β-HSD, resulting in progesterone, 17-hydroxy-progesterone and 
androstenedione, respectively [48]. In a further step, progesterone can be hydroxylated at C17 by 
CYP17 to form 17-hydroxy-progesterone. In addition, the lyase activity of CYP17 can cleave the C17-
C20 bond of 17-hydroxy-progesterone to yield androstenedione. Progesterone and 17-hydroxy-
progesterone also act as substrates for CYP21, which catalyzes the formation of 11-
deoxycorticosterone (DOC) and 11-deoxycortisol (RSS), respectively, by hydroxylation of these 
substrates at C21 position. These two intermediates move to the mitochondria where CYP11B1 
catalyses 11-hydroxylation to yield cortisol (catalyzing the last step in the cortisol (hydrocortisone) 
biosynthesis). DOC serves as substrate for CYP11B2 (P450 aldo), which catalyses three sequential 
reactions: hydroxylation of positions 11 and 18 of the carbon skeleton of DOC and the oxidation step 
at position 18 hydroxyl group to yield the C18 aldehyde group of aldosterone [24,49]. Finally, the 
biosynthesis of estrogens is performed by CYP19 (P450arom), which catalyzes the conversion of 
androgens (androstenedione, testosterone and 16α-hydroxy-testosterone) to estrogens (estrone, 
17β-estradiol and estriol, respectively) in a three-step reaction through the formation of 19-hydroxy 
and 19-aldehyde intermediates, followed by simultaneous elimination of the methyl group and 
aromatization of the A-ring [34]. 
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Figure 4: Biosynthesis of steroid hormones in adrenal glands and gonads. Schematic description of the different 
reactions taking place in the adrenal steroid hydroxylation system and all enzymes involved in the biosynthesis 
of the adrenal steroid hormones, corticosterone, cortisol, and aldosterone; and the gonadal steroid hormones, 
progesterone, estradiol, and testosterone [50]. 
The glucocorticoids, mineralocorticoids and adrenal androgens are produced in the adrenal cortex of 
the adrenal gland. Higher vertebrates possess two ovoid or bean-shaped adrenal glands situated 
above the kidney, embedded in fat tissue. The adrenal glands consist of three zones: medulla, cortex 
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and the capsule (Figure 5). In mammals, the structure of the adrenal cortex is complex and considered 
to be the largest section of the adrenal gland. In the adrenal cortex, three zones can be distinguished: 
the zona glomerulosa, the zona fasciculata and the zona reticularis. Each section contains different 
P450s, which together with two dehydrogenase enzymes are responsible for steroid hormone 
synthesis [9,36]. 
The distribution of different steroidogenic enzymes in the three zones of the adrenal cortex results in 
each zone’s unique steroidogenic output. Within the adrenal cortex, CYP11A1 is expressed in all three 
zones of the adrenal cortex, while the outer zona glomerulosa consists of cells, which contain the 
CYP11B2 enzyme [49] and lack the CYP17 enzyme. These cells are, therefore, responsible for the 
synthesis of the major mineralocorticoid, aldosterone. The middle layer, zona fasciculata contains 
both the CYP17 and the CYP11B1 and is, therefore, responsible for the production of cortisol and 
corticosterone and trace amounts of the androgen precursors, (DHEA) [47,49,51]. The inner section of 
the adrenal gland is the zona reticularis, which is responsible for the production of trace amounts of 
glucocorticoids and the adrenal androgens DHEA, DHEA sulphate (DHEAS) and androstenedione due 
to the activity of CYP17 (17-hydroxylase/17,20-lyase) [9,47,51]. 
 
 
Figure 5: The three sections of the adrenal gland (zones) and correlated products. The outer zona glomerulosa is 
responsible for synthesis of the major mineralocorticoid, aldosterone. The middle zona fasciculata and inner 
zona reticularis are responsible for the synthesis of glucocorticoid and androgens, respectively [47]. 
 
1.3- CYTOCHROME P450 SIDE-CHAIN CLEAVAGE (CYP11A1) 
1.3.1- GENERAL ASPECTS OF CYP11A1 
Cytochrome P450scc (CYP11A1), (EC 1.14.1.9), is a mitochondrial enzyme and the only known enzyme 
that cleaves the side-chain of cholesterol, yielding pregnenolone, the precursor of all steroid 
hormones. This is the first reaction in the process of steroidogenesis in all steroidogenic tissues 
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[52,53]. Among four enzymes in vertebrates (CYP7A1, CYP27A1, CYP46A1, and CYP11A1), CYP11A1 is 
the only one that initiates the biotransformation of cholesterol in different organs and thus plays an 
important role in the maintenance of cholesterol homeostasis. Furthermore, its deficiency leads to 
lipoid congenital adrenal hyperplasia, a lethal disease if untreated [54]. 
CYP11A1 is a membrane bound protein localized in the inner mitochondrial membrane of 
steroidogenic tissues such as the adrenal glands and gonads. CYP11A1 consists of 482 amino acids and 
has a molecular weight of about 54 kDa. It is expressed at all the major sites of steroidogenesis, 
namely the adrenal cortex, ovary, testis, and placenta under the control of pituitary hormones, 
through the cAMP-signaling pathway [9,24,55]. In the adrenal cortex, CYP11A1 is expressed in all 
three zones, the zona fasciculata, the zona reticularis, and the zona glomerulosa. In the ovary, 
CYP11A1 is expressed in the theca interna and the granulosa cells of ovulatory follicles, while in testis 
the only site of CYP11A1 expression are the Leydig cells. In addition, low expression levels of CYP11A1 
have been detected in the central and peripheral nervous system, skin and heart. Several other 
tissues, such as brain, gastrointestinal tract and kidney, also express CYP11A1 [43,56]. 
1.3.2- REACTION CATALYZED BY CYP11A1 
The conversion of cholesterol to pregnenolone by CYP11A1 is the first and rate-limiting enzymatic step 
in the biosynthesis of steroid hormones. Pregnenolone is formed via three sequential 
monooxygenation reactions. The details of the catalytic reactions in mitochondria involve two 
stereospecific sequential hydroxylations at position C22 and C20 (Scheme 3). First, cholesterol is 
hydroxlated at position C22 leading to the formation of 22R-hydroxy-cholesterol. This step is followed 
by the subsequent hydroxylation at position C20 with formation of 20R, 22R-dihydroxy-cholesterol, 
followed by the oxidative cleavage of the bond between C20 and C22 to yield the C21 steroid, 
pregnenolone and isocaproic acid [54,57]. 
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Scheme 3: Pathway of pregnenolone formation according to Stryer et al. [58]. 
As shown in Scheme 3, the reaction requires three molecules of oxygen, three molecules of NADPH 
and the mitochondrial electron transfer system [54,59]. On the other hand, another catalytic reaction 
of CYP11A1 was noticed to perform modification of the side-chain for a wide spectrum of cholesterol 
analogues as well as the hydroxlytion reactions in the steroid skeleton (Table 1)  
1.3.3- SUBSTRATE RANGE OF CYP11A1  
Besides cholesterol, a wide range of steroids can also serve as substrates for CYP11A1, suggesting that 
this P450 possesses a wide spectrum of substrate specificity. In these steroid substrates, not only the 
analogues of cholesterol with modified side-chain are efficiently converted to pregnenolone, but also 
the hydroxylation occurs in the steroid skeleton. Some known substrates of CYP11A1 and their 
products are shown in Table 1. 
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Table 1: Well-known CYP11A1 substrates and their corresponding products. 
Substrates Products References 
20α-hydroxy-cholesterol Pregnenolone [60] 
25-hydroxy-cholesterol Pregnenolone [61] 
25-methyl-cholesterol Pregnenolone [62] 
25,26-didehydro-cholesterol Pregnenolone [62] 
20α,21-dihydroxy-cholesterol 21-hydroxy-pregnenolone [63] 
22(R)-hydroxy-cholesterol Pregnenolone [64] 
22(R)-22, 23, 24, 25, 26-hydroxy-
cholesterol 
Pregnenolone [62] 
20(R),22(R)-20,22-dihydroxy-cholesterol Pregnenolone [62] 
20(S)-20-hydroxy-cholesterol Pregnenolone [62] 
20(S)-22-thia-cholesterol 
(20(S),22(R)-22-thia-cholesterol S -oxide 
and (20(S),22(S)-22-thia-cholesterol S -
oxide 
[65] 
(20S)-17α,20-dihydroxy-cholesterol 
(20S,22R)-17α,20,22-trihydroxy-
cholesterol and 17α-hydroxy-
pregnenolone 
[66] 
Vitamins D2 
20-hydroxy-vitamin D2; 17,20-
dihydroxy-vitamin D2 and 17,20,24-
trihydroxy-vitamin D2 
[67,68] 
20-hydroxy-vitamin D2 17,20,24-trihydroxy-vitamin D2 [67] 
17,20-dihydroxy-vitamin D2 17,20,24-trihydroxy-vitamin D2 [67] 
Vitamins D3 
20-hydroxy-vitamin D3; 20,22-
dihydroxy-vitamin D3; 20,23-dihydroxy-
vitamin D3 and 17,20,23-trihydroxy-
vitamin D3 
[57,69,70] 
20-hydroxy-vitamin D3 20,23-dihydroxy-vitamin D3 [70] 
20,23-dihydroxy-vitamin D3 17,20,23-trihydroxy-vitamin D3 [70] 
Pregn-5-en-3β-ol Pregnenolone [71] 
Cholest-5-ene-3β, 20α-diol Pregnenolone [71] 
Cholest-5-ene-3β, 24-diol Pregnenolone [71] 
Cholest-5-ene-3β, 25-diol Pregnenolone [71] 
Cholest-5-ene-3β, 26-diol Pregnenolone [71] 
23,24-bisnor-5-cholen-3β-ol Pregnenolone [71] 
5-cholen-3β-ol Pregnenolone [71] 
26-norcholest-5-en-3β-ol Pregnenolone [71] 
Desmosterol Pregnenolone [71] 
7-dehydrocholesterol 7-dehydro-pregnenolone [69,72] 
Ergosterol 17α,24-dihydroxy-ergosterol; 20- [56,73] 
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hydroxy-22,23-epoxy-22,23-dihydro-
ergosterol and 22-keto-23-hydroxy-
22,23-dihydro-ergosterol 
Sitosterol Pregnenolone [62,71] 
Campesterol Pregnenolone [62] 
Cholesterol sulfate Pregnenolone sulfate [74,75] 
11-deoxycorticosterone (DOC) 6β-hydroxy-deoxycorticosterone [76] 
Androstenedione 6β-hydroxy-androstenedione [76] 
 
1.4- STEROID ACETYLATION 
1.4.1- CHLORAMPHENICOL (CAM) 
Chloramphenicol (CAM) was one of the first broad spectrum antibacterial drugs, isolated from the soil 
bacterium Streptomyces venezuelae in 1948 [77,78]. CAM represents the most successful first 
generation species of broad spectrum antibiotics; it is chemically 2, 2-dichloro-[1, 3-dihydroxy-1-(4-
nitrophenyl) propan-2-yl] acetamide [79]. The relative simplicity of the CAM structure quickly led to 
economic routes of synthesis, and by 1950 the synthetic drug was in wide use clinically and had 
become accepted as a promising broad spectrum antibiotic [77,78,80]. CAM inhibits protein synthesis 
by interacting with the peptidyl transferase center of ribosomes, thereby blocking translation of the 
mRNA. The hydroxyl group of CAM is buried in the interface with the ribosome through direct 
hydrogen bonding, potassium ion-mediated electrostatic interactions as well as through van der 
Waals interactions with the RNA phosphosugar backbone [81,82]. 
1.4.2- MECHANISM OF ACTION OF CHLORAMPHENICOL ACETYLTRANSFERASE (CAT) 
The bacterial resistance to chloramphenicol is normally conferred by the enzyme chloramphenicol 
acetyltransferase (CAT) encoded by cat. CAT [EC 2.3.1.28] is a cytoplasmic bacterial enzyme that 
detoxifies CAM by covalently attaching an acetyl group, derived from acetyl-CoA (acyl donor), to one 
of the hydroxyl groups of CAM to form the acetylated CAM and thus preventing the antibiotic from 
binding to a ribosome. CAT can acetylate chloramphenicol at both, one or two sites, and neither the 
mono- nor the diacetate forms have antibiotic activity and are thus destroying its ability to inhibit 
bacterial growth [83,84]. Previous studies have demonstrated that three reactions describe the fate of 
chloramphenicol in bacteria containing CAT. In the first reaction, the CAT enzyme acetylates CAM at 
the hydroxyl group in C3 position in the presence of acetyl CoA to produce chloramphenicol-3-acetate 
(3-O-acetyl-CAM). In the second reaction, this acetyl moiety is then shifted to the C1 hydroxyl group 
via a non-enzymatic rearrangement yielding chloramphenicol-1-acetate (1-O-acetyl-CAM). In the third 
step, 1-O-acetyl-CAM undergoes a new enzymatic acetylation at the C3 site in the presence of acetyl 
CoA producing chloramphenicol-1,3-diacetate (1,3-O,O-diacetyl-CAM) (Scheme 4) [85,86].  
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Scheme 4: Role of chloramphenicol acetyltransferase in chloramphenicol acetylation. Reactions (1) and (3) are 
both catalyzed by CAT, whereas reaction (2) is a non-enzymatic re-arrangement [86]. 
The mechanism of the acetylation of CAM involves the abstraction of a proton from the hydroxyl 
group in C3 position of the CAM molecule, whereby the imidazole side-chain of the catalytic histidine 
residue acts as general base. Loss of the proton from the hydroxyl group facilitates the subsequent 
nucleophilic attack of the anion at the carbonyl group of the acetyl-CoA thioester bond [87,88]. 
1.4.3- ACETYLATED STEROIDS 
Steroid acetates represent important derivatives for pharmaceutical applications. Several steroid 
acetates have been used for the production of pharmaceuticals, which are administered in an acetate 
form [89,90], e.g: cortisol acetate to treat a variety of skin conditions and as anti inflammatory drug, 
or prednisolone acetate, which is used as anti-inflammatory agent for ophthalmic use.  
In general, the acetylation reaction in the organic chemistry is the insertion of an acetyl group into a 
molecule. More specifically, the reaction replaces the hydrogen from an alcohol group by an acetyl 
group. Acetylation of alcohols is an important and one of the routinely utilized transformations in 
organic synthesis [91]. Concerning steroids, the acetylation has been carried out to produce a wide 
range of steroid compounds such as phytostanyl esters [92], esters of DHEA [93], aldosterone acetate 
[94,95], 17α-acetate [96], cortisol-21-acetate [97] and acetate of several steroid hormone metabolites 
[98], by using different acetylating agents. The acetylation of these compounds can be applied to 
isolate specific steroids from biological mixtures [99], to determine steroids in biological samples [98], 
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as well as to produce intermediates and products for pharmaceutical purposes [100-102], thus, 
confirming that many therapeutically useful steroids are administered as esters with the widespread 
distribution of the esterase activity in mammalian tissue ensuring the cellular availability of the free 
steroid [93]. For aforementioned purposes of steroid acetate, several synthetic methods have been 
described for the synthesis of these compounds. The application of biocatalysts and whole-cell 
biotransformation offer a good alternative for the production of steroid acetates, allowing mild and 
environmentally friendly reaction conditions and it is currently the preferred way to achieve selective 
acetylation of steroid compounds. 
It is worth mentioning also that acetates of naturally occurring steroids have been detected as 
components of human blood. Cortisol-21-acetate is considered to be a regular blood constituent and 
the major portion is circulating endogenously. Corticosteroid acetates including corticosterone 
acetate, 11-dehydrocorticosterone acetate and other corticosteroid acetates also have been found to 
circulate in the human blood. The presence of acetylated steroids in circulating human peripheral 
blood is important for protein binding. It was demonstrated that acetylation of the C21-hydroxyl 
group of certain corticosteroids results in an increased interaction at carbon-3 with human albumin to 
facilitate the steroid transport [103,104]. Furthermore, the specific steroid binding albumin may 
protect steroids from degradation and thus avoids rapid fluctuations in active unbound steroid 
concentrations. 
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2- SCOPE AND OBJECTIVES OF THE THESIS 
The first part of this Thesis focuses on the initial stage of the steroidogenic process, where CYP11A1 is 
involved. Among all steroidogenic P450s, CYP11A1 might represent a vital target for the regulation of 
steroidogenesis at the cellular level. Therefore, the main objective of this part was to provide a 
comprehensive overview regarding the interaction of steroid metabolites with CYP11A1 and in depth 
focusing on the in vitro characterization of the CYP11A1 activity in the presence of steroid 
intermediates. Hence, a recombinant expression system for CYP11A1 was developed as well as a 
purification procedure was established. 
The in vitro conversion of cholesterol in the presence of some steroid metabolites was accompanied 
with the appearance of new product peaks in the HPLC chromatograms. Therefore, it was of special 
interest to determine whether CYP11A1 is also able to convert these steroids. For this reason, in vitro 
conversions were performed with these new steroids in absence of cholesterol. 
Since the whole-cell system expressing P450 is one of the most important strategies of steroid 
functionalization, which is widely applied for steroid hydroxylations [105,106], an Escherichia coli 
based whole-cell system using tricistronic expression vectors coding for CYP11A1 and its electron 
transfer partners was established and sufficient amounts of the novel products were obtained for 
NMR spectroscopy analysis. 
In the second part of this study, it was investigated whether a CYP11A1 whole-cell biocatalyst 
containing an expression vector (pACYC-FHH2) harboring a CAM resistance gene is able to perform the 
acetylation reaction at the hydroxyl group at C21 position of DOC. For this reason, we aimed to focus 
on the acetylation of steroids using the bacterial CATI to produce the acetylated steroids for 
pharmaceutical applications. In addition, the other objective of this study was to establish a novel and 
efficient E. coli based biocatalyst using chloramphenicol acetyltransferase I (CATI) for the 
regioselective acetylation of C21-hydroxyl groups in steroid compounds. In this study, a substrate 
screening for CATI was performed with 18 different biologically active steroids. Further, additional 
experiments were aimed to elucidate the optimization of the conversion assay. The study also aimed 
to prove that the acetylation activity of the whole-cell catalyst depends on CATI and that acetyl CoA is 
employed in that reaction as an acyl donor by performing the acetylation reactions of CAM as well 
as C21-hydroxysteroids with purified CATI. Therefore, an expression plasmid was constructed 
containing a gene coding for a His6-tagged CATI and consequently, an E. coli expression system was 
used for the expression of CATI. 
The third part of this study concentrates on the metabolism of sulfonated steroids, which are involved 
in steroidogenic pathway and might have a very important role in the production of biologically active 
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steroid hormones once they become de-sulfated. Therefore, it may contribute to the overall 
regulation of reproductive processes as well as affects steroid hormone biosynthesis on a molecular 
level [107,108]. Due to this reason, the third project aimed to illustrate the proposed steroidogenic 
pathway of sulfonated steroids using pregnenolone sulfate (PregS). The ability of PregS to serve as a 
substrate for CYP17 was assessed using the in vitro reaction by purified CYP17 and its electron transfer 
partner, CPR. Further, the effect of cytochrome b5, which is known to enhance the CYP17 dependent 
lyase reaction, was determined. To achieve this aim, the expression systems and the purification 
procedures for recombinant proteins, CPR, b5 and CYP17 were developed. 
Since the uses of cytochrome P450s for steroid hydroxylation is restricted to whole-cell catalysis, the 
last part of the Thesis consisted in the establishment of CYP11A1 whole-cell system to improve their 
steroid biotransformation efficiency under desired process conditions. This included the improvement 
of a whole-cell system for CYP11A1, which has not been published so far. In this aspect, we 
investigated whether the bioconversion can be improved by avoiding all side effects of the medium 
components using the resting cells in potassium phosphate buffer to perform the biotransformation 
experiments. Moreover, the inhibitory effect of indole on the CYP11A1 activity on the in vitro and in 
vivo conversion was also estimated. 
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The results produced during the present work are published in the articles listed below. 
3.1- MOSA ET AL., 2015 a 
2β-AND 16β-HYDROXYLASE ACTIVITY OF CYP11A1 AND DIRECT STIMULATORY EFFECT OF 
ESTROGENS ON PREGNENOLONE FORMATION  
A. Mosa, J. Neunzig, A. Gerber, J. Zapp, F. Hannemann, P. Pilak, R. Bernhardt  
Journal of Steroid Biochemistry & Molecular Biology 150 (2015) 1–10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Steroid Biochemistry & Molecular Biology 150 (2015) 1–102b- and 16b-hydroxylase activity of CYP11A1 and direct stimulatory
effect of estrogens on pregnenolone formation
A. Mosa a, J. Neunzig a, A. Gerber a, J. Zapp b, F. Hannemann a, P. Pilak a, R. Bernhardt a,*
a Institute of Biochemistry, Saarland University, 66123 Saarbrücken, Germany
b Institute of Pharmaceutical Biology, Saarland University, 66123 Saarbrücken, Germany
A R T I C L E I N F O
Article history:
Received 23 October 2014
Received in revised form 24 February 2015
Accepted 27 February 2015
Available online 3 March 2015
Keywords:
Cytochromes P450
Whole-cell system
Steroids
CYP11A1
Cholesterol
Steroid 2b,-6b- and 16b-hydroxylation
A B S T R A C T
The biosynthesis of steroid hormones in vertebrates is initiated by the cytochrome P450 CYP11A1, which
performs the side-chain cleavage of cholesterol thereby producing pregnenolone. In this study, we report
a direct stimulatory effect of the estrogens estradiol and estrone onto the pregnenolone formation in a
reconstituted in vitro system consisting of puriﬁed CYP11A1 and its natural redox partners. We
demonstrated the formation of new products from 11-deoxycorticosterone (DOC), androstenedione,
testosterone and dehydroepiandrosterone (DHEA) during the in vitro reaction catalyzed by CYP11A1. In
addition, we also established an Escherichia coli-based whole-cell biocatalytic system consisting of
CYP11A1 and its redox partners to obtain sufﬁcient yields of products for NMR-characterization. Our
results indicate that CYP11A1, in addition to the previously described 6b-hydroxylase activity, possesses
a 2b-hydroxylase activity towards DOC and androstenedione as well as a 16b-hydroxylase activity
towards DHEA. We also showed that CYP11A1 is able to perform the 6b-hydroxylation of testosterone, a
reaction that has been predominantly attributed to CYP3A4. Our results are the ﬁrst evidence that sex
hormones positively regulate the overall production of steroid hormones suggesting the need to reassess
the role of CYP11A1 in steroid hormone biosynthesis and its substrate-dependent mechanistic
properties.
ã 2015 Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry & Molecular Biology
journal homepage: www.else vie r .com/locate / j sbmb1. Introduction
In mammals, steroid hormones exhibit many vital functions
and are indispensable for normal development and reproduction.
They are synthesized in steroidogenic tissues or organs, such as the
adrenal glands or the gonads, in a series of reactions involving six
different cytochromes P450 (CYPs) [1–3]. Steroid hormones are
categorized into three main classes: the mineralocorticoids and
glucocorticoids, regulating the salt and sugar homeostasis,
respectively, as well as the sex hormones, which are necessary
for the development of the secondary sexual characteristics and for
reproduction [2,4]. Their availability is regulated by complicated
mechanisms at different levels. The concentration of aldosterone,
the main mineralocorticoid, is under the control of the renin–
angiotensin–aldosterone system [5], whereas the release of
cortisol, the main glucocorticoid, and the sex hormone supply
are controlled by two similar mechanisms: the hypothalamic–
pituitary–adrenal axis and the hypothalamic–pituitary–gonadal* Corresponding author at: Institute of Biochemistry, Campus B 2.2, Saarland
University, 66123 Saarbrücken, Germany. Tel.: +49 681 3024241.
E-mail address: ritabern@mx.uni-saarland.de (R. Bernhardt).
http://dx.doi.org/10.1016/j.jsbmb.2015.02.014
0960-0760/ã 2015 Elsevier Ltd. All rights reserved.axis, respectively [6,7]. The compartmentalization of the produc-
tion of steroid hormones in different organs or tissues represents
an additional mechanism of regulation [8]. In order to interact with
their corresponding receptors, steroid hormones need to be
present in their free and unbound form. Therefore, the conjugation
and deconjugation of steroids constitutes a further mechanism
that controls the availability of free steroids on a cellular level [9].
The biosynthesis of steroid hormones starts with the side-chain
cleavage of cholesterol producing pregnenolone. This is the ﬁrst
enzymatic and rate-limiting step and is catalyzed by the side-chain
cleaving cytochrome P450 CYP11A1 [10,11], a mitochondrial
cytochrome P450 found primarily in the steroidogenic cells of
the adrenal cortex and the gonads as well as in the skin and brain
[12]. The side chain cleavage of cholesterol by CYP11A1 is
performed through three consecutive steps: two hydroxylations
at C22 and C20, respectively, followed by the cleavage of the C20–
C22 bond [2,10,13]. The resulting product, pregnenolone, is the
precursor of all classes of steroid hormones: mineralocorticoids,
glucocorticoids and sex hormones [14,15]. Therefore,
CYP11A1 might represent a vital target for the regulation of
steroidogenesis at the cellular level.
Babischkin et al. demonstrated an increased enzymatic activity
of CYP11A1 in the presence of estrogens in the placenta of baboons
2 A. Mosa et al. / Journal of Steroid Biochemistry & Molecular Biology 150 (2015) 1–10and postulated that the formation of pregnenolone by
CYP11A1 might be regulated by estrogens [16].
For this reason, the aim of this study was to investigate whether
the CYP11A1 activity is inﬂuenced by the presence of various
steroid hormone metabolites employing a reconstituted in vitro
system with puriﬁed CYP11A1 and its electron transfer partners to
assess the effect of various steroids on the catalysis of CYP11A1 at a
molecular level. HPLC analysis revealed a direct activation of
CYP11A1 through the estrogens estradiol and estrone.
In addition, we identiﬁed new products from androstenedione,
DOC, DHEA and testosterone. In order to elucidate the structure of
these novel products, an Escherichia coli based whole-cells system
was established to obtain sufﬁcient amounts for NMR-characteri-
zation. These data revealed a novel hydroxylation pattern of
CYP11A1-dependent steroid conversions at the positions 2b, 6b
and 16b.
2. Materials
Cholesterol and other steroids were purchased from Sigma–
Aldrich. All the reagents and solvents were of the highest purity.
3. Experimental
3.1. Expression of CYP11A1
E. coli strain C43(DE3) was used as a host for the expression of
bovine CYP11A1, containing a C-terminal 6x-His tag. Cells were co-
transformed with a CYP11A1-encoding pTrc99A plasmid [17,18]
and the molecular chaperones GroEL/GroES-encoding plasmid
pGro12 [19], which possess ampicillin and kanamycin resistance
genes, respectively. Transformed cells were grown overnight at
37 C under shaking at 180 rpm in 50 ml Terriﬁc broth (TB) medium
supplemented with 100 mg/ml ampicillin and 50 mg/ml kanamy-
cin. To prepare the main culture, 200 ml TB medium supplemented
with 100 mg/ml ampicillin and 50 mg/ml kanamycin were inocu-
lated with 2 ml of the preculture and incubated in a 2 l Erlenmeyer
bafﬂed ﬂask with 180 rpm shaking at 37 C. When the culture
reached an optical density of 0.8–1.0 at 600 nm, the induction of
GroEL/GroES and the CYP11A1 synthesis was achieved by adding
1 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG), 1 mM delta-
aminolevulinic acid (d-ALA), 50 mg/ml ampicillin and 4 mg/ml
arabinose. The culture was further incubated for 48 h at 28 C and
95 rpm shaking and was harvested by centrifugation (4 C,
4000  g for 20 min) and the cell pellet was stored at 20 C.
3.2. Puriﬁcation of CYP11A1
The stored cell pellet was suspended in 50 ml lysis buffer
(50 mM potassium phosphate buffer, pH 7.4, containing 20% (v/v)
glycerol, 1.5% sodium cholate, 500 mM sodium acetate, 1.5%
Tween-20, 0.1 mM ethylenediaminetetraacetic acid (EDTA),
1,4-dithiothreitol (DTT) and phenylmethanesulfonyl ﬂuoride
(PMSF). Cells were disrupted by sonication on ice (15 s pulse,
15 min, 13% amplitude) and the cell debris was removed by
ultracentrifugation (4 C, 70,500  g for 30 min). The obtained
supernatant was used for protein puriﬁcation.
Approximately 50 ml of protein extract were applied to a
Ni–NTA agarose column after equilibrating the column with
equilibration buffer (50 mM potassium phosphate, pH 7.4, 500 mM
sodium acetate, 20% glycerol, 1% sodium cholate, 1% Tween-20,
0.1 mM EDTA, DTT and PMSF). The column was washed with 50 ml
washing buffer (50 mM potassium phosphate, pH 7.4, 500 mM
sodium acetate, 20% glycerol, 1% sodium cholate, 1% Tween-20,
20 mM imidazole and 0.1 mM of EDTA, DTT and PMSF), followed by
the same washing buffer containing 40 mM imidazole.The bound CYP11A1 was eluted from the column by the same
washing buffer containing 150 mM imidazole and was diluted with
three volumes of dilution buffer (20% glycerol, 0.1 mM DTT, 0.1 mM
EDTA and 1% sodium cholate). The dialyzed protein solution was
applied to a SP-sepharose column equilibrated with 50 ml
calibration buffer (20 mM potassium phosphate, pH 7.4, 20%
glycerol, 0.1 mM DTT, 0.1 mM EDTA, 10 mM imidazole, 1% sodium
cholate, and 0.1% Tween-20). The column was washed once again
with 20 ml of equilibrium buffer followed by the second washing
step with 30 ml of 40 mM phosphate buffer containing 20%
glycerol, 0.1 mM DTT, 0.1 mM EDTA, 10 mM imidazole, 1% sodium
cholate and 0.1% Tween-20. The column-bound protein was eluted
with the 100–300 mM NaCl gradient of washing buffer. Finally, the
protein was concentrated using a centrifugal ﬁlter (30 kDa)
followed by washing with the dilution buffer (50 mM potassium
phosphate, 20% glycerol, 1% sodium cholate, 0.05% Tween-20,
0.1 mM EDTA and 0.1 mM DTT). The protein was again concentrat-
ed in a centrifugal ﬁlter and stored at 80 C until use.
3.3. Protein expression and puriﬁcation of redox partners
Heterologous expression and puriﬁcation of bovine adreno-
doxin (Adx) and bovine adrenodoxin reductase were performed as
described by Uhlmann et al. [20] and Sagara et al. [21], respectively.
3.4. Spectroscopic studies
UV–vis spectrum of CYP11A1 was measured at room tempera-
ture on a UV–vis scanning spectrophotometer (Shimadzu-2101PC).
The concentration of expressed CYP11A1 was determined by
reduced carbon-monoxide difference spectroscopy according to
Omura and Sato [22], applying an extinction coefﬁcient of
91 mM1 cm 1 at 450 nm. The solution of CYP11A1 was treated
with a few grains of reducing agent (sodium dithionite) and the
baseline of the reduced spectrum was recorded between 400 and
500 nm. The sample was slowly bubbled with carbon monoxide for
20 s and the spectrum was recorded.
To determine the substrate binding spectra, difference spec-
troscopy was applied at room temperature using a Jasco
V-630 spectrophotometer and two tandem cuvettes according to
Schenkman [23]. Binding afﬁnities for the different substrates of
CYP11A1 were estimated by using 2 mM CYP11A1 in 800 ml 50 mM
potassium phosphate buffer (pH 7.4) containing 20% glycerol, 0.5%
sodium cholate and 0.05% Tween-20. A baseline was recorded from
360 to 450 nm.
3.5. In vitro conversion of cholesterol by CYP11A1
The in vitro cholesterol conversion by CYP11A1 was performed
as described before [24] with some modiﬁcations. In this study, the
reaction mixture consisting of 1 mM CYP11A1, 20 mM adrenodoxin
(Adx) and 0.5 mM adrenodoxin reductase was used in a ﬁnal
volume of 500 ml of 50 mM HEPES buffer (pH 7.4, 0.05% (v/v)
Tween-20). In order to regenerate the NADPH, glucose-6-
phosphate (5 mM), MgCl2 (1 mM) and glucose-6-phosphate
dehydrogenase (1U) were added to the reaction mixture. The
substrate cholesterol was dissolved in 45% 2-hydroxypropyl-
b-cyclodextrin prior to the addition to the reaction tube. The
ﬁnal concentration of cholesterol in the conversion buffer was
15 mM, the ﬁnal cyclodextrin concentration was 0.337%. The
enzymatic reaction was initiated by the addition of NADPH
(500 mM) and incubated at 37 C and 900 rpm in the Eppendorf
thermomixer for 7 min. The assay was terminated by boiling the
samples in a water bath for 5 min. In order to detect the cholesterol
and pregnenolone product at 240 nm, a cholesterol oxidase
reaction was performed during which cholesterol and
Fig. 1. (A) SDS-polyacrylamid gel electrophoresis. Lane M: protein marker (peqGOLD Protein–Marker IV); lane 1: cell lysate, lane 2: eluted protein after IMAC, lane 3: eluted
protein after SP-sepharose chromatography, displaying pure CYP11A1. The cell lysate was mixed with an equal volume of SDS loading buffer and used for lane 1 while the
samples of CYP11A1 after the two puriﬁcation steps (lane 2 and 3) were analyzed by using 1 mg of puriﬁed protein in each well. (B) Dithionite reduced CO-difference spectrum
of puriﬁed CYP11A1 exhibiting a characteristic peak at 450 nm.
Table 1
Yields of puriﬁed bovine CYP11A1.
CYP11A1 yield (nmol/l) Reference
40–60 [17]
50 [29]
250 [30]
400 [31]
640 [28]
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respectively. For this, the samples were incubated with the
cholesterol oxidase at 37 C for 40 min and 900 rpm [25]. The
oxidase reaction was stopped and the steroids were extracted
twice with ethyl acetate after adding either cortisol or DOC as an
internal standard. The organic layer was pooled, evaporated and
after complete drying the steroid extract was dissolved in 200 ml
20% acetonitrile prior to the RP-HPLC analysis. All conversions
were performed for ﬁve times, and the product values represented
the mean value of ﬁve separate conversions.
To quantify the formed pregnenolone by RP-HPLC, a calibration
curve was prepared. The comparisons of the conversions with and
without the inﬂuence of steroid metabolites were statistically
analyzed using the t-test by comparing the pregnenolone
concentration between the control group (performed without
any metabolite) and the metabolite group (cholesterol with
metabolites). The results were displayed as mean values with
standard deviations (SD) and the statistical signiﬁcance was
assessed applying a p-value of <0.05.
The effect of ﬁfteen different steroid metabolites which occur
during mammalian steroid hormone biosynthesis was tested during
the conversion of cholesterol by CYP11A1. These tested steroids were
11-deoxycorticosterone (DOC), testosterone, estradiol, estrone,
estriol, aldosterone, cortisol, prednisolone, corticosterone,
11-deoxycortisol, androstenedione, dehydroepiandrosterone
(DHEA), adrenosterone, 17a-hydroxy-progesterone and 17a-hy-
droxy-pregnenolone.
3.6. In vitro conversion of steroid metabolites by CYP11A1
In vitro conversions of 11-deoxycorticosterone (DOC), testos-
terone, androstenedione and dehydroepiandrosterone (DHEA)
with CYP11A1 were performed using the same assay conditions
as used for the cholesterol conversion, except that 300 mM of these
steroids (stock solution dissolved in absolute ethanol, ﬁnal ethanol
concentration in the incubation 1%) were added to the
CYP11A1 reaction mixture and incubated for 30 min. Since the
oxidase reaction is not required for DOC, testosterone and
androstenedione, the conversion was stopped by addition of an
equal volume of ethyl acetate, while the samples containing DHEA
were treated similar to the cholesterol conversions.3.7. Kinetic analysis
The conversion assays were carried out to determine kcat and Km
or K0.5 values for the CYP11A1-catalyzed reactions, applying
substrate concentration ranging from 0–60 mM for cholesterol in
cyclodextrin, 0–800 mM for DOC in DMSO and from 0–1200 mM for
androstenedione and DHEA in DMSO (the ﬁnal DMSO concen-
trations were 1–1.2%), with ﬁxed concentrations of CYP11A1
(1 mM). All other components and the assay conditions were
similar as described above for the in vitro conversions. The
quantiﬁed product represents the mean values of three experi-
ments. The kinetic constants, kcat and Km or K0.5 were determined
by plotting the product (n mol product/nmol CYP11A1/min)
against the corresponding substrate concentrations (mM).
Michaelis–Menten or Hill equation (hyperbolic or sigmoidal ﬁt,
respectively) were used applying Origin 8.1G.
3.8. HPLC analysis
The extracted steroids were measured by high performance
liquid chromatography (HPLC). Isocratic steroid separation was
carried out on a Jasco HPLC system of the LC2000 series using a
4.0 mm  125 mm Nucleodur C18ec reverse phase column
(Macherey-Nagel) with a mobile phase consisting of 20% acetoni-
trile in water at the ﬂow rate of 1 ml/min. The substrates were
detected at 240 nm and the oven-temperature was 40 C.
3.9. Whole cell biotransformation and puriﬁcation of novel
metabolites
TricistronicexpressionvectorPP04,basedonpBR322 [26], coding
for adrenodoxin (Adx), ferredoxin reductase (FpR) and
Fig. 2. Pregnenolone concentration (mean  SD) after CYP11A1-dependent in vitro
conversions using 15 mM cholesterol as a ﬁnal substrate concentration in the
presence of the same amount of steroid metabolites. * indicates signiﬁcance
(p < 0.05).
Table 2
Percentage of product obtained from the in vitro conversion of 300 mM steroid by
CYP11A1 for 30 min. Each value represents the mean  S.D of three replicates.
Steroids Percentage of products (%)
Main product Minor product
DOC 11.0  0.6 3.3  0.4
Androstenedione 18.0  1.7 5.0  0.4
DHEA 5.0  0.9 2.0  0.6
Testosterone 10.0  0.3 –
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formations. E. coli C43(DE3) cells were co-transformed with
PP04 and the chaperone GroEL/GroES-encoding plasmid pGro12,
possessing ampicillin and kanamycin resistance genes, respectively.
Transformed cells were grown overnight in 50 ml Terriﬁc broth (TB)
medium supplemented with 100 mg/ml ampicillin and 50 mg/ml
kanamycin at 37 C and shaking at 180 rpm.
For the preparative puriﬁcation of the products, 200 ml TB
medium containing 100 mg/ml ampicillin and 50 mg/ml kanamycin
were inoculated (1:100) with the transformed cells and cultivated at
37 C with rotary shaking at 180 rpm. After the optical density at
600 nm reached to 0.8–1.0, the culture was induced with 1 mM
(IPTG), 1 mM (d-ALA) and 4 mg/ml arabinose. The temperature and
shaking speed were then reduced to 28 C and 100 rpm, respective-
ly. After incubation for 24 h, cells were harvested by centrifugation
(4000 g) for 20 min at 4 C and washed once with 200 ml 50 mM
potassium phosphate buffer (KPP) (pH 7.4) in order to prevent side
reactions and unspeciﬁc conversions of components of the complex
medium [27]. After a second centrifugation, the cell pellets were
resuspended in 200 ml KPP buffer supplemented with 100 mM
glucose. The substrate was added to a ﬁnal concentration of 300 mM
and the culture was incubated for another 48 h at 30 C and 140 rpm.
Steroids were extracted twice with the same volume of ethyl acetate
and the organic phase was evaporated using a rotary evaporator.
Steroids were separated by reversed phase HPLC on a C18ec column
(Nucleodur 250/8) (Macherey-Nagel) with a mobile phase consist-
ing of 20% acetonitrile in water. The fraction containing the product
was collected, evaporated and subjected to subsequent NMR
spectroscopy analysis.
3.10. NMR analysis
The NMR spectra analysis of the hydroxylated products (6b-
hydroxy-DOC, 2b-hydroxy-DOC, 6b-hydroxy-androstenedione,2b-hydroxy-androstenedione, 6b-hydroxy-testosterone and
16b-hydroxy-DHEA) were recorded in CDCl3 using a Bruker DRX
500 or a Bruker Avance 500 NMR spectrometer at 298 K. The
chemical shifts were relative to CHCl3 at d 7.26 (1H NMR) and CDCl3
at d 77.00 (13C NMR), respectively, using the standard d notation in
parts per million. The 1D NMR (1H and 13C NMR, DEPT135) and the
2D NMR spectra (gs-HH-COSY, gs-NOESY,
gs-HSQCED, and gs-HMBC) were recorded using the BRUKER
pulse program library. All assignments were based on extensive
NMR spectral evidence.
4. Results
4.1. Expression and puriﬁcation of CYP11A1
CYP11A1 was successfully expressed in E. coli C43(DE3) cells,
transformed with the CYP11A1-encoding pTrc99A and pGro12. The
recombinant protein was puriﬁed from the cell lysate using
immobilized-metal afﬁnity chromatography (IMAC) followed by
SP-sepharose chromatography. The purity of the eluted fractions
was assessed by SDS-PAGE for each puriﬁcation step (Fig. 1A). As
shown in Fig. 1A, after puriﬁcation by IMAC two bands could be
seen in the gel (lane 2), one at approximately 54 kDa corresponding
to the relative molecular mass of CYP11A1, and a second band
corresponding to the expressed chaperone complex. The subse-
quent puriﬁcation using SP-sepharose chromatography yielded a
pure CYP11A1 protein, as displayed by the single band in lane 3
(Fig. 1A). The puriﬁed CYP11A1 showed the characteristic
absorbance peak at 450 nm after CO binding by the dithionite
reduced protein representing the stable Fe II(CO)-complex
(Fig. 1B).
The yield of the puriﬁed protein calculated from the
CO-difference spectrum was 712  63 nmol/l E. coli cell culture,
which represents the highest published value for this protein to
date (Table 1) and is also in the range of our recent publication
(640 nmol/l) [28]. The improved yield reﬂects the advantages of
E. coli C43(DE3) strain as an expression host together with the co-
expression of molecular chaperones.
4.2. Inﬂuence of steroid metabolites on the pregnenolone yield of
CYP11A1-dependent in vitro reactions
To test the inﬂuence of steroid metabolites on the CYP11A1-
catalyzed conversion of cholesterol, in vitro conversion assays were
performed. The assay mixture consisted of CYP11A1 and its natural
redox partners, which provided the required electrons necessary
for the cytochrome P450 monooxygenases activity [1,32]. CYP11A1,
wild type bovine adrenodoxin (Adx) and bovine adrenodoxin
reductase were used in a molar ratio of 1:20:2. The activity of
CYP11A1 with cholesterol as a substrate was successfully assessed
using HPLC (Fig. S1, Supplemental data).
In order to test the inﬂuence of various intermediates of the
steroid hormone biosynthesis on the CYP11A1-catalyzed choles-
terol conversion, in vitro assays were performed in the presence of
different steroid metabolites. Conversion rates were compared to
Fig. 3. Pregnenolone concentration (mean  SD) after CYP11A1-dependent in vitro conversion of 15 mM cholesterol in the presence of the different concentrations of steroid
metabolites. (A) Estrone, (B) Estradiol. * indicates signiﬁcance (p < 0.05).
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corresponding to the Km value of cholesterol. The effects of equal
amounts (15 mM) of 11-deoxycorticosterone (DOC), testosterone,
estradiol, estrone, estriol, aldosterone, cortisol, prednisolone,
corticosterone, 11-deoxycortisol, androstenedione, dehydroepian-
drosterone (DHEA), adrenosterone, 17a-hydroxy-progesterone
and 17a-hydroxy-pregnenolone on the conversion of cholesterol
by CYP11A1 in vitro are shown in Fig. 2. In the presence of equal
concentrations of estrone and estradiol, CYP11A1-mediated
cholesterol metabolism was signiﬁcantly increased (p < 0.05)
compared with the control reactions. The presence of otherFig. 4. Kinetic parameters for the conversion of cholesterol and other steroid substrates 
product formation was determined by HPLC and each value is represented as mean  Ssteroids did not show any signiﬁcant increase or decrease of the
CYP11A1-dependent pregnenolone formation.
Because of the signiﬁcant enhancement of the cholesterol
conversion with 15 mM estrone and estradiol, we further
investigated the inﬂuence of these steroids in more detail
employing a broader concentration range of these steroids. The
HPLC analysis (Fig. 3) showed a concentration-dependent increase
of the CYP11A1-catalyzed cholesterol conversion in the presence of
estrone and estradiol. Interestingly, amounts as low as 5 mM of
estrone and estradiol already increased the CYP11A1-dependent
cholesterol conversion, while very high concentrations of estradiolcatalyzed by CYP11A1. (A) Cholesterol, (B) DOC, (C) Androstenedione, (D) DHEA. The
D of three separate measurements.
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tion exhibited by this steroid. Furthermore, 1 mM of both steroids
had no signiﬁcant effect on the product formation compared to
control measurements.
4.3. Identiﬁcation of new CYP11A1 substrates
Previous studies demonstrated that CYP11A1 is able to cleave
the side chain of the cholesterol precursor 7-dehydrocholesterol
[33], hydroxylate and epoxidate ergosterol [10], hydroxylate
vitamin D2 [34,35] and vitamin D3 [31,33] as well as perform
the 6b-hydroxylation of DOC and androstenedione [36].
During our studies, in some cases we observed the occurrence
of new peaks in the HPLC chromatograms, although the tested
steroid metabolites did not signiﬁcantly affect the CYP11A1-
dependent pregnenolone conversion. Therefore, we analyzed
whether CYP11A1 is also able to accept these steroids as a
substrate during in vitro conversions in the absence of cholesterol.
Of the applied steroids, a successful in vitro conversion was
achieved with DOC, androstenedione, testosterone and DHEA. The
obtained data in Table 2 shows that the in vitro conversion of DOC,
androstenedione and DHEA resulted in the formation of one major
product (P1) and one minor product (P2), whereas testosterone
conversion resulted in the formation of one major product (P2) and
several minor products (see Fig. S2, Supplemental data).
4.4. Kinetic analysis
CYP11A1-dependent substrate conversion was examined using
cholesterol, DOC, androstenedione or DHEA as substrates. As
shown in Fig. 4A, the recombinant enzyme was able to convert
cholesterol to pregnenolone with kcat and Km values of 1.33  0.07Fig. 5. HPLC chromatograms of the conversion of 300 mM steroid substrates in KPP buffe
Deoxycorticosterone (DOC), (B) Androstenedione, (C) Testosterone, (D) DHEA.min1 and 15.6  2.4 mM, respectively, and a regression coefﬁcient
(R2) of 0.99.
The kinetic parameters were also calculated for DOC, andro-
stenedione and DHEA conversion utilizing the same reaction
conditions as used for cholesterol, except that the steroids were
dissolved in DMSO and the conversion time was extended from
7 min to 30 min. Since the conversions of DOC, androstenedione
and DHEA gave one major and one minor product each, the
catalytic activity was calculated for the total product amount.
The conversion of DOC showed two products with a kcat of
2.0  0.06 min1 and K0.5 value of 281 12 mM (R2 = 0.99,
n = 1.9  0.19) (Fig. 4B). Likewise, CYP11A1 converted androstene-
dione into two products with a kcat of 7  0.4 min1 and a K0.5 value
of 566  33 mM (R2 = 0.99, n = 2.30  0.16) (Fig. 4C). Similarly, with
DHEA as a substrate, the kcat and K0.5 values were 1.34  0.2 min1
and 944 151 mM (R2 = 0.99, n = 1.90  0.15), respectively (Fig. 4D).
Interestingly, cholesterol exhibited a hyperbolic ﬁt, while the curve
shapes of the kinetic measurements of CYP11A1 with DOC,
androstenedione and DHEA revealed a sigmoidal nature. This is
indicative for multiple binding sites. Whether these binding sites
are speciﬁc as shown for CYP3A4 with testosterone [37,38] and
progesterone [39], where two molecules of substrate enter into the
active site, or unspeciﬁc as postulated for CYP17A1 with sulfonated
pregnenolone [40], still has to be elucidated. The kinetic
parameters were not determined for testosterone because of the
formation of multiple products.
In a next step, we aimed to determine the binding constants (Kd)
of the substrates to CYP11A1. The Kd of CYP11A1 for cholesterol was
calculated to be 43  3 mM (see Fig. S3, Supplemental data).
However, none of the other substrates caused a spectral shift of
CYP11A1, so that no Kd values could be calculated for DOC,
androstenedione, DHEA and testosterone.r after 48 h using recombinant E. coli whole cell systems expressing CYP11A1. (A) 11-
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Since the in vitro conversion of DOC, androstenedione,
testosterone and DHEA by CYP11A1 resulted in the formation of
novel products, we aimed to characterize their structures using
NMR spectroscopy. In order to gain sufﬁcient amounts of these
steroids, an E. coli based whole-cell biocatalytic system was
established. The conversions were performed in potassium
phosphate buffer (KPP) to avoid possible side-product formations
from components of the TB medium. Therefore, after 24 h of
protein expression, the culture medium was shifted from TB to
50 mM KPP buffer (pH 7.4), containing 100 mM glucose. The
respective substrates were added to a ﬁnal concentration of
300 mM and the culture was incubated for another 48 h at 30 C
and 140 rpm. The samples of steroid bioconversions were then
collected and extracted for HPLC analysis (Fig. 5). In addition,
untransformed E. coli cells were used as a negative control for the
steroid conversions (Fig. S4, Supplemental data).
As displayed in Fig. 5(A–D), the in vivo product patterns
measured after the biotransformation are identical to those shown
in the chromatograms obtained after the in vitro incubations
(Fig. S2, Supplemental data). The in vivo conversion of DOC resulted
in the formation 36  1.6% of P1 product and 17  1% P2 product.
CYP11A1 forms two products with the yield of 60  3% (P1) andFig. 6. The structures and product yields (in percent) of steroids converted by CYP11A1 a
and E. coli cells expressing CYP11A1 and its redox partners in KPP buffer. The obtained21  2% (P2) from androstenedione. Furthermore, CYP11A1 was
also able to convert DHEA into two products; the major product
(P1) yield reached 20  0.5% conversion. Moreover, several
products were formed by incubation of testosterone and the
bioconversion assay of testosterone produced 36  2% P2 of
testosterone as a major product.
4.6. NMR analysis
The structural identiﬁcation of the obtained products was done
by NMR spectroscopy as described in the method section. All
products were puriﬁed in sufﬁcient amounts, except for the minor
products of testosterone and product 2 (P2) of DHEA. The amounts
of the puriﬁed hydroxylated products were between 1 and 5 mg.
The structural assignments of the products as obtained from the
NMR data are shown in Fig. 6. The conversion of DOC and
androstenedione resulted in the formation of two hydroxylated
products; in both cases the 2b-hydroxy and 6b-hydroxy-deriva-
tives were formed. The conversion of DHEA led to the production of
16b-hydroxy-DHEA as the main product, while testosterone
conversion resulted in the formation of 6b-hydroxy-testosterone
as a major product (P2).
The proton shifts of ring A and B in the 2b-hydroxylated
steroids (DOC and androstenedione) were very close to each otherccording to the NMR data after 48 h conversion. Reactions contained 300 mM steroid
 values are represented as mean  SD of three separate experiments.
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same relation was found between the 6b-hydroxylated DOC and
androstenedione and the known 6b-hydroxy-progesterone [41].
Matsuzaki et al. [42] reported selected 1H NMR shifts for
6b-hydroxy-DOC, which are in good agreement to those of
6b-hydroxylated DOC as described. Jacobsen et al. [43] published
the complete assignment of 2b-hydroxy-androstenedione mea-
sured in CD3OD. Their data match perfectly with our additionally
recorded data of 2b-hydroxy-androstenedione in methanol-d4.
1H NMR shifts of 6b-hydroxy-androstendione and 6b-hydroxy-
testosterone could be found among others in the survey of high-
ﬁeld proton NMR spectra of steroid hormones by Kirk et al. [41].
They support our structures of 6b-hydroxy-androstendione and
6b-hydroxy-testosterone. Our data of 16b-hydroxy-DHEA showed
a fair correlation with those of 16b-hydroxy-DHEA published in a
mixture of C6D6/CD3OD [44] and was reﬁned by a re-measurement
in the solvent mixture. The detailed NMR data for the formed
products are shown in the Supplemental section.
5. Discussion
In this study, we investigated the inﬂuence of different steroid
metabolites on the in vitro conversion of cholesterol to pregneno-
lone by CYP11A1. The functionality of the recombinant enzyme was
analyzed by performing CYP11A1-dependent substrate conver-
sions using cholesterol as a substrate (Fig. S1, Supplemental data).
Because of the low solubility of cholesterol in aqueous solutions,
the steroid was solubilized in 45% 2-hydroxypropyl-b-cyclodex-
trin prior to the addition into the conversion buffer. Cyclodextrins
are commonly applied for the characterization of reaction kinetics
with hydrophobic substrates [45]. Moreover, cyclodextrins are the
solutes of choice for cholesterol and are mainly utilized for the
conversion of cholesterol by CYP11A1 [46,47]. They, however,
exhibit certain disadvantages: Tuckey et al. demonstrated the
impact of cyclodextrins on the Kmvalue of CYP11A1 and cholesterol
and found it to be dose-dependent [48]. Although this effect should
be taken into consideration, in our study the ﬁnal concentration of
cyclodextrins was only 0.337%. Therefore, the CYP11A1 activity
should not be considerably altered in the presence of the utilized
cyclodextrin concentration.
In order to investigate whether steroid intermediates have an
inﬂuence on the CYP11A1-dependent pregnenolone formation, in
vitro conversion experiments were carried out using 15 mM
cholesterol, which corresponds to the Km-value of CYP11A1 and
cholesterol [28]. At this substrate concentration the enzyme
exhibits its half-maximal velocity, allowing the sensitive monitor-
ing of activations or inhibitions.
Among all 15 tested steroid metabolites, only estrone and
estradiol signiﬁcantly affected the pregnenolone formation (Fig. 2),
excluding an artiﬁcial effect from the displacement of cholesterol
from the cyclodextrin molecules by these steroids, which would
possibly affect the substrate conversion rate.
Determination of pregnenolone formation catalyzed by
CYP11A1 in the presence of different concentrations of either
estrone or estradiol revealed that the latter one is the more potent
activator, exhibiting a stimulation of the CYP11A1 activity at a
concentration as low as 5 mM (Fig. 3). This enhanced activity might
be due to allosteric binding of these steroids to CYP11A1 resulting
in conformational changes that lead to a more rapid sequential
hydroxylation of the side-chain of cholesterol, an increase of the
enzyme’s afﬁnity for the substrate or the redox proteins. However,
the effect of estrone and estradiol on the CYP11A1 activity still
needs to be elucidated at a molecular level in further inves-
tigations. We also observed that the presence of very high
concentrations of estrone and estradiol (150 mM), resulted in less
formation of pregnenolone by CYP11A1, suggesting that thestructural changes of the enzyme become unfavorable for the
substrate conversion or that higher concentrations of estrogens
inhibit binding of cholesterol, the natural substrate.
It remains difﬁcult to postulate a physiological relevance of the
described activation of CYP11A1, as the concentrations of estrogens
used were not in a physiological range. Moreover, concentrations
and a possible enrichment of estrogens within cells are unknown,
making it impossible to mimic physiological conditions in our
reconstituted in vitro system.
Nevertheless, the impact of estrogens for the stimulation of the
CYP11A1 activity is in agreement with a previous study analyzing
the estradiol formation in human placental syncytiotrophoblasts,
where a positive inﬂuence of estradiol on the pregnenolone
formation has been shown [49]. In addition, an increased
CYP11A1 activity and mRNA formation by estrogens in pregnant
baboons was found, suggesting that pregnenolone formation is
regulated by estrogens in the primate placenta [16]. In our study,
we observed an increased pregnenolone formation in the presence
of estrogens by 20%. It is well known that the stimulation of
pregnenolone synthesis is also induced by the expression of the
steroidogenic acute regulator protein (StAR), which facilitates the
transport of cholesterol to the inner mitochondrial membrane,
representing the non-enzymatic rate-limiting step of the steroido-
genesis. It has been shown that stimulation of the StAR expression
in rat astrocyte cultures through dbcAMP caused an increase in the
level of pregnenolone synthesis by 50% [50], which is of the same
order of magnitude as the estrogen stimulation observed in this
study. Moreover, in the preovulatory surge phase of the menstrual
cycle, concentrations of estrogens and luteinizing hormone (LH)
are highly elevated. LH is involved in the hypothalamic–pituitary–
gonadal (HPG)-axis, which regulates the production of androgens
and estrogens. In the gonads, LH stimulates the expression of the
steroidogenic acute regulator protein (StAR) and thus the delivery
of cholesterol to the inner mitochondrial membrane, where
CYP11A1 is located. In this context, the enhanced activity of
CYP11A1 through estrogens might be a mechanism to save cell
resources, as less additional CYP11A1 is required to metabolize the
increased cholesterol concentrations.
Interestingly, during our in vitro assays, we observed a slight
decrease in the level of pregnenolone formation in the presence of
DOC, testosterone, androstenedione and DHEA, accompanied by
the formation of additional products in the HPLC measurement;
however they are not statistically signiﬁcant. Therefore, we carried
out in vitro conversions with these four potential substrates and,
indeed, all of them were converted by CYP11A1, resulting into two
products from DOC, androstenedione and DHEA, and multiple
products from testosterone (Fig. S2, Supplemental data; see Table 2
for product ratios).
Since these new CYP11A1 substrates did not induce a type I
spectral shift as opposed to cholesterol, these steroids might not
bind in close proximity of the heme or do not displace the H2O
molecule from the sixth position of the heme iron. These ﬁndings
are in agreement with the results of Simgen et al. [51], in which
CYP106A2 from Bacillus megaterium showed the conversion of
deoxycorticosterone without any spin shift of the heme iron.
Likewise, Girhard et al. [52] also demonstrated the absence of spin-
state shifts when testosterone or (+)-valencene were used for
binding experiments with CYP109B1 from Bacillus subtilis,
although these substances are converted by this enzyme.
Comparing the afﬁnity of CYP11A1 towards cholesterol with the
afﬁnities for DOC, androstenedione and DHEA, the latter ones were
remarkably lower as observed in the kinetic measurements.
However, since the local concentration of the steroids in
mitochondria under physiological and pathological conditions
are not known and physiological effects of hydroxysteroids and
hydroxycholesterol have been described on a picomolar to
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effect on physiological parameters.
In order to reveal the structures of the hydroxylated products of
DOC, androstenedione, testosterone and DHEA, an E. coli based
whole-cell system was established to produce sufﬁcient amounts
for NMR-analysis. Adequate yields of products 1 and 2 of DOC and
androstenedione as well as of product 1 of DHEA and product 2 of
testosterone could be obtained. In addition to the previously
described 6b-hydroxylase activity of CYP11A1 towards DOC and
androstenedione using the recombinant CYP11A1 enzyme [36,54],
we identiﬁed a 2b-hydroxylation of both steroids. This suggests
that these substrates enter the active site in a reverse orientation
compared to cholesterol, suggesting that the previously described
complexation of cholesterol at the entrance of the active site via
hydrogen bonds is not necessary for these substrates [55].
Furthermore, testosterone and DHEA turned out to be new
substrates for CYP11A1 producing 6b-hydroxy-testosterone and
interestingly, 16b-hydroxy-DHEA, indicating that the presence of
the hydroxy group at C3 inﬂuences the orientation of the steroid
molecule in the active site of the enzyme.
In conclusion, the results from our in vitro experiments suggest
that CYP11A1 might play a more vital role in the metabolism of
steroids than previously assumed. For instance, the 6b-hydroxyl-
ation of testosterone has been ascribed mainly to CYP3A4 before
[56–59]. In addition, 16b-hydroxy-DHEA serves as a substrate for
human type I 3bHSD [60]. The resulting product, 16b-hydroxy-
androstenedione might be a potential inhibitor of 17b-HSD.
Furthermore, 16b-hydroxy-DHEA has been found to be a compo-
nent of plasma and urine of adult humans. Plasma 16b-hydroxy-
DHEA levels in normal subjects rise sharply during adolescence
and then decline slowly throughout adult life. It is inferred that
16b-hydroxy-DHEA is secreted directly by the adrenal cortex and
probably the gonads [61]. The functions of the other two new
products remain to be elucidated, although 4b-hydroxy-andro-
stenedione, with a structure closely similar to 2b-hydroxy-
androstenedione, has been described as a suicide inhibitor of
the aromatase CYP19A1 [62]. CYP19A1 is a target in anti-cancer
therapy, since a correlation between estrogens and breast cancer is
known and the development of speciﬁc inhibitors of CYP19A1 is of
great importance. For this reason, 2b-hydroxy-androstenedione
formation might be of particular interest and its potential ability to
act as inhibitor of CYP19A1 should be investigated, since
reasonable amounts of 2b-hydroxy-androstenedione can easily
be produced using our whole-cell system.
In summary, we hereby report that the sex hormones estrone
and estradiol directly stimulate the side-chain cleavage activity of
CYP11A1 at a molecular level. In addition, it was shown that DOC,
androstenedione, testosterone and DHEA are substrates of
CYP11A1. After establishing an efﬁcient whole-cell system for
CYP11A1-dependent substrate conversion, we were able to
identify novel 2b-hydroxylation activity towards DOC and
androstenedione and 16b-hydroxylation of DHEA as well as 6b-
hydroxylation of testosterone. Furthermore, we have demonstrat-
ed, for the ﬁrst time, the ability of a CYP11A1 whole-cell
biotransformation system to catalyze the hydroxylation reaction
of these steroids. Our results imply that the role of CYP11A1 in
steroid hormone biosynthesis might be broader than previously
known, and that the new hydroxylated products of CYP11A1 might
be useful to generate pharmaceutically interesting compounds.
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NMR DATA 
The NMR spectra analysis of the hydroxylated products (6β-hydroxy DOC, 2β-hydroxy DOC, 6β-hydroxy 
androstenedione, 2β-hydroxy androstenedione, 6β-hydroxy testosterone and 16β-hydroxy DHEA) were 
recorded in CDCl3 with a Bruker DRX 500 or a Bruker Avance 500 NMR spectrometer at 298 K. The 
chemical shifts were relative to CHCl3 at δ 7.26 (1H NMR) and CDCl3 at δ 77.00 (13C NMR), respectively, 
using the standard δ notation in parts per million. The 1D NMR (1H and 13C NMR, DEPT135) and the 2D 
NMR spectra (gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-HMBC) were recorded using the BRUKER 
pulse program library. All assignments based on extensive NMR spectral evidence. The obtained NMR data 
for the formed products are as follows: 
2β-hydroxy-11-deoxycorticosterone: 1H NMR (CDCl3, 500 MHz): δ 0.70 s (3xH-18), 1.07 m (H-7a), 1.18 s 
(3xH-19), 1.19 m (H-14), 1.33 m (H-15a), 1.39 m (H-12a), 1.44 m (H-9), 1.54 m (H-11a), 1.55 m (H-1a), 1.67 
m (H-8), 1.73 m (H-15b), 1.77 m (H-16a), 1.80 m (H-11b), 1.97 m (H-12b), 1.99 m (H-7b), 2.22 m (H-16b), 
2.26 m (H-6a), 2.46 m (H-1b), 2.47 m (H-17), 2.54 m (H-6b), 4.15 dd (8.5 and 5.5 Hz, H-2), 4.16 d (19.0 Hz, 
H-21a), 4.22 d (19.0 Hz, H-21b), 5.82 d (1.0 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 13.66 (CH3, C-18), 
22.79 (2C, CH2 and CH3, C-11 and C-19), 23.03 (CH2, C-16), 24.45 (CH2, C-15), 32.94 (CH2, C-6), 34.85 
(CH2, C-7), 35.76 (CH, C-8), 38.33 (CH2, C-12), 39.40 (CH2, C-1), 41.32 (C, C-10), 45.11 (C, C-13), 48.89 
(CH, C-9), 56.06 (CH, C-14), 58.94 (CH, C-17), 68.52 (CH, C-2), 69.38 (CH2, C-21), 118.87 (CH, C-4), 
174.51 (C, C-5), 199.57 (C, C-3), 210.03 (C, C-20). 
6β-hydroxy-11-deoxycorticosterone: 1H NMR (CDCl3, 500 MHz): δ 0.72 s (3xH-18), 0.96 ddd (12.2, 10.5 
and 4.2 Hz, H-9), 1.18 ddd (12.0, 11.0 and 7.0 Hz, H-14), 1.28 m (H-7a), 1.38 s (3xH-19), 1.39 m (H-12a), 
1.40 m (H-15a), 1.51 dddd (3x13.0 and 4.0 Hz, H-11a), 1.62 m (H-11b), 1.72 ddd (2x14.5 and 4.5 Hz, H-1a), 
1.78 m (H-15b), 1.79 m (H-16a), 1.97 ddd (13.0, 4.0 and 3.0 Hz, H-12b), 2.02 m (H-8), 2.03 m (H-7b), 2.05 m 
(H-1b), 2.25 m (H-16b), 2.40 dddd (17.0, 4.5, 2.7 and 1.0 Hz, H-2a), 2.47 dd (2x9.0 Hz, H-17), 2.51 ddd (17.0, 
15.0 and 5.0 Hz, H-2b), 4.17 d (19.0 Hz, H-21a), 4.22 d (19.0 Hz, H-21b), 4.36 dd (2x3.0 Hz, H-6), 5.83 d (1.0 
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Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 13.49 (CH3, C-18), 19.52 (CH3, C-19), 20.86 (CH2, C-11), 22.91 
(CH2, C-16), 24.42 (CH2, C-15), 29.37 (CH, C-8), 34.18 (CH2, C-2), 37.10 (CH2, C-1), 37.94 (C, C-10), 38.24 
(2C, 2xCH2, C-7 and C-12), 44.75 (C, C-13), 53.38 (CH, C-9), 56.06 (CH, C-14), 59.09 (CH, C-17), 69.37 
(CH2, C-21), 72.99 (CH, C-6), 126.49 (CH, C-4), 167.68 (C, C-5), 200.13 (C, C-3), 210.07 (C, C-20). 
2β-hydroxyandrost-4-ene-3,17-dione: 1H NMR (CDCl3, 500 MHz) : δ 0.92 s (3xH-18), 1.13 dddd (3x13.0 
and 4.5 Hz, H-7a), 1.21 s (3xH-19), 1.33 m (H-14), 1.34 m (H-12a), 1.47 ddd (12.5, 10.0 and 3.5 Hz, H-9), 
1.55 m (H-11a), 1.57 m (H-1a), 1.58 m (H-15a), 1.85 m (H-8), 1.89 m (2H, H-11b and H-12b), 1.94 m (H-15b), 
2.11 m (2H, H-7b and H-16a), 2.32 m (H-6a), 2.48 m (2H, H-1b and H-16b), 2.57 dddd (2x13.0, 5.0 and 1.5 
Hz, H-6b), 4.18 dd (8.5 and 5.5 Hz, H-2), 5.84 d (1.0 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 13.90 (CH3, C-
18), 21.76 (CH2, C-15), 22.14 (CH2, C-11), 22.76 (CH3, C-19), 31.23 (CH2, C-12) 32.72 (CH2, C-6), 33.66 
(CH2, C-7), 35.37 (CH, C-8), 35.73 (CH2, C-16), 39.40 (CH2, C-1), 41.36 (C, C-10), 47.96 (C, C-13), 50.14 
(CH, C-9), 50.79 (CH, C-14), 68.46 (CH, C-2), 119.02 (CH, C-4), 174.09 (C, C-5), 199.53 (C, C-3), 219.87 (C, 
C-17).  
6β-hydroxyandrost-4-ene-3,17-dione: 1H NMR (CDCl3, 500 MHz) : δ 0.95 s (3xH-18), 0.98 m (H-9), 1.30 m 
(H-12a), 1.31 m (H-14), 1.33 m (H-7a), 1.41 s (3xH-19), 1.53 m (H-11a), 1.62 m (H-15a), 1.70 m (H-11b), 1.73 
m (H-1a), 1.89 ddd (13.0, 4.0 and 2.8 Hz, H-12b), 2.00 m (H-15b), 2.06 m (H-1b), 2.10 m (H-16a), 2.15 m (H-
7b), 2.19 ddd (2x11.3 and 3.0 Hz, H-8), 2.41 m (H-2a), 2.50 m (H-16b), 2.51 ddd (17.0, 15.0 and 5.0 Hz, H-
2b), 4.41 dd (2x3.0 Hz, H-6), 5.84 d (1.0 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 13.76 (CH3, C-18), 19.55 
(CH3, C-19), 20.25 (CH2, C-11), 21.69 (CH2, C-15), 29.39 (CH, C-8), 31.25 (CH2, C-12), 34.16 (CH2, C-2), 
35.74 (CH2, C-16), 37.07 (CH2, C-1), 37.19 (CH2, C-7), 38.10 (C, C-10), 47.61 (C, C-13), 50.89 (CH, C-14), 
53.63 (CH, C-9), 72.82 (CH, C-6), 126.55 (CH, C-4), 167.61 (C, C-5), 200.11 (C, C-3), 220.44 (C, C-17).  
3β,16β-dihydroxyandrost-5-ene-17-one: 1H-NMR (CDCl3, 500 MHz): δ 0.89 s (3H, 3xH-18), 1.03 m (H-9), 
1.04 s (3H, 3x-H-19), 1.10 m (H-1a), 1.26 m (H-12a), 1.27 m (H-14), 1.52 m (H-11a), 1.53 m (H-2a), 1.54 m 
(H-15a), 1.65 m (H-7a), 1.68 m (H-8), 1.69 m (H-11b), 1.85 m (H-12b), 1.86 m (H-1b), 1.87 m (H-2b), 2.13 m 
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(H-7b), 2.25 m (H-4a), 2.33 m (H-4b), 2.38 m (H-15b), 3.54 m (H-3), 3.96 dd (2x8.7 Hz, H-16), 5.39 d (5.3 Hz, 
H-6). 13C-NMR (CDCl3, 125 MHz): δ 13.54 (CH3, C-18), 19.41 (CH3, C-19), 20.37 (CH2, C-11), 30.79 (CH2, 
C-15), 30.97 (CH2, C-7), 31.45 (CH2, C-12), 31.54 (CH, C-8), 31.58 (CH2, C-2), 36.65 (C, C-10), 37.11 (CH2, 
C-1), 42.18 (CH2, C-4), 46.01 (CH, C-14), 47.54 (C, C-13), 50.47 (CH, C-9), 71.58 (CH, C-3), 75.34 (CH, C-
16), 120.94 (CH, C-6), 141.01 (C, C-5), 221.14 (C, C-17).  
6β-hydroxytestosterone: 1H NMR (CDCl3, 500 MHz): δ 0.83 s (3xH-18), 0.91 ddd (12.0, 11.0 and 4.5 Hz, H-
9), 0.98 ddd (12.0, 11.0 and 7.0 Hz, H-14), 1.10 m (H-12a), 1.21 m (H-7a), 1.36 m (H-15a), 1.39 s (3xH-19), 
1.47 m (H-16a), 1.49 m (H-11a), 1.60 m (2H; H-11b and 15b), 1.70 ddd (2x14.3 and 4.5 Hz, H-1a), 1.88 ddd 
(13.0, 4.0 and 3.0 Hz, H-12b), 2.01 m (H-7b), 2.02 m (H-8), 2.05 m (H-1b), 2.09 m (H-16b), 2.40 dddd (17.0, 
4.5, 2.7 and 1.0 Hz, H-2a), 2.53 ddd (17.0, 15.0 and 5.0 Hz, H-2b), 3.66 dd (2x8.5 Hz, H-17), 4.36 dd (2x3.0 
Hz, H-6), 5.82 d (1.0 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 11.09 (CH3, C-18), 19.56 (CH3, C-19), 20.61 
(CH2, C-11), 23.30 (CH2, C-15), 29.79 (CH, C-8), 30.31 (CH2, C-16), 34.24 (CH2, C-2), 36.42 (CH2, C-12), 
37.16 (CH2, C-1), 38.04 (CH2, C-7), 38.05 (C, C-10), 42.92 (C, C-13), 50.49 (CH, C-14), 53.74 (CH, C-9), 
73.11 (CH, C-6), 81.70 (CH, C-17), 126.45 (CH, C-4), 168.05 (C, C-5), 200.23 (C, C-3).  
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Figure S1. In vitro conversion assay for the conversion of cholesterol by purified CYP11A1, using cortisol (F) 
as an internal standard (for the detection of cholesterol and pregnenolone at 240 nm, cholesterol and 
pregnenolone were converted to cholestenone and pregnenolone via an oxidase reaction using cholesterol-
oxidase). 
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Figure S2. HPLC chromatograms of the conversion of 300 µM steroid substrates by CYP11A1 in vitro 
conversion after 30 min. (A) 11-Deoxycorticosterone (DOC), (B) Androstenedione, (C) Testosterone, (D) 
DHEA. 
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Figure S3. Determination of the spectral shift for the titration of different concentrations of cholesterol (2, 4, 6, 
8, 10, 12, 14, 16, 18, 20, 22, 26, 30, 34, 38, 42, 52, 62, 82, 102, 122, 142, 162, 182 µM) in 2-hydroxypropyl-β-
cyclodextrin with 2 µM CYP11A1. The reaction was carried out using potassium phosphate buffer containing 
20% glycerol, 1% sodium cholate and 0.05% Tween-20. The inset shows the spectral shift induced by 
cholesterol binding to CYP11A1. 
 
 
 
 
 
 
 
 
 
8 
 
Figure S4. HPLC chromatograms for the negative control using E. coli C43(DE3) cells without plasmid in 
KPP buffer using 300 µM steroid substrates.(A) 11-Deoxycorticosterone (DOC), (B) Androstenedione, (C) 
Testosterone, (D) DHEA. 
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Regioselective Acetylation of C21 
Hydroxysteroids by the bacterial 
Chloramphenicol Acetyltransferase I 
 
Azzam Mosa,[a] Michael C. Hutter,[b] Josef Zapp,[c] Rita Bernhardt,[a] and Frank Hannemann*[a] 
 
The chloramphenicol acetyltransferase I (CATI) detoxifies the 
antibiotic chloramphenicol and confers a corresponding resistance to 
bacteria. In this study we identified this enzyme as a steroid 
acetyltransferase and designed a novel and efficient E. coli based 
biocatalyst for the regioselective acetylation of C21 hydroxyl groups in 
steroids of pharmaceutical interest. The cells carried a recombinant 
catI gene controlled by a constitutive promoter. The capacity of the 
whole-cell system to modify different hydroxysteroids was investigated 
and NMR spectroscopy revealed that all substrates were selectively 
transformed into the respective 21-acetoxy derivatives. The 
biotransformation was optimized and the reaction mechanism is 
discussed on the basis of a computational substrate docking into the 
crystal structure of CATI. 
Introduction 
Chloramphenicol (CAM), a broad-spectrum antibiotic, was first 
isolated in 1947 from the soil bacterium Streptomyces 
venezuelae.[1] In general, CAM inhibits protein biosynthesis by 
binding to the 50S subunit of the bacterial ribosome. Recently 
solved crystal structures of the Escherichia coli ribosome’s 50S 
subunit in complex with CAM revealed that CAM directly binds to 
the A-site of the 50S subunit and occupies the binding site for the 
aminoacyl moiety of the A-site tRNA.[2] 
Resistance to CAM was recognized in some bacteria, being 
provided by a chloramphenicol acetyltransferase [EC 2.3.1.28], 
which covalently modifies CAM by transferring the acetyl group of 
acetyl-CoA to one of the hydroxyl groups of CAM, thus preventing 
the antibiotic from binding to the ribosome.[3] The mechanism of 
CAM acetylation (Scheme 1A) involves the abstraction of a proton 
from the hydroxyl group in C-3 position of the CAM molecule, 
whereby the imidazole side chain of the catalytic histidine residue 
in CATI acts as base. Loss of the proton from the hydroxyl group 
facilitates the subsequent nucleophilic attack of the anion at the 
carbonyl group of the acetyl-CoA thioester and the transfer of the 
acetyl group. [4] 
 
Scheme 1. Proposed mechanism of the CATI-catalyzed acetylation of A) 
chloramphenicol according to Day and Shaw [4a] , B) steroids, showing cortisol 
as a model substrate. 
 
Various CAT enzymes have been isolated from bacterial strains, 
and in all cases the enzyme was identified as a homo-trimer, each 
subunit in the molecular weight range between 24 to 26 kD.[3a, 4a] 
CAT enzymes are divided into three classes: CATI, CATII, and 
CATIII, whereby the enzymes of all three classes catalyze the 
acetyl transfer to CAM yielding 3-O-acetyl-CAM.[4b, 5] Members of 
class I appear to be most prevalent and show a preference for 
binding various ligands. The substrate specificity of CATI includes 
perillyl alcohol (POH) in addition to CAM [6]. The enzyme also 
binds steroidal derivatives such as fusidic acid and bile salts, and 
has a high affinity for triphenylmethane dyes, such as crystal 
violet.[1a, 3b, 4b] Kinetic studies revealed that fusidic acid and bile 
salts bind to the active center of CATI, thus competing with CAM. 
This competitive inhibition could not be shown for other CAT 
types.[1a, 7] So far, neither the inhibitor fusidic acid nor other 
steroids have been reported to be acetylated in CATI reactions. 
Acetylation of hydroxyl groups in steroids has been carried out 
chemically to produce a wide range of steroid compounds. 
Depending on the reaction conditions, most of the hydroxyl 
groups commonly found in steroids, except the highly hindered 
tertiary 17α- and secondary 11β-hydroxyls, can undergo an 
acetylation reaction with acetic anhydride-pyridine mixtures, for 
example.[8].However, the chemical acetylation of steroids has 
disadvantages. Chemical compounds and solvents required for 
the reaction, such as acid anhydrides or chlorides and pyridine, 
are highly polluting.[9] Moreover, choosing a suitable mixture and 
amount of acetylating agents is a demanding task for the stereo- 
and regioselective preparation of steroid acetates because of the 
differences in the reactivity of the targeted reactive groups in 
steroid molecules.[8, 10] 
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As an alternative to chemical reactions, hydrolases from different 
sources were shown to be effective biocatalysts for the mild and 
selective acetylation for a series of steroids. The applied 
hydrolases modified hydroxyl groups either on the A- or D-ring or 
on the side-chain of steroids. P. cepacia lipase, for example, 
performed the regio- and stereoselective acylation of primary and 
secondary hydroxyl groups in positions 22, 25 or 26 of steroid 
side chains,[11] while C. viscosum lipase reacts exclusively with 
OH groups in the C-3 position and B. subtilis protease shows a 
marked preference for the OH in the C-17 position.[12] However, 
the acetylation of C21 hydroxyl groups by isolated enzymes has 
not been documented so far, although there are indications that 
microorganisms can perform this reaction.[13] 
We identified E.coli CATI as the first enzyme selectively 
performing this reaction, and developed a biotransformation in 
whole-cells, being prospectively competitive to chemical synthesis, 
and converted several synthetic and natural mineralo- and 
corticosteroids to their acetylated derivatives. Finally, we discuss 
potential pharmaceutical applications of the acetylated products. 
Results 
CATI-dependent whole-cell catalyst 
 
E.coli CATI was expressed in E. coli JM109(DE3) cells, which 
harbored the plasmid pTG10 encoding the catI gene under the 
control of its own constitutive promoter (Figure 1A). These cells 
were used as whole-cell biocatalyst for exploring the steroid 
substrate spectrum as well as for analyzing the products of the 
CATI dependent reactions. 
 
 
 
 
Figure 1. A) Plasmid map of pTG10 containing the catI gene, B) Coomassie-
Brilliant Blue stained polyacrylamide gel after SDS-PAGE of E. coli 
JM109(DE3)pTG10 samples. M indicates the lane containing the molecular 
weight marker; lanes 1, 2, 3, 4, 5 and 6 represent samples of whole cell lysates 
collected at 3, 6, 12, 24, 48 and 72 h after culture inoculation, respectively, C) 
Polyacrylamid gel of samples taken during the purification of CATI (Lane M: 
protein marker; lane 1: whole cell lysate of an BL21(DE3)pET22b-CatI 
expression culture; lane 2: eluted protein after IMAC). 
 
Steroid substrate spectrum of CATI  
In order to explore the substrate spectrum of CATI, a substrate 
screening with resting cells of JM109(DE3)pTG10 in Tris-HCl 
buffer was performed utilizing 18 different biologically active 
steroids. The steroids were representatives of the major classes 
of steroids: androgens, estrogens, glucocorticoids, 
mineralocorticoids and progestagens. Particular consideration 
was given to the fact that the selected steroids contain available 
OH groups at positions 3, 11, 16, 17 and 21 in order to analyze 
the regioselectivity of the CATI catalyzed acetylation. 
The HPLC analysis of reaction extracts showed that 6 steroids 
(11-deoxycorticosterone (DOC), cortisol (F), 11-deoxycortisol (S), 
aldosterone (ALDO), corticosterone (B) and prednisolone (PRL)) 
were new substrates of CATI (Figure 2). Each substrate was 
selectively converted to a product eluting at a higher retention 
time (13.48, 12.04, 12.95, 12.1, 13.0 and 12.33 min respectively). 
HPLC chromatograms of bioconversions performed with the other 
12 steroids (cholesterol, pregnenolone, progesterone, 
testosterone, 17α-hydroxypregnenolone, 17α–
hydroxyprogesterone, estrone, estriol, estradiol, adrenosterone, 
dehydroepiandrosterone and androstenedione) showed no 
apparent peak of a reaction product. 
 
Whole-cell conversion of CAM 
The activity of CATI toward chloramphenicol was analyzed at 
reaction conditions identical to that toward steroids. The HPLC 
separation of reaction extracts (Figure 2G) showed that 
chloramphenicol was converted to the expected acetylated 
products chloramphenicol-1-acetat (CAM-1-A), chloramphenicol-
3-acetat (CAM-3-A), and chloramphenicol-1, 3-diacetate (CAM-1, 
3-A)[1a], which was confirmed by comparing the retention time of 
the reference substances. The total amount of all three products 
was used to calculate a product concentration of 267 mg/L after 
30 min conversion time (Fig.3 D, light gray bar).  
 
Figure 2. HPLC chromatograms of steroid and CAM conversions. The dark gray 
and black lines represent reaction extracts of JM109(DE3) (negative control) 
and JM109(DE3)pTG10 cultures, respectively. Light gray lines show 
chromatograms derived from conversions with purified CAT. The indicated 
substrates and corresponding products are A) DOC and DOC-A (11-
deoxycorticosterone acetate), B) F and F-A (cortisol acetate), C) S and S-A (11-
deoxycortisol acetate), D) ALDO and ALDO-A (aldosterone acetate), E) B and 
B-A (corticosterone acetate), F) PRL and PRL-A (prednisolone acetate) and G) 
CAM and CAM-1-A, CAM-3-A, and CAM-1,3-A. 
 
Expression of CATI in JM109(DE3)pTG10 
In order to characterize the reaction products of CATI by NMR 
spectroscopy, a sufficient amount of the steroids had to be 
synthesized and purified. Therefore the bioconversion of the 
steroids was optimized by studying the effect of various 
parameters. These parameters included in the first series of 
experiments the time-dependent analysis of the CATI synthesis. 
The expression level of CATI was estimated by SDS-PAGE of 
samples taken at different time points from JM109(DE3)pTG10 
cultures grown in TB medium, whereas the maximum of CATI 
expression was observed 24 h after inoculation. The amount of 
CATI decreased after 48 h, indicating that the protein was 
degraded after prolonged expression time (Figure 1B). 
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Effect of media and buffer composition on steroid conversion 
In the second set of experiments, the effect of different media and 
buffers on the steroid conversion was investigated using DOC as 
representative. The substrate conversion was analyzed 24 h after 
feeding of 300 µM substrate. In case of bioconversions with 
growing cells, the product concentration was found to be higher 
when cells were cultivated in Enpresso tablet medium (50 ± 1.3 
mg L–1) than in TB medium (41 ± 3.5 mg L–1), whereas the 
conversion performed with resting cells proved to be best in Tris-
HCl (50 ± 1.4 mg L–1) buffered cell suspensions compared with 
HEPES (42 ± 2.0 mg L–1) or potassium phosphate buffer (43 ± 1.0 
mg L–1). The product concentration in Enpresso tablet medium 
and in Tris-HCl was similar but since the HPLC analysis of resting 
cell extracts showed a better separation of steroids and lower 
background, the following steroid conversions were performed 
using resting cells in Tris-HCl buffer. 
In order to analyze the conversion time, cells were incubated in 
TB medium, suspended in 50 mM Tris–HCl buffer (pH 7.4), 300 µM 
DOC and 100 mM glucose. Samples of the bioconversion were 
collected 24, 48, and 72 h after substrate feeding and subjected to 
HPLC analysis. The HPLC analysis revealed that the reactions in 
Tris-HCl buffer resulted in a substrate conversion of 48 ± 2.2, 56 ± 
1.9, and 58 ± 3.5 mg L–1, respectively. However, the product 
concentration increased between 24 h and 48 h and remained on 
that level until 72 h conversion time. Thus, 48 h conversion time 
was selected for subsequent experiments.  
 
Effect of glucose, substrate concentration and conversion 
time on steroid conversion 
In the third set of optimization experiments, the glucose 
concentration and substrate concentration were studied and the 
conversion time was verified applying the newly obtained 
conditions. To estimate the effect of the glucose concentration on 
the steroid conversion, the conversion mixture in Tris-HCl buffer 
was supplemented with 1 mM DOC and different glucose 
concentrations (50 – 1000 mM) and incubated for 48 h. The best 
product concentration (301.3 ± 0.9 mg L–1) was obtained in 
presence of 500 mM glucose (Figure 3A). Further increase of the 
glucose concentration to 600, 800, and 1000 mM in the conversion 
buffer decreased the product formation. 
The influence of the substrate concentration was analyzed using 
cells suspended in Tris-HCl buffer and 500 mM glucose, after 
feeding with different DOC concentrations (0.3, 0.4, 1, 1.5, 2.0, 
3.0, and 4.0 mM). The obtained data (Figure 3B) showed that the 
substrate was almost completely converted, if the suspensions 
contained 0.3 and 0.4 mM DOC, resulting in a product 
concentration of 95 ± 1.4 and 125 ± 3 mg L–1, respectively. In the 
cultures, which contained 1 mM DOC the product concentration 
reached the maximum value of 292 ± 2 mg L–1. We also observed 
that the product formation was lower in the presence of 1.5 and 
2.0 mM substrate and further decreased at substrate 
concentrations of 3.0 and 4.0 mM. 
The newly determined optimum conditions (24 h for protein 
expression, Tris-HCl buffer at pH 7.4, 500 mM glucose and 1 mM 
DOC) were applied to the whole-cell system and the optimum 
conversion time was reassessed. Samples were taken after 3, 6, 
12, 24, 48 and 72 h conversion time and subjected to HPLC 
analysis. It was verified that the whole-cell system produces the 
maximum product concentration after 48 h conversion time 
(Figure 3C). In the next set of conversion experiments, all six 
steroid substrates identified in the substrate screening were 
added under optimum conditions obtained for DOC reactions. The 
bioconversions of DOC, F, S, ALDO, B and PRL resulted in a 
single reaction product. In each case, the concentration for the 
different steroid derivatives considerably varies between 89 ± 1.4 
and 298 ± 4 mg L–1 for the substrates PRL and DOC, respectively 
(Figure 3D). 
Since the DOC conversions shown in Figure 3C indicated that the 
catalytic activity of the system is changing with the time, further 
experiments were performed to characterize the initial rate of the 
CATI catalyzed reactions for all tested steroids at three different 
substrate concentrations. The product concentration increased in 
all cases in a linear manner in the analyzed time period of 6 h 
(Figure 4). The values of the initial catalytic activity of the whole-
cell catalyst was, as expected, substrate concentration-dependent 
and reached values of 5.4 ± 0.1, 4.7 ± 0.05, 4.3 ± 0.08, 3.1 ± 0.01, 
2.7 ± 0.05 and 2.7 ± 0.05 mg L–1 h–1 for the steroids DOC, F, S, 
ALDO, B and PRL, respectively, at a substrate concentration of 1 
mM (Table 1). 
 
 
Figure 3. Product formation of whole-cell conversions using E. coli 
JM109(DE3)pTG10, A) in Tris-HCl buffer supplemented with 1 mM DOC and 
different concentrations of glucose after 48 h reaction time, B) in Tris-HCl buffer, 
500 mM glucose and different concentrations of DOC after 48 h reaction time, C) 
in Tris-HCl buffer (50 mM, pH 7.4), 500 mM glucose and 1 mM DOC at different 
conversion times, and D) Product concentration after conversion of various 
steroids by the whole-cell biocatalyst in Tris-HCl buffer (50 mM, pH 7.4), 500 mM 
glucose, 1 mM steroid substrate after 48 h conversion time (dark gray bars) and 
1 mM CAM after 30 min conversion time (light gray bar). The product 
concentration of CAM conversion represents the total amount of acetylated 
product. The standard deviation of each bar was calculated for three replicate 
experiments. 
 
Table 1. Initial catalytic activity of CATI-catalyzed steroid bioconversions at 
different substrate concentrations. Values were calculated from a linear 
regression of the substrate concentration against the time shown in Figure 4. 
 
Substrates Catalytic activity in mg L–1 h–1 
0.2 mM 0.6 mM 1.0 mM 
DOC 2.4 ± 0.06 3.2 ± 0.06 5.4 ± 0.1 
F 2.0 ± 0.06 2.8 ± 0.06 4.7 ± 0.05 
S 2.4 ± 0.03 3.2 ± 0.06 4.3 ± 0.08 
ALDO 1.4 ± 0.02 2.1 ± 0.03 3.1 ± 0.01 
B 1.2 ± 0.01 2.2 ± 0.04 2.7 ± 0.05 
PRL 1.5 ± 0.03 2.3 ± 0.03 2.7 ± 0.05 
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Figure 4. Product formation measured in the initial 6 h of the bioconversions. 
The slope of the linear regression lines represents the initial catalytic activity of 
the whole-cell catalyst for different steroids at the substrate concentrations 0.2 
mM (), 0.6 mM (), and 1 mM (). A) DOC, B) F, C) S, D) ALDO, E) B and F) 
PRL. 
 
A sufficient amount of DOC-A, F-A, S-A, ALDO-A, B-A, and PRL-
A products was produced by whole-cell biotransformation in a 
culture volume of 200 mL followed by preparative purification 
yielding 20.4 mg, 20.2 mg, 17.3 mg, 14.6 mg, 13.3 mg, and 13.4 
mg, respectively. A detailed H1 and C13 NMR spectroscopy 
identified the products all being acetylated at the C21 OH function. 
The structures of substrates and products are summarized in 
Scheme 2.  
  
 
Scheme 2. Reaction equations showing the CATI-catalyzed conversions of 
C21-OH steroids to the corresponding acetoxy steroids. 
 
Activity determination of purified CATI 
In order to show that the acetylation activity of the whole-cell 
catalyst is dependent on the catI gene and that acetyl CoA is 
employed in that reaction as an acyl donor, we constructed an 
expression plasmid containing a gene coding for a His6-tagged 
CATI. The gene was successfully expressed in E. coli and the 
protein was purified to homogeneity by IMAC. A single 
polypeptide band on an SDS-PAGE gel stained with Coomassie 
blue was taken as indication of a pure protein (Figure 1C). 
Substrate conversions of CAM or steroids in absence of acetyl-
CoA failed (data not shown), whereas conversions in presence of 
the co-substrate resulted in the same reaction products as in the 
whole-cell conversions (Figure 2), which clearly indicates that the 
acetylation of CAM as well as steroids is catalyzed by CATI and 
that the transfer of acetyl groups by CATI is conducted by acetyl-
CoA in both cases. 
 
Substrate docking  
To obtain a deeper insight into the structural basis of the substrate 
binding to the active site of CATI and the selectivity of steroid 
acetylation, we performed molecular docking of the substrates 
and of fusidic acid as control.  
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Except for DOC and S all of the steroids used for docking (DOC, 
F, S, ALDO, B, and PRL) had their energetically most preferred 
binding pose showing hydrogen-bonding between their C21-OH 
group and Nε of His193, as well as between their C11-OH group 
and the side chain of Tyr133 (Figure 5). 
 
 
 
Figure 5. The energetically most preferred docking position found for cortisol 
(grey) shows hydrogen-bonding (blue lines) between the C21-OH group and 
His193, as well as between Tyr133 and the 11-OH group and the 20-carbonyl 
group. Phe166 is a close hydrophobic contact. Cyan: chain A, pink: chain B of 
1Q23.pdb. 
 
The obtained position for fusidic acid was found to be almost 
identical to that in the X-ray structure (1Q23.pdb, Figure 6). Since 
the conformations of the ring systems of fusidic acid given in the 
crystallographic data are almost planar, they deviate from the 
force field optimized geometry used for docking, whereas the 
overall orientation is preserved. 
 
 
 
Figure 6. Overlay of fusidic acid (orange) and chloramphenicol (brown) as 
present in the crystallographic structures 1Q23.pdb and 3U9F.pdb, respectively. 
Nitrogen, oxygen and chlorine atoms are show in their respective CPK colors. 
Like for the steroid substrates, hydrogen-bonds to His193 and Tyr133 are 
realized, whereas the terminal sites of fusidic acid are solvent exposed. 
Compared to chloramphenicol, fusidic acid also occupies a much larger part of 
the binding pocket. 
Discussion 
Biocatalysts are applied for biotechnological conversions because 
of lower costs, less time consumption and less polluting 
processes compared to chemical reactions.[14] They are often 
used to convert the substrate in a one-step reaction to the desired 
product. Specifically in the steroid field, enzyme catalysis provides 
an alternative tool for the mild conversion of functional groups via 
regio- and stereoselective transformations of synthetic and related 
natural compounds.[15] 
In our study, we identified the bacterial CATI as acetyltransferase 
for steroids and, for the first time, showed its ability to acetylate 
the 21-OH group of several steroids selectively in vitro and in a 
recombinant whole-cell biocatalyst. So far, only a few 
microorganisms including some fungal species[13b, 13c] and the 
bacterium Clostridium sporogenes,[13a] revealed the ability to 
acetylate the C21-hydroxyl function of steroids. Both, the 
enzymes conferring the acetylation activity and the corresponding 
genes are unknown, so far. The bacterium C. sporogenes has 
never been applied for whole-cell bioconversions of steroids 
because in addition to the acetylation activity the strain shows 
strong hydrolysis activity of steroid C21 acetates. Although 
different hydrolases were employed for the acetylation of steroids 
as described, [9b, 11-12, 15-16] however an enzyme capable of C21 
hydroxyl acetylation has not been characterized. 
The new whole-cell biocatalyst based on the E. coli enzyme CATI 
was successfully applied in our study to convert CAM and the 
steroids DOC, F, S, ALDO, B and PRL, respectively. The 
conditions for the bioconversion were optimized in shake flask 
cultures resulting in yields of 267 ± 4.2, 298 ± 4, 272 ± 6.2, 156 ± 
10, 129 ± 8.1, 93 ± 2 and 89 ± 1.4 mg L–1, which represent 
promising starting values for developing a bioconversion process 
in fermenter cultures and following industrial scale-up. Besides 
improving substrate concentration, expression and reaction time, 
the variation of the glucose concentration during the steroid 
conversion turned out to have a strong influence on the catalytic 
activity; because the substrate conversion was significantly 
improved in response to increased glucose concentration. The 
best product concentration was obtained after increasing the 
glucose concentration up to a critical value of 500 mM (Figure 3A). 
This effect is probably due to a higher concentration of the 
essential reaction cofactor acetyl-CoA. It was described before 
that glucose availability is linked to acetyl-CoA production in yeast 
and in E. coli and that the acetyl-CoA levels are consistently high 
when glucose concentration is abundant.[17] We noticed a 
decreased product formation upon increasing concentrations of 
glucose beyond the critical value of 500 mM (600, 800, and 1000 
mM). This might be caused by a metabolic overflow leading to the 
acidification of the buffer solution during the maintenance of 
bacteria under aerobic conditions when the glucose uptake 
overrides a critical value.[18] 
All reaction products obtained with the six steroid substrates were 
isolated and NMR analysis clearly demonstrated that only the 21-
OH group was acetylated whereas other hydroxyl groups present 
in the converted steroids (11β-OH and 17α-OH), as well as other 
functional groups like the carbonyl groups at positions 3, 18, 20 
and the double bonds at positions 1, 2 and 4, 5 were not modified. 
This can be attributed to the fact that position 21 has less steric 
constraints compared to OH-groups for example in positions 11 
and 17, because it is separated from the steroid skeleton by a 
rotatable bond. In addition, due to the carbonyl group at the 
adjacent C20 position in the analyzed steroids, the 21-OH group 
becomes more acidic compared to OH-groups in other positions 
and can, thus, form an effective nucleophile for the subsequent 
attack at the carbonyl group of the acetyl-CoA more easily.  
We suggest that the acetylation mechanism of steroids is similar 
to that proposed for CAM. This mechanism involves His193, 
which has been demonstrated to be one of the primary conserved 
catalytic residues to change its protonation pattern. The 
conformation of the protein ensures that the imidazole ring of 
His193 is aligned appropriately to deprotonate the 3-hydroxyl 
group of chloramphenicol, promoting a nucleophilic attack of 
acetyl-CoA to yield acetylated chloramphenicol and CoA-SH 
(Scheme 1A).[1b, 4a] In case of the acetylation of the C21 hydroxyl 
group of steroids the proposed reaction mechanism requires the 
His193 imidazole side chain to abstract a proton from the C21-
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hydroxyl group of steroid compounds, thus facilitating the 
nucleophile formation. The subsequent attack at the acetyl-CoA-
thioester bond would then produce acetoxy steroids and CoA-SH 
(Scheme 1B). 
Additional support for a similar reaction mechanism for CAM and 
steroid substrates was provided in a study describing the crystal 
structure of CATI in complex with the steroidal antibacterial fusidic 
acid.[1b] In the CATI-fusidic acid complex, fusidic acid occupies the 
same binding site as CAM and its hydrophobic steroid ring system 
forms numerous hydrophobic contacts with active site residues, 
which explains the observed characteristic of fusidic acid as a 
competitive inhibitor of CATI (Figure 6). Also, the hydroxyl moiety 
of ring A of fusidic acid closely aligns with the 3-hydroxyl of CAM 
and forms a very strong hydrogen bond with the active site 
residue His 193. The side chains of Ala24 and Ala29 of CATI can 
accommodate the ring D and the 2-methylhex-2-ene tail of fusidic 
acid by providing a substrate binding cavity. The similarity in the 
steroid backbone of fusidic acid and C21-OH-steroids led us to 
assume that CATI binds both substrate types in a similar manner, 
and we decided to prove that hypothesis by molecular docking 
experiments. 
The docking results corroborate the substrate binding and the 
proposed mechanism, showing the 21-OH group hydrogen-
bonded to Ne of His193 (Figure 5). Where present in the steroids, 
also a hydrogen-bond between the 11-OH group and the side 
chain of Tyr133 is established. The same kind of interactions was 
also found between fusidic acid and the active site of CATI when 
fusidic acid was applied in a docking control, which is in excellent 
agreement with the X-ray crystallographic data. The absence of 
the 11-OH group in DOC and S is most likely the reason why we 
did not obtain corresponding docking positions for these two 
molecules, although they were found to be acetylated in position 
21 as well. Since all residues were kept fixed during docking, we 
therefore assume that the side chain of Tyr133 undergoes a 
conformational change to form an alternative hydrogen-bond with 
another residue, when either DOC or S is bound to CATI. 
Steroid acetates are used as pharmaceuticals and administered 
either orally, parenterally, or topically depending on the disease 
and the desired duration and effect of medication. The 
corticosteroid products of the new biocatalyst, DOC-A, F-A, S-A, 
and PRL-A respectively, are active pharmaceutical ingredients 
themselves or are important intermediates in pharmaceutical 
synthesis. DOC-A was used as an effective drug for treating 
adrenal insufficiency and Addison's disease in former days.[19] It 
has also been reported to regulate the salt appetite in brain of 
experimental animals,[20] and when it is administered together with 
sodium chloride to rats, the resulting DOC-A salt hypertensive rats 
represent an animal model of oxidative and inflammatory stress 
and can be applied to study hypertension and related diseases of 
the cardiovascular system.[21] S-A was not described as drug but it 
was used as substrate for the preparation of the effective 
corticosteroid drugs cortisol and cortisol-21-acetate. [14b, 22] F-A in 
turn was applied as an important intermediate for the synthesis of 
steroidal drugs such as triamcinolone acetonide[14b, 23] and, above 
all, it is known as drug to treat joint problems (e.g., arthritis, 
bursitis) and skin conditions (e.g. eczema, dermatitis, rash, and 
allergies). Less well-known is the application of F-A as drug in 
replacement therapies in adrenocortical insufficiency. PRL-A has, 
similar to F-A, a pronounced immune suppressive and also 
inflammatory and anti-allergic effect and is one of the most 
commonly used drugs for the treatment of corresponding 
diseases. 
Conclusions 
In our study, we discovered that CATI regioselectively acetylates 
the C21-OH group of steroids. A reaction mechanism similar to 
that for the natural substrate CAM was proposed based on 
molecular docking experiments. We established a whole-cell 
biotransformation using E. coli as host and demonstrated the 
biosynthesis of pharmaceutical important acetoxy steroids. The 
results lead us to expect that the new biocatalyst is competitive to 
chemical acetylation reactions and should be considered as an 
alternative approach for the industrial production of acetylated 
steroids. 
Experimental Section 
Chemicals 
Steroids, solvents, media and other chemicals used were of analytical 
grade. Stock solutions of steroids were dissolved in dimethylsulfoxide 
(DMSO). 
 
Bacterial strains and plasmids 
E. coli strain JM109(DE3) was applied as host for whole-cell conversions. 
JM109(DE3) cells were transformed with the vector pTG10 (Figure 1A) [24] 
carrying the chloramphenicol acetyltransferase gene as a resistance 
marker resulting in the strain JM109(DE3)pTG10. E. coli strain BL21(DE3) 
containing the plasmid pET22b-CatI was used as host for the expression 
and purification of CATI. 
 
Purification of CATI 
A PCR fragment encoding a His6-tagged CATI was amplified using plasmid 
pTG10 as template and inserted between the NdeI and XhoI sites of 
plasmid pET22b. E. coli strain BL21(DE3) was transformed with the 
resulting vector pET22b-CatI and cultures were grown to an optical density 
of 0.4 at 600 nm in 200 mL LB medium. The synthesis of the protein was 
induced by adding 1 mM isopropyl-β-D-1-thiogalactopyranoside. Cells were 
harvested after additional 3 h by centrifugation and suspended in 
potassium phosphate buffer (50 mM, pH 7.8) containing glycerol (10 %), 
sodium chloride (200 mM), β-mercaptoethanol (2 mM) and 
ethylenediaminetetraacetic acid (EDTA) (0.1 mM). Cells were disrupted by 
sonication on ice and the supernatant after centrifugation (4 °C, 70,500 g 
for 30 min) was used for protein purification by immobilized metal affinity 
chromatography (IMAC) on a Ni–NTA agarose column. CATI was eluted 
by potassium phosphate buffer (50 mM, pH 7.8) containing imidazole (250 
mM), sodium chloride (200 mM) and glycerol (10 %). After buffer exchange 
to potassium phosphate (50 mM, pH 7.8), glycerol (10 %) and sodium 
chloride (200 mM) the protein was concentrated to ~10 mg mL–1using 
centrifugal filter units and stored at -80 °C until use. The protein 
concentration was determined by the bicinchoninic acid assay using bovine 
serum albumin as a standard. 
 
Activity determination of purified CATI  
 
In order to determine the activity of purified CATI, substrate conversions 
were performed in a final volume of 1 mL Tris-HCl buffer (100 mM, pH 7.8) 
containing 0.2 mM of the co-substrate acetyl Coenzyme A and 200 µM of 
the substrate dissolved in DMSO. The reaction was initiated by the addition 
of 4 µM CATI, incubated at 37°C for 1h (steroids) or 5 min (CAM), and 
terminated by extracting the sample twice with an equal volume of ethyl 
acetate. The organic layer was isolated and completely evaporated prior to 
RP-HPLC analysis. 
 
Steroid conversion with growing cells in TB medium 
TB medium (30 mL) supplemented with chloramphenicol (25 µg mL–1) was 
inoculated with a JM109(DE3)pTG10 seed culture (0.3 mL) and incubated 
in a 300 mL baffled flask at 37 °C with shaking at 180 rpm. When the 
optical density at 600 nm of the main culture reached a value between 0.4 
- 0.6, the substrate (300 µM) was added and the cells were incubated for 
additional 24 h at the same temperature and shaking speed. The product 
formation was monitored by taking 1 mL samples 24 h after substrate 
feeding. In this study the following substrates were tested: cholesterol, 
pregnenolone, progesterone, testosterone, 17α-hydroxypregnenolone, 
17α–hydroxyprogesterone, estrone, estriol, estradiol, cortisol, 
dehydroepiandrosterone, adrenosterone, 11-deoxycorticosterone, 
aldosterone, prednisolone, androstenedione, corticosterone and 11-
deoxycortisol. 
 
Steroid conversion with resting cells in buffer 
 
JM109(DE3)pTG10 cultures were grown for 24 h at 37 °C with 180 rpm in 
300 mL baffled flasks containing TB medium (30 mL) supplemented with 
chloramphenicol (25 µg mL–1). Cells were then harvested by centrifugation 
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(20 min, 4000 g, 4 °C) and the pellet was washed once with 30 mL of 50 
mM buffer (pH 7.4) (Tris-HCl, HEPES or potassium phosphate (KPP)) and 
centrifuged again for 20 min. After suspending the pellet in buffer (30 mL, 
50 mM, pH 7.4) containing different concentrations of glucose and 
substrate, the suspensions were further incubated at 180 rpm and 37 °C. 
Further, time and concentration depending experiments using resting cells 
in Tris-HCl buffer (50 mM, pH 7.4, 500 mM glucose) were performed to 
determine the initial catalytic activity. Substrate concentration studies were 
carried out using substrate concentrations of 0.2, 0.6 and 1.0 mM. In time 
course experiments, incubations were carried out for 0, 1, 2, 4, and 6 h.  
 
Steroid conversion in an EnPressoTM Tablet Cultivation set  
In order to perform the steroid conversion in a medium based on 
EnPressoTM tablets (BioSilta), the medium (50 mL) was prepared as 
described by the manufacturer and was inoculated with the seed culture of 
E. coli JM109(DE3) (2 mL) cells and incubated at 37 °C and 180 rpm. The 
substrate (300 µM) was added after 4 - 5 h simultaneously with the booster 
tablet, and the culture was further incubated at 30 °C and 180 rpm. 
 
SDS-polyacrylamide gel electrophoresis 
To determine the time period with the highest CATI expression level, 
cultures inoculated with a seed culture (0.3 mL) of E. coli 
JM109(DE3)pTG10 and grown at 37 °C and 180 rpm in TB medium (30 
mL) supplemented with chloramphenicol (25 µg mL–1). Samples were 
collected at different time points (3, 6, 12, 24, 48 and 72 h), cells were 
pelleted and suspended in SDS loading buffer and SDS-polyacrylamide gel 
electrophoresis was performed (Figure 1B). 
To determine the purity of the CATI preparation, samples taken from an 
expression culture of BL21(DE3)pET22b-CatI and after the IMAC 
purification were separated by SDS-PAGE (Figure 1C). 
 
Substrate extraction and analytic HPLC  
Samples (1 mL) of the steroid or CAM conversions were extracted twice 
with ethyl acetate (1 mL). The organic phase was evaporated under 
vacuum. The residuum of steroid extracts was dissolved in a small amount 
of the mobile phase (20 % acetonitrile) for subsequent isocratic HPLC 
using a Jasco system of the 2000 series with a 4.0 mm x 125 mm 
Nucleodur C18ec RP column (Macherey-Nagel). The flow rate was 1 mL 
min–1 at 40 °C and steroids were detected at 240 nm. The residuum of 
CAM extracts was dissolved in 10 % ACN and analyzed using a gradient 
elution of acetonitrile 10-100 % containing 0.1 % trifluoroacetic acid from 0-
18 min. The UV detection was monitored at 259 nm. 
 
Preparative purification of steroids for NMR analysis 
After optimizing the conditions for the whole cell biotransformation of 
steroids on an analytical scale, the procedure was applied for the 
preparative purification of the products for NMR spectroscopy. 200 mL of 
Terrific broth (TB) medium containing chloramphenicol (25 µg mL–1) was 
inoculated with a JM109(DE3)pTG10 seed culture (2 mL) and cultivated for 
24 h at 37 °C with rotary shaking at 180 rpm. Cells were harvested by 
centrifugation (4000 g, 20 min, 4 °C) and washed once with Tris–HCl buffer 
(200 mL, 50 mM, pH 7.4). After a second centrifugation cell pellets were 
suspended in Tris–HCl buffer (200 mL, 50 mM, pH 7.4) complemented with 
glucose (500 mM). The substrate (400 µM) was added and the culture was 
incubated for another 48 h at 37 °C and 180 rpm. Steroids were extracted 
twice using ethyl acetate (200 mL) and the organic layer was transferred to 
a 1 L round bottom flask for subsequent rotary evaporation. Steroids were 
separated by reversed phase HPLC on a C18ec column (Nucleodur 250/8, 
Macherey-Nagel) with a mobile phase consisting of 20% ACN. The fraction 
containing the product was collected and subjected to subsequent NMR 
analysis. 
 
NMR analysis 
The NMR spectra of 11-deoxycorticosterone-21-acetate (DOC-A), cortisol-
21-acetate (F-A), 11-deoxycortisol-21-acetate (S-A), aldosterone-21-
acetate (ALDO-A), corticosterone-21-acetate (B-A) and prednisolone-21-
acetate (PRL-A) were recorded in CDCl3 or CD3OD with a Bruker DRX 500 
or a Bruker Avance 500 NMR spectrometer at 300 K. The chemical shifts 
were relative to CHCl3 at δ 7.26 or CH3OD at δ 3.30 (1H NMR) and CDCl3 
at δ 77.00 or CD3OD at δ 49.00 (13C NMR), respectively, using the 
standard δ notation in parts per million. The 1D NMR (1H and 13C NMR, 
DEPT135) and the 2D NMR spectra (gs-HH-COSY, gs-NOESY, gs-
HSQCED, and gs-HMBC) were recorded using the BRUKER pulse 
program library. All assignments based on extensive NMR spectral 
evidence. The obtained NMR data for the steroid acetates are as follows: 
 
11-Deoxycorticosterone-21-acetate:1H NMR (CDCl3, 500 MHz): δ 0.71 s 
(3xH-18), 0.98 m (H-9), 1.07 m (H-7a), 1.18 ddd (12.7, 11.0 and 7.0 Hz, H-
14), 1.19 s (3xH-19), 1.33 m (H-15a), 1.39 m (H-12a), 1.48 dddd (3x13.0 
and 4.0 Hz, H-11a), 1.58 m (H-8), 1.64 m (H-11b), 1.71 m (H-1a), 1.73 m 
(H-16a), 1.74 m (H-15b), 1.86 m (H-7b), 2.04 ddd (13.5, 5.0 and 3.2 Hz, H-
1b), 2.09 m (H-12b), 2.17 s (3H, 21-OAc), 2.23 m (H-16b), 2.28 m (H-6a), 
2.33 m (H-2a), 2.39 m (H-6b), 2.40 ddd (17.0, 15.0 and 5.0 Hz, H-2b), 2.51 
dd (2x9.0 Hz, H-17), 4.52 d (17.0 Hz, H-21a), 4.72 d (17.0 Hz, H-21b), 5.74 
brs (H-4). 13C NMR (CDCl3, 125 MHz): δ 13.18 (CH3, C-18), 19.50 (CH3, C-
19), 20.97 (CH3, 21-OAc), 22.69 (CH2, C-11), 22.83 (CH2, C-16), 24.46 
(CH2, C-15), 31.87 (CH2, C-7), 32.73 (CH2, C-6), 33.93 (CH2, C-2), 35.53 
(CH, C-8), 35.70 (CH2, C-1), 38.33 (CH2, C-12), 38.55 (C, C-10), 44.65 (C, 
C-13), 53.56 (CH, C-9), 56.17 (CH, C-14), 59.07 (CH, C-17), 69.13 (CH2, 
C-21), 123.97 (CH, C-4), 170.32 (C, C-5), 170.81 (C, 21-OAc), 199.48 (C, 
C-3), 203.62 (C, C-20). 
 
Cortisol-21-acetate:1H NMR (CD3OD, 500 MHz) : δ 0.90 s (3xH-18), 1.02 
dd (11.2 and 3.5 Hz, H-9), 1.13 m (H-7a), 1.41 m (H-15a), 1.48 s (3xH-19), 
1.49 m (H-16a), 1.79 m (-15b), 1.80 m (H-12a), 1.89 ddd (2x13.5 and 4.5 
Hz, H-1a), 2.05 m (H-7b), 2.07 m (H-12b), 2.09 m (H-8), 2.14 s (3H, 21-
OAc), 2.24 ddd (13.5 and 2x4.8 Hz, H-1b), 2.28 m (H-6a), 2.33 ddd(17.0 
and 2x4.3 Hz, H-2a), 2.51 ddd (17.0, 13.7 and 5.0 Hz, H-2b), 2.57 dddd 
(2x14.5, 5.0 and 1.5 Hz, H-6b), 2.68 ddd (15.0, 11.5 and 3.0 Hz, H-16b), 
4.42 ddd (3x3.3 Hz, H-11), 4.92 d (17.5 Hz, H-21a), 5.07 d (17.5 Hz, H-
21b), 5.67 d (1.5 Hz, H-4). 13C NMR(CD3OD, 125 MHz): δ 17.39 (CH3, C-
18), 20.47 (CH3, 21-OAc), 21.45 (CH3, C-19), 24.60 (CH2, C-15), 32.87 
(CH, C-8), 33.30 (CH2, C-6), 34.32 (CH2, C-7), 34.62 (CH2, C-2), 34.71 
(CH2, C-16), 35.87 (CH2, C-1), 40.49 (CH2, C-12), 40.73 (C, C-10), 48.59 
(C, C-13), 53.45 (CH, C-14), 57.64 (CH, C-9), 68.74 (CH2, C-11), 69.29 
(CH2, C-21), 90.60 (C, C-17), 122.50 (CH, C-4), 172.34 (C, 21-OAc) , 
176.63 (C, C-5), 202.51 (C, C-3), 207.33 (C, C-20). 
 
11-Deoxycortisol-21-acetate:1H NMR (CDCl3, 500 MHz) : δ 0.73 s (3xH-
18), 0.98 ddd (12.2, 10.5 and 4.0 Hz, H-9), 1.10 dddd (13.5, 12.5, 11.5 and 
4.5 Hz, H-7a), 1.19 s (3xH-19), 1.37 m (H-15a), 1.46 dddd (3x13.5 and 4.5 
Hz, H-11a), 1.52 ddd (15.0, 9.0 and 6.0 Hz, H-16a), 1.63 m (H-8), 1.65 m 
(H-12a), 1.66 m (H-11b), 1.71 m (H-1a), 1.73 m (1.79 m (H-12b), -15b), 
1.87 m (H-7b), 2.04 ddd (13.5, 5.0 and 3.2 Hz, H-1b), 2.17 s (3H, 21-OAc), 
2.29 m (H-6a), 2.36 m (H-2a), 2.41 m (H-6b), 2.43 m (H-2b), 2.74 ddd 
(15.0, 11.5 and 3.0 Hz, H-16b), 4.85 d (17.5 Hz, H-21a), 5.07 d (17.5 Hz, 
H-21b), 5.74 d (1.5 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 14.77 (CH3, C-
18), 17.62 (CH3, C-19), 20.78 (CH3, 21-OAc), 20.86 (CH2, C-11), 23.85 
(CH2, C-15), 30.27 (CH2, C-12), 32.26 (CH2, C-7), 33.02 (CH2, C-6), 34.16 
(CH2, C-2), 35.08 (CH2, C-16), 35.88 (CH, C-8), 35.95 (CH2, C-1), 38.81 (C, 
C-10), 48.53 (C, C-13), 50.71 (CH, C-14), 53.54 (CH, C-9), 68.15 (CH2, C-
21), 90.22 (C, C-17), 124.19 (CH, C-4), 170.88 (C, 21-OAc), 171.22 (C, C-
5), 194.83 (C, C-3), 205.36 (CH, C-20). 
 
Aldosterone-21-acetate: According to literature,[25] this acetate exists in 
two tautomeric forms as (11-18) hemi-acetal and (18-20) hemi-ketal. In 
CDCl3 the (18-20) hemi-ketal tautomer dominates as shown in the following 
data. 1H NMR (CDCl3, 500 MHz) : δ 1.07 m (H-9), 1.25 m (H-7a), 1.32 s 
(3xH-19), 1.46 m (H-15a), 1.48 m (H-12a), 1.49 m (1.64 m (H-16a), 1.72 
ddd (2x 14.8 and 4.5 Hz, H-1a), 1.77 m (H-8), -15b), 2.04 m (H-7b), 2.13 s 
(3H, 21-OAc), 2.18 m (H-1b), 2.23 m ( H-16b), 2.32 m (H-6a), 2.37 m (H-
12b), 2.39 ddd(17.0 and 2x3.5 Hz, H-2a), 2.46 m (H-6b), 2.47 brd (10.0 Hz, 
H-17), 2.52 ddd (17.0, 15.0 and 5.0 Hz, H-2b), 4.02 d (11.3 Hz, H-21a), 
4.19 d (11.3 Hz, H-21b), 4.86 m (H-11), 5.45 brs(H-18), 5.74 brs (H-4). 13C 
NMR (CDCl3, 125 MHz): δ 18.42 (CH3, C-19), 20.79 (CH3, 21-OAc), 25.77 
(CH2, C-16), 29.85 (CH2, C-15), 31.95 (CH2, C-7), 32.89 (CH2, C-6), 33.63 
(CH2, C-2), 36.02 (CH2, C-1), 38.17 (CH, C-8), 38.97 (C, C-10), 40.20 
(CH2,C-12), 47.85 (CH, C-17), 48.75 (CH, C-14), 57.16 (CH, C-9), 64.18 
(C, C-13), 69.21 (CH2, C-21), 81.61 (C, C-11), 104.88 (C, C-20), 106.72 
(CH, C-18), 124.33 (CH, C-4), 169.79 (C, C-5), 170.80 (C, 21-OAc), 
199.24 (C, C-3). 
 
Corticosterone-21-acetate:1H NMR (CDCl3, 500 MHz): δ 0.93 s (3xH-18), 
0.98 dd (11.5 and 3.0 Hz, H-9), 1.07 m (H-7a), 1.12 m (1.39 m (H-15a), 
1.43 s (3xH-19), 1.60 m (H-12a), -15b), 1.83 m (H-1a), 1.99 m (2H, H-7b 
and H-8), 2.15 s (3H, 21-OAc), 2.18 m (H-1b), 2.19 m (2H, H-12b and H-
16b), 2.28 m (H-6a), 2.33 m (H-2a), 2.40 m (H-6b), 2.41 m (H-17),2.47 m 
(H-2b), 4.39 m (H-11), 4.48 d (17.0 Hz, H-21a), 4.71 d (17.0 Hz, H-21b), 
5.67 d (1.5 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 15.50 (CH3, C-18), 
20.48 (CH3, 21-OAc), 20.92 (CH3, C-19), 22.52 (CH2, C-16), 24.43 (CH2, 
C-15), 31.34 (CH, C-8), 32.56 (CH2, C-7), 33.54 (CH2, C-6), 33.80 (CH2, C-
2), 34.99.12 (CH2, C-1), 39.25 (C, C-10), 43.76 (C, C-13), 47.91 (CH2, C-
12), 56.33 (CH, C-9), 57.64 (CH, C-14), 59.43 (CH, C-17), 67.99 (CH, C-
11), 68.96 (CH2, C-21), 59.43 (CH, C-17), 122.42 (CH, C-4), ), 177.04 (C, 
C-5), 177.04 (C, 21-OAc), C-3, C-20 and 21-OOCCH3 not detected).  
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Prednisolone-21-acetate:1H NMR (CDCl3, 500 MHz) : δ 0.96 s (3H, H-18), 
1.06 d (11.2 and 3.5 Hz, H-9), 1.11 dddd(3x13.0 and 4.5 Hz, H-7a), 1.43 s 
(3xH-19), 1.46 m (H-15a), 1.47 m (H-16a), 1.64 m (1.70 m (H-12a), -15b), 
2.05 m (H-12b), 2.09 m (H-7b), 2.15 m (H-8), 2.16 s (3H, 21-OAc), 2.32 
ddd (13.5, 5.0 and 2.0 Hz, H-6a), 2.55 dddd(2 x 13.5, 5.5 and 1.5 Hz, H-
6b), 2.75 dddd (2 x 13.7 and 2x 3.5 Hz, H-16b), 4.47 ddd (3 x 3.5 Hz, H-
11), 4.84 d (17.3 Hz, H-21a), 4.97 d (17.3 Hz, H-21b), 6.00 dd (2x1.8 Hz, 
H-4), 6.25 dd(10.0 and 1.8 Hz, H-2), 7.25 d (10.0 Hz, H-1). 13C NMR 
(CDCl3, 125 MHz): δ 16.97 (CH3, C-18), 20.54 (CH3, 21-OAc), 21.08 (CH3, 
C-19), 23.83 (CH2, C-15), 31.24 (CH, C-8), 31.96 (CH2, C-6), 34.00 (CH2, 
C-7), 34.71 (CH2, C-16), 39.63 (CH2, C-12), 44.05 (C, C-10), 47.85 (C, C-
13), 51.38 (CH, C-14), 55.32 (CH, C-9), 67.89 (CH2, C-21), 70.16 (CH, C-
11), 89.68 (C, C-17), 122.46 (CH, C-4), 127.88 (CH, C-2), 156.12 (CH, C-
1), 169.92 (C, C-5), 170.79 (C, 21-OAc), 186.56 (C, C-3), 204.77 (C, C-20). 
 
Computational Methods 
The high resolution crystallographic structure of CATI from E. coli (pdb 
entry 1Q23.pdb, accession code P62577) contains a total of 12 chains. 
Here, only chain A and B were used, because fusidic acid and likewise 
chloramphenicol are bound in between the two monomeric units. 
Furthermore, all water molecules were removed. Compounds for docking 
were generated manually and energetically optimized applying the MM+ 
force field as implemented in HYPERCHEM. (HYPERCHEM, version 6.02, 
Hypercube Inc., Gainsville, FL, 1999). Gasteiger-Marsili charges were 
calculated with an in-house PERL script.[26] Further preparation steps for 
ligands and receptor were carried out by using the Windows version 1.5.6 
of Autodock Tools.[27] His193 was modelled as being protonated only at Nδ. 
Flexible bonds of the compounds were assigned automatically and verified 
by manual inspection. To the protein part AMBER charges were assigned. 
A rectangular grid box (46 x 44 x 46 points) with a grid spacing of 0.375 Å 
was centered at 2.595, 13.265, -3.437 to comprise all potential amino acids 
that contribute to ligand binding. AUTODOCK (version 4.2) was applied for 
docking while keeping the protein part rigid.[28] For each of the ligands 200 
docking runs were carried out applying the Lamarckian genetic algorithm 
using default parameter settings. 
Acknowledgements  
This work was supported by a fellowship awarded by Deutscher 
Akademischer Austausch Dienst (DAAD) (Germany) and ministry 
of Higher Education and Scientific Research (MoHER) (Iraq). 
 
Keywords: biotransformation•steroid acetylation• 
chloramphenicol acetyltransferase• 
[1] a) W. V. Shaw, CRC Crit. Rev. Biochem. 1983, 14, 1-46; b) T. Biswas, J. L. 
Houghton, S. Garneau-Tsodikova, O. V. Tsodikov, Protein Sci. 2012, 21, 
520-530. 
[2] D. Bulkley, C. A. Innis, G. Blaha, T. A. Steitz, Proc. Natl. Acad. Sci. USA 
2010, 107, 17158-17163. 
[3] a) I. A. Murray, A. R. Hawkins, J. W. Keyte, W. V. Shaw, Biochem. J. 1988, 
252, 173-179; b) W. V. Shaw, A. G. Leslie, Annu. Rev. Biophys. Biophys. 
Chem. 1991, 20, 363-386; c) T. de Rond, P. Peralta-Yahya, X. Cheng, T. R. 
Northen, J. D. Keasling, Anal. Bioanal. Chem. 2013, 405, 4969-4973. 
[4] a) P. J. Day, W. V. Shaw, J. Biol. Chem. 1992, 267, 5122-5127; b) I. A. 
Murray, W. V. Shaw, Antimicrob. Agents Chemother. 1997, 41, 1-6. 
[5] I. A. Murray, J. V. Martinez-Suarez, T. J. Close, W. V. Shaw, Biochem. J. 
1990, 272, 505-510. 
[6] J. Alonso-Gutierrez, R. Chan, T. S. Batth, P. D. Adams, J. D. Keasling, C. J. 
Petzold, T. S. Lee, Metab. Eng. 2013, 19, 33-41. 
[7] A. D. Bennett, W. V. Shaw, Biochem. J. 1983, 215, 29-38. 
[8] O. V. Dominguez, J. R. Seeley, J. Gorski, Anal. Chem. 1963, 35, 1243-1247. 
[9] a) W. He, C. Jia, Y. Ma, Y. Yang, X. Zhang, B. Feng, L. Yue, J. Mol. Catal. B: 
Enzym. 2010, 67, 60-65; b) A. C. Bruttomesso, A. Tiscornia, A. Baldessari, 
Biocatal. Biotransform. 2004, 22, 215-220; c) J. Manosroi, M. Abe, A. 
Manosroi, Bioresour. Technol. 1999, 69, 67-73. 
[10] X. Hu, Z. Zhang, X. Zhang, Z. Li, X. X. Zhu, Steroids 2005, 70, 531-537. 
[11] E. Santaniello, P. Ferraboschi, S. Reza-Elahi, Monatsh. Chem. 2000, 131, 
617-622. 
[12] S. Riva, A. M. Klibanov, J. Am. Chem. Soc. 1988, 110, 3291-3295. 
[13] a) J. Winter, C. H. Shackleton, G. N. Morris, S. Locascio, V. D. 
Bokkenheuser, Steroids 1986, 48, 381-394; b) S. B. Mahato, A. Mukherjee, 
Phytochemistry 1984, 23, 2131-2154; c) A. Christy Hunter, K. R. Watts, C. 
Dedi, H. T. Dodd, J. Steroid Biochem. Mol. Biol. 2009, 116, 171-177. 
[14] a) K. E. Jaeger, T. Eggert, Curr. Opin. Biotechnol. 2002, 13, 390-397; b) J. 
Manosroi, S. Saowakhon, A. Manosroi, Enzyme Microb. Technol. 2007, 41, 
322-325. 
[15] M. M. Cruz Silva, S. Riva, M. L. Sá e Melo, Tetrahedron 2005, 61, 3065-
3073. 
[16] a) P. Ferraboschi, S. Rezaelahi, E. Verza, E. Santaniello, Tetrahedron: 
Asymmetry 1998, 9, 2193-2196; b) W. Panpipat, X. Xu, Z. Guo, Biochem. 
Eng. J. 2013, 70, 55-62; c) S. Riva, R. Bovara, G. Ottolina, F. Secundo, G. 
Carrea, J. Org. Chem. 1989, 54, 3161-3164. 
[17] a) L. Cai, B. P. Tu, Cold Spring Harbor symposia on quantitative biology 
2011, 76, 195-202; b) E. Fischer, U. Sauer, J. Biol. Chem. 2003, 278, 
46446-46451. 
[18] a) G. N. Vemuri, E. Altman, D. P. Sangurdekar, A. B. Khodursky, M. A. 
Eiteman, Appl. Environ. Microbiol. 2006, 72, 3653-3661; b) R. Fasan, N. C. 
Crook, M. W. Peters, P. Meinhold, T. Buelter, M. Landwehr, P. C. Cirino, F. 
H. Arnold, Biotechnol. Bioeng. 2011, 108, 500-510; c) O. A. Olaofe, C. J. 
Fenner, R. K. Gudiminchi, M. S. Smit, S. T. Harrison, Microb. Cell Fact. 
2013, 12:8., 10.1186/1475-2859-1112-1188. 
[19] a) D. C. Darrow, H. C. Miller, J. Clin. Invest. 1942, 21, 601-611; b) K. Lovas, 
E. S. Husebye, Expert Opin. Invest. Drugs 2008, 17, 497-509. doi: 
410.1517/13543784.13543717.13543784.13543497 . 
[20] a) S. J. King, J. W. Harding, K. E. Moe, Brain Res. 1988, 448, 140-149; b) A. 
De Nicola, A. Seltzer, K. Tsutsumi, J. Saavedra, Cell. Mol. Neurobiol. 1993, 
13, 529-539. 
[21] a) R. J. Grekin, J. M. Terris, D. F. Bohr, Hypertension 1980, 2, 326-332; b) 
A. Iyer, V. Chan, L. Brown, Curr. Cardiol. Rev. 2010, 6, 291-297. doi: 
210.2174/157340310793566109. 
[22] J. Wang, C. Chen, B. Li, J. Zhang, Y. Yu, Enzyme Microb. Technol. 1998, 
22, 368-373. 
[23] C. W. Shoppee, Annu. Rev. Biochem. 1953, 22, 261-298. 
[24] P. Goloubinoff, A. A. Gatenby, G. H. Lorimer, Nature 1989, 337, 44-47. 
[25] P. Genard, Org. Magn. Resonance 1978, 11, 478-480. 
[26] J. Gasteiger, M. Marsili, Tetrahedron 1980, 36, 3219-3288. 
[27] M. F. Sanner, J. Mol. Graphics Modell. 1999, 17, 57-61. 
[28] a) R. Huey, G. M. Morris, O. A. J, D. S. Goodsell, J. Comput. Chem. 2007, 
28, 1145-1152; b) G. M. Morris, G. D. S, R. S. Halliday, R. Huey, W. E. Hart, 
R. K. Belew, A. J. Olson, J. Comput. Chem. 1998, 19, 1639-1662. 
 
FULL PAPER    
 
 
 
 
 
 
Entry for the Table of Contents (Please choose one layout) 
 
Layout 1: 
 
FULL PAPER 
The bacterial chloramphenicol 
acetyltransferase I was identified as a 
steroid acetyltransferase. A novel and 
highly efficient E. coli based 
biocatalyst was designed for the 
regioselective acetylation of C21 
hydroxyl groups in steroids of 
pharmaceutical interest. 
   
Azzam Mosa, [a]Michael C.Hutter,[b] 
Josef Zapp, [c] Rita Bernhardt, [a] 
and Frank Hannemann* [a] 
 
Page No. – Page No. 
A New and Regioselective Acetylation 
of C21 Hydroxysteroids by the 
bacterial Chloramphenicol 
Acetyltransferase I 
 
  
 
 
 
 
 
 
48 
 
3.3- NEUNZIG ET AL., 2014 
A STEROIDOGENIC PATHWAY FOR SULFONATED STEROIDS: THE METABOLISM OF PREGNENOLONE 
SULFATE 
J. Neunzig, A. Sánchez-Guijo, A. Mosa, M.F. Hartmann, J. Geyer, S.A. Wudy, R. Bernhardt 
Journal of Steroid Biochemistry & Molecular Biology 144 (2014) 324–333.  
 
 
 
 
 
 
 
 
 
 
 
Journal of Steroid Biochemistry & Molecular Biology 144 (2014) 324–333A steroidogenic pathway for sulfonated steroids: The metabolism of
pregnenolone sulfate
J. Neunzig a, A. Sánchez-Guijo b, A. Mosa a, M.F. Hartmann b, J. Geyer c, S.A. Wudy b,
R. Bernhardt a,*
aDepartment of Biochemistry, Faculty of Technical and Natural Sciences III, Saarland University, 66123 Saarbrücken, Germany
b Steroid Research & Mass Spectrometry Unit, Division of Pediatric Endocrinology & Diabetology, Center of Child and Adolescent Medicine, Justus-Liebig
University, 35392 Giessen, Germany
c Institute of Pharmacology and Toxicology, Justus-Liebig University of Giessen, 35392 Giessen, Germany
A R T I C L E I N F O
Article history:
Received 7 May 2014
Received in revised form 11 July 2014
Accepted 14 July 2014
Available online 16 July 2014
Keywords:
CYP17A1
Steroidogenesis
Sulfonated steroids
Pregnenolone sulfate
Mass spectrometry
A B S T R A C T
In many tissues sulfonated steroids exceed the concentration of free steroids and recently they were also
shown to fulﬁll important physiological functions. While it was previously demonstrated that cholesterol
sulfate (CS) is converted by CYP11A1 to pregnenolone sulfate (PregS), further conversion of PregS has not
been studied in detail. To investigate whether a steroidogenic pathway for sulfonated steroids exists
similar to the one described for free steroids, we examined the interaction of PregS with CYP17A1 in a
reconstituted in-vitro system. Difference spectroscopy revealed a Kd-value of 74.8  4.2 mM for the
CYP17A1–PregS complex, which is 2.5-fold higher compared to the CYP17A1–pregnenolone (Preg)
complex. Mass spectrometry experiments proved for the ﬁrst time that PregS is hydroxylated by CYP17A1
at position C17, identically to pregnenolone. A higher Km- and a lower kcat-value for CYP17A1 using PregS
compared with Preg were observed, indicating a 40% reduced catalytic efﬁciency when using the
sulfonated steroid. Furthermore, we analyzed whether the presence of cytochrome b5 (b5) has an
inﬂuence on the CYP17A1 dependent conversion of PregS, as was demonstrated for Preg. Interestingly,
with 17OH-PregS no scission of the 17,20-carbon–carbon bond occurs, when b5 is added to the
reconstituted in-vitro system, while b5 promotes the formation of DHEA from 17OH-Preg. When using
human SOAT-HEK293 cells expressing CYP17A1 and CPR, we could conﬁrm that PregS is metabolized to
17OH-PregS, strengthening the potential physiological meaning of a pathway for sulfonated steroids.
ã 2014 Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry & Molecular Biology
journa l homepage: www.e l sev ier .com/ loca te / jsbmb1. Introduction
CYP11A1 initiates steroid hormone biosynthesis (Fig.1) through
a side-chain cleavage reaction on cholesterol yielding pregneno-
lone [1,2] which represents the precursor of all steroid hormones.
In a series of reactions where six different cytochromes P450
(CYPs) and three hydroxysteroid dehydrogenases (HSD) partici-
pate, mineralocorticoids, glucocorticoids and sex hormones are
formed.
In order to induce a biological response, steroid hormones
interact with their corresponding receptor and thus e.g., regulation
of blood pressure, provision of carbon hydrates or development of
secondary sexual characteristics take place in mammalian
organisms. Interestingly, sulfonated steroids or sulfated steroids
[3] often circulate in mammals in considerably higher* Corresponding author. Tel.: +49 681 302 3005; fax: +49 681 302 4739.
E-mail address: ritabern@mx.uni-saarland.de (R. Bernhardt).
http://dx.doi.org/10.1016/j.jsbmb.2014.07.005
0960-0760/ã 2014 Elsevier Ltd. All rights reserved.concentrations than unconjugated steroids [4–6]. Dehydroepian-
drosterone (DHEA) for example, one of the most abundant steroid
in humans, occurs to 99% in its sulfonated form [7], reaching
concentrations of up to 10 mM in young adults [8]. Steroid sulfates
are generated by sulfonation of free steroids by three different
sulfotransferases (SULT1E1, SULT2B1, SULT2A1). These enzymes
are widely distributed in mammalian organism, as NCBI EST
proﬁles indicate. Sulfonation of unconjugated steroids seems to
contribute to the modulation of the genomic action of steroids. For
instance, SULT1E1 is highly active in cultured normal breast
epithelial cells compared to tumor cell lines [9]. Since it is known
that increased exposure of estrogens increases breast cancer
development, sulfonation of estrogens might be a crucial mecha-
nism to impede the danger of excessive estrogenic exposure [9]. In
addition, alterations of steroid sulfonation have a severe impact on
the development in mammals. DHEA is mainly produced in the
adrenals and the gonads. In the gonads DHEA is further
metabolized to sex hormones, but in the adrenals, due to the
presence of SULT2A1, most of the DHEA is sulfonated. In case of
Fig. 1. Steroid hormone biosynthesis involving six cytochromes P450 and three hydroxysteroid dehydrogenases.
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yielding to an excess of androgens and thus, virilization occurs
in women [10].
On the other hand, excess of sulfonated steroids can lead to
diseases, like the X-linked ichtiosis, which is caused by the
accumulation of cholesterol sulfate in the epidermis [11].
Cell uptake of steroid sulfates depends on transporters of the
SLC or SLCO family [12–14] as their hydrophilicity caused by the
sulfate moiety hinders a passive passage. These transporters are
expressed in many tissues, like liver, ovary, adrenal gland and
hippocampus [15].
Sulfonated steroids have been regarded for a long time either as
an end-product of xenobiotic metabolism designated for renal
clearance [16] or as an inactive reservoir for unconjugated, active
steroids [17]. Although the knowledge about the physiological role
of steroid sulfates is still scarce, investigations about their
biological function increased in the last decade. Recent studiesshowed that sulfonated steroid metabolites are involved in many
different processes in mammalian organisms. Cholesterol sulfate
(CS) possesses a stabilizing function in cell membranes; it is
involved in the regulation of serine proteases and, moreover, in the
differentiation of keratinocytes [18]. Recently, DHEAS was shown
to induce a non-classical signaling pathway in spermatogenic cells
[19]. Pregnenolone sulfate (PregS), on the other hand, represents a
reservoir for pregnenolone (Preg), the precursor of mineralo-, and
glucocorticoids, as well as sex hormones and it is described to act
as neurosteroid modulating a big variety of ion channels, trans-
porters, and enzymes [15]. For example, PregS was demonstrated
to inhibit GABA-receptors [20], which play a crucial role in the
neuronal network and to modulate N-methyl-D-aspartate
(NMDA)-receptors. These receptors, which are essential for
neuronal development and synapse formation, are heterodimers
formed by several subunits (NR1, NR2A–D, NR3A–B). PregS
modulates these receptors by enhancing the generation of
326 J. Neunzig et al. / Journal of Steroid Biochemistry & Molecular Biology 144 (2014) 324–333NR1/NR2A and NR1/NR2B receptors and inhibiting the formation
of NR1/NR2C and NR1/NR2D receptors [21]. Further studies
revealed that PregS promotes NMDA-receptor insertion in the
cell surface [22] and thus, enhances the function of
NMDA-receptors.
Moreover, PregS seems to play an essential role in reproduction
as extremely increased concentrations during birth, pregnancy and
parturition indicate [15].
It was demonstrated that PregS can be formed from CS through
a side-chain cleavage reaction catalyzed by CYP11A1 [23] and
seems to be metabolized to further sulfonated steroids as Korte
et al. showed using tissue from human adrenals [24]. These
ﬁndings inevitably lead to the question, whether a steroidogenic
pathway for sulfonated steroids exists similar to the one described
for free steroids. Trying to elucidate this question, we decided to
investigate whether PregS serves as substrate for CYP17A1, a
microsomal cytochrome P450 involved in the steroid hormone
biosynthesis. CYP17A1 catalyzes the hydroxylation at position C17
of Preg or progesterone (Prog) yielding 17OH-Preg and 17OH-Prog,
respectively, and subsequently catalyzes a 17,20-lyase reaction
yielding dehydroepiandrosterone (DHEA) and androstenedione
(andro) [25] (Fig. 2). In human and bovidae families (sheep, goat,
bovine, bison), CYP17A1 exhibits lyase activity only toward
delta5-steroids, like Preg and 17OH-Preg [26]. In these mammalian
species CYP17A1 hydroxylates Prog at position C17 but 17OH-Prog
is not further converted to androstenedione. Compared to the
17-hydroxylase activity, the 17,20-lyase reaction using 17OH-Preg
as substrate is weak, but it is strongly enhanced in the presence of
cytochrome b5 (b5) [27] or through phosphorylation of CYP17A1 at
position 258 of its amino acid chain [28].
Here, we investigated the reaction of CYP17A1 with PregS as
substrate in a reconstituted in-vitro system, consisting of
recombinantly expressed and puriﬁed CYP17A1 and its electron
transfer partner CPR, and were able to demonstrate for the ﬁrst
time its conversion to 17OH-PregS, but not to DHEAS.
2. Materials
Steroids were obtained from Sigma–Aldrich (Taufkirchen,
Germany) or from C/D/N Isotopes Inc. (Quebec, Canada).
1,2-Dilauroyl-sn-glycero-3-phosphocholine (DLPC), kanamycin
sulfate, arabinose, magnesium chloride, sodium hydroxide, sulfur
trioxide triethylamine, sulfatase from Helix pomatia Type H-1 and
HPLC-grade acetonitrile were from Sigma–Aldrich (Taufkirchen,
Germany). Yeast extract, technical was from Becton, Dickinson and
Company (Heidelberg, Germany). Pepton, pancreatically digested
and Na-acetate were from Merck (Darmstadt, Germany). LCMS
grade water and ammonium hydroxide were purchased from Fluka
(Taufkirchen, Germany). Methanol, pyridine and ethanol were
obtained from Merck (Darmstadt, Germany). SepPak C18 (360 mg)
columns were from Waters Corporation (Milford, MA, USA).
DMEM/F12 cell culture media and fetal calf serum were from
Gibco by Life Technologies (California, USA). Imidazole and
ampicillin were from CarlRoth (Karlsruhe, Germany). NADPHFig. 2. Reaction catalyzed by CYP17A1. Pregnolone is hydroxylated at position C17 yield
takes place yielding DHEA.was from Carbolution (Saarbrücken, Germany). Glucose-6-phos-
phate and glucose-6-phosphate dehydrogenase were purchased
from Roche (Basel, Switzerland). Protino Ni-NTA was obtained
from Macherey-Nagel (Düren, Germany). 17OH-PregS was synthe-
sized in the Steroid Research & Mass Spectrometry Unit, Division of
Pediatric Endocrinology & Diabetology, Center of Child and
Adolescent Medicine, Justus-Liebig University. All other chemicals
were of highest purity available.
3. Experimental
3.1. Construction of recombinant expression plasmids in E. coli
The plasmid pET-17b was utilized to express bovine CYP17A1,
b5 and CPR in E. coli. Each cDNA was cloned via the restriction sites
NdeI and BamHI into the vector. The cDNAs of b5 and CPR were
obtained through ampliﬁcation from a cDNA library of bovine liver
(Zyagen, California, USA). CYP17A1 cDNA was kindly provided by
Prof. M. Waterman (Vanderbilt University, Nashville, USA). The
amino acid sequence of CYP17A1 is lacking its N-terminal
hydrophobic anchor [29] and is extended at the C-terminus by a
hexa-histidine-tag to facilitate puriﬁcation. The CPR amino acid
sequence is extended at the C-terminus by three glycines and six
histidines and at the N-terminus has a lack of the ﬁrst 27 amino
acids [30]. Cytochrome b5 is extended at the C-terminus by a
hexa-histidine-tag. For human cell culture studies, the plasmid
pVITRO1-neo-mcs (Invivogen) was used to express CYP17A1 and
CPR. The cDNAs of CYP17A1 and CPR were cloned via the restriction
sites AgeI and BsrGI (CYP17A1) and BspEI and AvrII (CPR) into the
vector. Both cDNAs were obtained from a cDNA library of bovine
adrenal (CYP17A1) and bovine liver (CPR).
3.2. Protein expression and puriﬁcation
Bovine CYP17A1 was co-expressed with chaperones GroEL and
GroES similar to CYP21 expression [31]. As host E. coli strain
C43DE3 was used. The expression was performed in 2 L bafﬂed
ﬂasks containing 400 ml TB medium supplemented with
100 mg/ml ampicillin and 50 mg/ml kanamycin. The expression
culture was inoculated from an overnight culture and grown at
37 C and 120 rpm. Protein expression was induced at OD600 = 0.6
with 1 mM IPTG, 4 mg/ml arabinose, 1 mM d-ALA and 50 mg/ml
ampicillin. Afterwards, temperature was decreased to 26 C and
the cells incubated at 95 rpm for 48 h. Cells were harvested and
sonicated as described elsewhere [32]. The puriﬁcation was
performed as described for CYP11B1 [33].
Bovine CPR was expressed in E. coli strain C43DE3 using similar
conditions as described for bovine CYP17A1 with slight modiﬁ-
cations: 2 L bafﬂed ﬂasks containing 300 ml TB medium were used
and after induction of protein expression temperature was reduced
to 30 C and incubated at 100 rpm for 30 h. Cells were harvested
and sonicated as described elsewhere [32]. CPR was puriﬁed via
IMAC as described elsewhere [33] with 40 mM imidazole in the
washing buffer and 200 mM imidazole in the elution buffer.ing 17OH-pregnenolone, and subsequently the 17,20-carbon–carbon bond scission
Table 1
LC Table-ﬂows and gradients.
Start Seconds Flow % H2O % MeOH
0.00 60 0.45 70 30
1.00 60 0.50 55 45
2.00 20 0.50 40 60
2.33 80 0.50 5 95
3.67 60 0.50 40 60
4.67 30 0.50 55 45
5.17 30 0.45 70 30
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using E. coli strain C43DE3. Puriﬁcation was done as described for
bovine CPR.
3.3. UV–vis spectroscopy
The protein concentration of the CPR was determined using a
molar extinction coefﬁcient e585 = 2.4 mM1 cm1 [35]. Cyto-
chrome b5 concentration was calculated by using a difference
extinction coefﬁcient of 185 mM1 cm1 for the absorbance change
at 424–409 nm [34]. CYP17A1 concentration was calculated from a
reduced carbon-monoxide difference spectroscopy according to
Omura and Sato [36] with e448 = 91 mM cm1. Binding of Preg and
PregS was investigated using difference spectroscopy, which was
carried out in tandem cuvettes according to Schenkman [37]. Preg
and PregS were dissolved in DMSO. The buffer utilized was
composed of 50 mM HEPES (pH 7.4), 20% glycerol, and 100 mM
dilauroyl phosphatidylcholin (DLPC). Difference spectra were
recorded from 370 to 450 nm. To determine the dissociation
constant (Kd), the values from three titrations were averaged and
the resulting plots were ﬁtted with hyperbolic regression.
3.4. Enzyme activity assay
In-vitro substrate conversion assays were done as described
elsewhere [38] with slight modiﬁcations. The conversion buffer
(50 mM HEPES, pH 7.4, 20% glycerol, 100 mM DLPC) contained
1 mM CYP17A1, 1 mM CPR, 1 mM MgCl2, 5 mM glucose-6-
phosphate, 1 U glucose-6-phosphate dehydrogenase for NADPH
regeneration and varying concentrations of Preg or PregS as
substrate. When substrate conversion assays were performed to
investigate the inﬂuence of b5, 4 mM of b5 were added to the
conversion buffer. After starting the reaction with 1 mM NADPH
at 37 C for 40, 50 and 60 min, the conversion was stopped in a
boiling water bath for 5 min. Preg and the resulting product
17OH-Preg had to be converted to the corresponding 3-one-4-en
form by cholesterol oxidase, to be detectable at 240 nm during
HPLC analysis. Therefore, cholesterol oxidase was added to the
boiled reaction mixture and incubated for 40 min at 37 C
according to Yamato [39]. Cortisol was added as internal standard.
The reaction was stopped by addition of one reaction volume of
ethylacetate. Extraction of steroids was performed twice with
ethylacetate and the ethylacetate phase was evaporated. The
steroids were resuspended in 20% acetonitrile for subsequent
HPLC analysis. Steroids were separated on a Jasco reversed phase
HPLC system LC2000 using a 4 mm  125 mm Nucleodur C18
reversed phase column (Macherey-Nagel) with an acetonitrile/
water gradient and a ﬂow rate of 1 ml/min. Detection of the
steroids was performed at 240 nm within 30 min at 40 C. For
analysis of sulfonated steroids mass spectrometry and liquid
chromatography were utilized.
3.5. Substrate conversion in SOAT-HEK293 cells
For substrate conversion studies, 6-well plates were coated
with poly-D-lysine for better attachment of the cells as described
elsewhere [40]. 3  105 cells/well were plated and maintained in
DMEM/F-12 (Invitrogen) medium with 10% fetal calf serum
(Sigma), L-glutamine (4 mM), penicillin (100 units/ml) and
tetracycline (1 mg/ml) (for SOAT expression). The cells were grown
for 16 h at 37 C and 5% CO2 until they reached a conﬂuency of 70%.
Afterwards, they were transiently transfected with a plasmid
containing the cDNAs of CYP17A1 and CPR with the Effectene
Transfection Kit of Qiagen. After 5 h of incubation (37 C and 5%
CO2), PregS (10 and 20 mM) was added and the cells were furtherincubated for 70 h, 37 C and 5% CO2. Subsequently, samples of
1 ml/well were collected and prepared for LC/MS-analysis.
3.6. Sample analysis by liquid chromatography-tandem mass
spectroscopy (LC-MS/MS)
The studies were performed using a triple quadrupole mass
spectrometer (TSQ, Quantum Ultra, Thermo Fisher Scientiﬁc,
Dreieich, Germany) with electrospray ionization (ESI) in negative
mode. Mass spectrometric parameters for sulfonated steroids were
as described elsewhere [41]. For the in-house synthesized
compound, 17OH-PregS, the collision energy and tube lens values
were calculated, being similar to other sulfonated steroids. The
selected quantiﬁer transition was 411 !97. The collision energy
was 32 eV and the tube lens value was 180 V. A C18 reverse phase
column was used for the chromatographic method (Hypersil Gold
column 50  2.1 mm, 5 mm, Thermo Fisher Scientiﬁc, Dreieich,
Germany), mounted within a HPLC system (Agilent 1200SL,
Waldbronn, Germany). Different concentrations of pure water
and pure methanol (MeOH) were applied to achieve the separation
of the compounds (Table 1). The retention time for both the
enzymatically obtained 17OH-PregS and for the synthetic
17OH-PregS were the same.
3.7. Sample preparation and calibrations
The samples were always diluted due to the high concen-
trations of the analytes, and of the presence of buffer components
that may affect the ionization process. At least two dilutions had
to be used for each sample, as the concentrations of PregS and
17OH-PregS after enzymatic conversion were very different (high
concentrations of PregS when compared to 17OH-PregS concen-
trations). The dilutions were made in a mixture containing MeOH,
water and ammonia to facilitate dissolution and to improve the
ionization of the analytes in negative mode (90.00% MeOH, 9.95%
H2O and 0.05% NH3). In case a precipitate was observed, the
samples were centrifuged and the clear supernatant was
analyzed. The dilution was usually performed in glass vials
which were ﬁrst vortexed and later shaked for 30 min to allow
equilibration with the internal standards. The calibration points
for the calibration curve were prepared adding the same amount
of buffer and internal standards (IS). d6DHEAS was used as IS for
17OH-PregS and d4PregS for PregS. Calibrations showed values
always higher than 0.99 for R2. Data analysis was performed with
Thermo Xcalibur 2.1 software (Thermo Fisher Scientiﬁc, Dreieich,
Germany).
3.8. Determination of kinetic parameters
Km and kcat-values were determined by plotting the substrate
conversion velocities versus the corresponding substrate concen-
trations and by using Michaelis–Menten kinetics (hyperbolic ﬁt)
for Preg or Hill kinetics (sigmoidal ﬁt) for PregS utilizing the
program OriginPro 8.6G.
Fig. 3. SDS-polyacrylamide gel electrophoresis. (A) Lane 1: supernatant; lane 2: CYP17A1 after puriﬁcation via IMAC; lane 3: CYP17A1 after puriﬁcation via IMAC and
DEAE-sepharose; lane 4: CYP17A1 after puriﬁcation via IMAC, DEAE-sepharose and SP-sepharose; lane M: marker. (B) Lane M: marker; lane 1: supernatant; lane 2: b5 after
IMAC puriﬁcation; lane 3: CPR after IMAC puriﬁcation.
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The method is based on Dusza et al. [42], with some
modiﬁcations. Brieﬂy, 1 mg of 17OH-Preg and 0.85 mg of triethyl-
amine sulfur trioxide were mixed in 100 ml of anhydrous pyridine,
in a 2 ml glass vial. The mixture was shaked at low speed during 3 h
at room temperature, and consecutively evaporated. The residue
was redissolved in 500 ml of ethanol. Then, 500 ml of NaOH 0.2 M in
methanol were added, and a white precipitate was observed. After
evaporation, the precipitate was washed twice with methanol.
Several HPLC-MS/MS analyses were performed to assess the
purity of the reaction product. An aliquot of the solution was
dissolved in a mixture of water:MeOH (1:1 v/v) and analyzed in
positive full scan mode as previously described [41]. The product
was free of 17OH-Preg, as no peak was present at 4.2 min, whereas
a peak with m/z 297.2 at 0.75 min was observed. This
mass-to-charge ratio value is identical to that of 17OH-Preg, and
it is due to (M  H2O  H2SO4 + H)+.
The same chromatographic method was applied to ESI negative
mode. The m/z value of the peak at 0.75 min was 411, molecular ion.
A minority peak at 0.18 min was then found in negative mode. This
peak corresponded to the disulfate fraction of 17OH-Preg, with m/z
of 245, (M  2H)2. Sulfonation of the hydroxyl group in position
3beta is favored over the sterically hindered 17alpha position.
Next, the mixture was puriﬁed with a solid phase extraction
step. The precipitate was re-dissolved in a water:MeOH solutionFig. 4. Spectra of puriﬁed recombinant CYP17A1 (A), CPR (B) and b5 (C). (A) Full spec
CO-difference spectrum from 500 nm to 400 nm. (B) Spectrum of puriﬁed CPR recorded f
and difference spectrum (reduced–oxidized) (solid line).(70:30 v/v) and loaded onto a Sep-Pak column after activation. A
gradient of MeOH was then applied (0–100%) and the fractions
corresponding to 40–50% of MeOH were collected, discarding the
rest. Those fractions were free of disulfate component, showing a
clear single peak in the same chromatographic conditions
described before.
The fractions collected after puriﬁcation step were evaporated
under nitrogen ﬂow and weighed. A standard working solution was
then prepared (250 mg/mL in MeOH).
In order to calculate the purity of the ﬁnal solution, two
aliquots, of 20 ml and 40 ml, were treated with 75 units of sulfatase
at 37 C during 6 h. The reaction products were then quantiﬁed
using the aforementioned procedure described in Galuska et al.
[41] for 17OH-Preg quantiﬁcation. The analysis in negative mode
proved that they were free of 17OH-PregS. The calculated purity
was 90%.
4. Results and discussion
The levels of sulfonated steroids exceed in many species and
tissues considerably the levels of the corresponding unconjugated
steroids. In human, the plasma level of PregS varies signiﬁcantly
during life. The highest level is reached after birth with
concentrations between 2–3 mM, depending on the gender, and
afterwards rapidly decreases in the ﬁrst year up to concentrations
of about 30–50 nM [43]. During and after adrenarche, the PregStrum of puriﬁed CYP17A1 recorded from 700 nm to 260 nm. The inset shows the
rom 600 nm to 300 nm. (C) Spectrum of puriﬁed b5 in its oxidized form (dotted line)
Table 2
Amount of heterologously expressed CPR, b5 and CYP17A1.
Yield of puriﬁed protein (mg/l)
CPR 34
b5 22
CYP17A1 73
Fig. 6. Difference spectroscopy of CYP17A1 titrated with 150 mM PregS (red) and
150 mM 17OH-PregS (black). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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130–140 nM [43]. Although PregS represents a steroid hormone
displaying high abundance in human and other mammalian
organism [44] and exceeding its unconjugated form (0.9–6 nM
[45]) by several folds, its inﬂuence on steroid hormone
biosynthesis is poorly investigated. Moreover, it was already
demonstrated that CS is converted to PregS through a CYP11A1
dependent reaction [23] leading necessarily to the issue whether
also other sulfonated steroids are converted by enzymes involved
in the steroid hormone biosynthesis, equally to free steroids.
Korte et al. [24] suggested that CS is converted to PregS and
afterwards to dehydroepiandrosterone sulfate (DHEAS), based on
their observation that the fetal plasma contains very high levels of
PregS and DHEAS. However, experiments to support this
assumption were not performed in this early study. The
conversion of PregS to sulfonated products was demonstrated
by Jaffe et al. [46] and Lamont et al. [47] in the early 70 s, but, they
did not identify the enzyme involved in this reaction. Therefore, it
was the aim of our study to investigate, whether CYP17A1 is able
to convert PregS.
4.1. Expression and puriﬁcation of CPR, b5 and CYP17A1
The three proteins necessary to perform in-vitro conversions of
PregS were expressed in bacteria and puriﬁed from there.
For expression of the three proteins, E. coli C43DE3 were chosen
as host, as this strain was described to display high expression
yields for membrane-bound cytochrome P450’s [33,38,48] and
other membrane-bound proteins [49].
CPR and b5 were puriﬁed by IMAC NTA, whereas CYP17A1 was
puriﬁed at ﬁrst by IMAC NTA followed by an anion exchange
DEAE-sepharose and, in a last step, by an ion exchange
SP-sepharose. The purity of the proteins was determined via
SDS-gel electrophoresis (Fig. 3), in which a single band was
obtained for CYP17A1 at 45 kDa and for b5 at 17 kDa. CPR showed a
main band at 70 kDa and two unknown bands located above and
below the band corresponding to CPR. Further experiments, likeFig. 5. Determination of substrate binding afﬁnity to CYP17A1. The enzyme (1 mM)
was titrated with increasing concentrations of Preg (dotted line) and PregS (solid
line) dissolved in DMSO. The absorbance changes were plotted against the substrate
concentration and ﬁtted as described; R2: 0.99; n = 3.the cytochrome c test (data not shown), spectral characterization
(Fig. 4B) and substrate conversion experiments with CYP17A1
suggested an undisturbed catalytic function of CPR.
The UV–vis spectrum categorizes the expressed CYP17A1 as a
low-spin protein with the characteristic cytochrome P450
absorption spectrum: the Q bands at 569 nm (a-band) and
541 nm (b-band), the Soret band at 418 nm, the UV band at
360 nm and the protein-band at 278 nm (Fig. 4A). Moreover, the
enzyme displays a typical CO-difference spectrum, with a major
peak at 450 nm and a minor peak at 420 nm (Fig. 4A inset). Spectral
analysis of CPR also reveals its typical absorption spectrum: the
enzyme shows its major peaks at 360 nm, 380 nm, and at 453 nm,
indicating its air-stable semiquinone (FMNH, FAD) form [50]
(Fig. 4B). Cytochrome b5 exhibits a major peak at 412 nm in its
oxidized state, as well as a major peak at 424 nm and a minor peak
at 409 nm in the difference (reduced–oxidized) spectrum [34]
(Fig. 4C).
The amounts of CPR, b5 and CYP17A1, respectively, obtained
after puriﬁcation are listed in Table 2.
Using E. coli C43DE3 as host, the expression yield of b5 is similar
to literature data [51], that of CYP17A1 achieved 73 mg/l, which is a
great improvement compared to published data [29]. The
expression yield of bovine CPR described here for the ﬁrst time
was 34 mg/l.Fig. 7. Merged chromatogram of the analytes obtained from a conversion sample,
as detected by ID-LC-MS/MS (peak at 1.66 min is d6-DHEAS, peak at 1.91 min is
17OH-PregS whereas peak at 2.28 min is PregS).
Fig. 8. Product-ion mass spectra of the molecular ion of 17OH-PregS (collision
energy 32 eV). The predominant fragment ion at m/z 96.9 is due to the
hydrogensulfate anion (HSO4).
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pregnenolone and pregnenolone sulfate
In order to investigate the binding afﬁnity of Preg and PregS
with CYP17A1 in detail, we performed spectroscopic studies to
determine dissociation constants (Kd). The experiments revealed a
Kd-value for CYP17A1 and Preg of 28.9  3.1 mM and for CYP17A1
and PregS of 74.8  4.2 mM (Fig. 5), indicating a higher afﬁnity of
CYP17A1 toward the unconjugated pregnenolone.
Moreover, we aimed to compare the afﬁnity of CYP17A1 toward
PregS and its product 17OH-PregS. As the spectral change of
CYP17A1 in the presence of 17OH-PregS was too low to determine
the Kd-value, we compared the spectral change of CYP17A1 in the
presence of 150 mM PregS and 150 mM 17OH-PregS (Fig. 6). In
contrast to PregS, which induces a type I shift typical for substrates,
17OH-PregS does not, or only to a very low extend, inﬂuence the
spectral properties of CYP17A1. This is an indication that
17OH-PregS might not be in a binding position suitable for further
conversion.
4.3. Sample analysis by liquid chromatography-tandem mass
spectrometry (LC-MS/MS)
In order to analyze the conversion of sulfonated steroids, we
established a new LC-MS/MS method. This is the ﬁrst time, to our
knowledge, that 17OH-PregS has been quantiﬁed by LC-MS/MS,
which represents the technique of choice to analyze sulfonatedFig. 9. (A) Kinetics of Preg to 17OH-Preg conversion catalyzed by CYP17A1 using CPR as 
CYP17A1 utilizing CPR as redox partner; R2: 0.98.steroids [41]. In Fig. 7 a merged chromatogram for PregS,
17OH-PregS and DHEAS is displayed (detection by multiple reaction
monitoring). All three steroid sulfates are baseline-resolved.
Fig. 8 shows the product-ion mass spectra of 17OH-PregS
(molecular ion with m/z value of 411). This methodological
development facilitates the analytical basis for the PregS metabo-
lism in our reconstituted in-vitro system.
4.4. CYP17A1 dependent 17OH-pregnenolone and 17OH-pregnenolone
sulfate conversion
Since we could clearly demonstrate that PregS efﬁciently
interacts with CYP17A1, the next step was to evaluate whether the
sulfonated steroid can be converted by CYP17A1. In mammalian
steroidogenesis, CYP17A1 catalyzes the conversion of Preg to
17OH-Preg and DHEA. In our reconstituted in-vitro system nearly
no lyase reaction and thus very little DHEA formation could be
observed, because of the absence of b5. Using PregS, we could
demonstrate that it serves as a substrate for CYP17A1 and is
converted to a considerable amount to 17OH-PregS. The kinetic
parameters were determined to be Km= 30.00  3.31 mM and
kcat = 0.60  0.02 (min1) for 17OH-Preg formation using Preg as
substrate and Km= 36.72  3.22 mM and kcat = 0.44  0.03 (min1)
for 17OH-PregS formation when PregS was utilized as substrate
(Fig. 9). Comparing the curve shapes of the kinetics of CYP17A1
with Preg or with PregS a signiﬁcant difference can be observed: in
contrast to the hyperbolic shape of CYP17A1 with Preg (Fig. 9A), the
kinetics of CYP17A1 with PregS display a sigmoidal form (Fig. 9B).
When considering the surface of the CYP17A1 crystal structure
[52], several positively charged regions that might act as potential
interaction sites with the negatively charged sulfate moiety of
PregS are found. This could lead to a decreased conversion rate at
low substrate concentrations until these unspeciﬁc binding sites
are saturated and could thus explain the sigmoidal character of the
kinetics of CYP17A1 with PregS.
In Table 3, the kinetic parameters are summarized, revealing a
catalytic efﬁciency kcat/Km for CYP17A1 toward Preg of
20.0 (min1mM1), which is two-fold higher compared to the
catalytic efﬁciency toward PregS with kcat/Km= 11.9 (min1mM1).
Consequently, the nearly 2-fold increased catalytic efﬁciency of
CYP17A1 converting Preg in comparison with PregS seems to be
due to a higher afﬁnity, as the Kd- and Km-values indicate and to an
higher kcat-value. The Kd-value for CYP17A1 and PregS is about
2.5-fold higher compared with Preg (Fig. 5). Thus, PregS possesses
less afﬁnity to CYP17A1. By favoring Preg as a substrate,
CYP17A1 might be able to compensate for the lower concentrationredox partner; R2: 0.99. (B) Kinetics of PregS to 17OH-PregS conversion catalyzed by
Table 3
Kinetic parameters of CYP17A1 metabolizing Preg and PregS, respectively.
Pregnenolone Pregnenolone sulfate
Km (mM) kcat (min1) kcat/Km (min1mM1) Km (mM) kcat (min1) kcat/Km (min1mM1)
0.030  0.003 0.60  0.02 20.00 0.036  0.003 0.44  0.03 11.98
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PregS in tissues expressing CYP17A1 are unknown, the physiologi-
cal importance of this observation is not clear yet.
4.5. Effect of b5 on CYP17A1 dependent substrate conversions
The ﬁrst reaction step of CYP17A1 consists of a 17-hydroxyl-
ation of Preg and is followed by a 17,20-carbon–carbon bond
scission yielding DHEA, as shown in Fig. 2. The augmentation by
several folds of the lyase of CYP17A1 in the presence of b5 is well
reported [53,54]. It is postulated that the effect of b5 on this second
reaction step of CYP17A1 is based on an allosteric interaction of b5
with CYP17A1, enhancing the alignment of the iron–oxygen
complex onto the C20 rather than the C17 atom of the steroid,
hence augmenting the lyase reaction [27]. Further studies are
necessary to conﬁrm this hypothesis. Very recently, Scott and
co-workers [55] demonstrated that structural changes occur at the
proximal surface of CYP17A1 depending on the substrate binding.
In reverse, they claim that binding of b5 to the proximal surface of
CYP17A1 induces changes in the active site of CYP17A1, leading to
an enhanced lyase activity.
For this reason, we investigated the effect of b5 on CYP17A1
dependent conversion of Preg and PregS. In our reconstituted
in-vitro system, the lyase reaction was nearly absent without
addition of b5. Using 30 mM Preg as substrate for CYP17A1,
0.08  0.02 mM DHEA is formed. In contrast, in the presence of b5
the CYP17A1 dependent conversion of Preg to DHEA is strongly
increased, forming 1.02  0.07 mM DHEA, thus augmenting the
lyase activity about 10-fold (Fig. 10). The relatively low lyase
activity is in accordance with previous studies of Barnes et al. [56]
demonstrating that the formation of DHEA is time-depending and
starts after accumulation of the intermediate 17OH-Preg. Studies
using 17OH-Preg instead of Preg as substrate also show higher
levels of DHEA formation [57].
To our surprise, the conversion of PregS was not inﬂuenced by
addition of b5. Whether or not b5 was present, no scission of the
17,20-carbon–carbon bond took place and, consequently, no
DHEAS was formed. It seems that the sulfate moiety hinders
the alignment of the iron–oxygen complex onto the C20 atom of
17OH-PregS, possibly due to the increased size of the molecule
and/or to the negative charge of the sulfate, which ﬁnally prevents
the lyase reaction of CYP17A1 on 17OH-PregS. As discussed beforeFig. 10. Comparison of DHEA and DHEAS formation by CYP17A1 in absence and in
the presence of b5 using Preg and PregS, respectively, as substrate (n = 5).and shown in Fig. 6, difference spectroscopy performed with
CYP17A1 in the presence of 17OH-PregS showed that this
metabolite might not to be capable to enter in the active site
of CYP17A1, as nearly no spectral change of CYP17A1 was induced.
This means that DHEAS seems to be produced solely by
sulfonation of DHEA catalyzed by sulfotransferases, whereas
PregS and 17OH-PregS can either be synthesized by sulfonation of
unconjugated Preg and 17OH-Preg or by further conversion of CS
or PregS.
4.6. CYP17A1 dependent substrate conversion in SOAT-HEK293 cells
To investigate whether the results concerning the conversion
of PregS observed in our reconstituted in-vitro system may
possess potential physiological meaning, we performed conver-
sion experiments in SOAT-HEK293 cells. This cell line exhibits an
integrative gene encoding for the human sodium-dependent
organic anion transporter (SOAT), which was shown to display
high speciﬁcity toward PregS [40]. SOAT-HEK293 cells were
transiently transfected with a plasmid containing genes encoding
for CYP17A1 and its electron transfer partner, CPR. LC-MS/MS
analysis after three days of incubation with PregS could clearly
conﬁrm the formation of reasonable amounts of 17OH-PregS. As
shown in Fig. 11, 2.30  0.30 mM 17OH-PregS was synthesized
when 20 mM PregS was used as substrate. Also in this case, no
DHEAS could be detected, conﬁrming our in-vitro results, where no
17,20-lyase activity could be attributed to CYP17A1 using PregS as
substrate. In contrast, when using 20 mM Preg as substrate,
5.30  0.35 mM 17OH-Preg, as well as 0.86  0.2 mM DHEA are
formed (Fig. 11).
The utilized cell line exhibits RNA expression of b5 and
MAPK14 as “The Human Protein Atlas” indicates. MAPK14
(p38alpha) is a kinase that phosphorylates CYP17A1 at position
258 of the amino acid chain [58]. This post-translational
modiﬁcation of CYP17A1 is described to enhance the lyase reaction
of CYP17A1, similar to the effect of b5 [28]. The presence of these
two proteins (b5, MAPK14) obviously supports the formation to
17OH-Preg and DHEA using Preg as substrate. However, the lyase
reaction of CYP17A1 does not take place in these cells with PregS as
substrate. In cell culture as well as in the reconstituted in-vitro
system 17OH-PregS represents the end product of the
CYP17A1 catalyzed reaction using PregS as substrate.Fig. 11. Conversion of 20 mM PregS (black) and 20 mM Preg (grey) in SOAT-HEK293
cells. The product formation analyzed by LC-MS/MS (black) and HPLC (grey) is
represented as mean  standard deviation of ﬁve (black) and three (grey) individual
experiments.
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In this work we could clearly demonstrate that PregS serves
as a substrate for CYP17A1, being converted to 17OH-PregS.
Summarizing, we demonstrated for the ﬁrst time that CYP17A1,
which is involved in the steroid hormone biosynthesis, can
convert sulfonated steroids in a similar manner as free steroids
indicating a potential alternative steroidogenic pathway for
sulfonated steroids. As already described, this pathway is
initiated by the side-chain cleavage of CS by CYP11A1, yielding
PregS [23]. Subsequently, PregS is metabolized in a CYP17A1
dependent hydroxylation reaction to 17OH-PregS, but not to
DHEAS. At this point the steroidogenic pathway for sulfonated
steroids differs from the one for free steroids yielding DHEA in
large quantities. The kcat- and Km-values, as well as the Kd-value
were determined for CYP17A1 with PregS. Moreover, we showed
that b5 does not enhance the 17,20-lyase activity of CYP17A1
when PregS was used as substrate, highlighting fundamental
differences between the metabolism of free Preg and sulfonated
Preg by CYP17A1. Utilizing a SOAT-HEK293 whole cell system,
expressing SOAT, CYP17A1 and CPR, we conﬁrmed the conver-
sion of PregS into 17OH-PregS and the absence of the CYP17A1
dependent lyase reaction, indicating a potential physiological
relevance of our ﬁndings.
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4- GENERAL DISCUSSION 
The PhD topic is divided into the following parts: 
 
4.1- STIMULATORY EFFECT OF ESTROGENS ON PREGNENOLONE FORMATION AND 
CHARACTERIZATION OF NOVEL 2β- AND 16β-HYDROXYLASE ACTIVITY OF CYP11A1  
The goal of the first part of the work was to analyze the possible effects of steroid hormone 
intermediates on the activity of CYP11A1 in a reconstituted in vitro system. We reported a successful 
expression and purification of recombinant CYP11A1 in an E. coli cells in which different approaches 
have been performed. The expression of the protein was performed in E. coli C43(DE3) cells, which are 
particularly suitable for overproduction of membrane proteins [109] such as CYP11A1. The E. coli 
C43(DE3) cells are advisable for the efficient expression of other membrane bound P450s as well, as it 
was previously demonstrated for the expression of human CYP11B2 [110] and human CYP11B1 [111]. 
Further, lowering the temperature from 37 °C to 28 °C after the induction of the culture resulted in 
the increase of the amount of active protein, since a lower cell-divison rate improves the folding of the 
protein into an active form. Reduced temperature usually helps to control metabolic fluctuations and 
protein synthesis rates thereby avoiding the formation of insoluble protein aggregates typical of cells 
at higher growth rate [112]. 
To achieve high production of CYP11A1, the effect of media simultaneously with the co-expression 
with molecular chaperones GroEL/GroES on CYP11A1 expression was optimized. The results clearly 
showed that CYP11A1 expression can be dramatically enhanced by using Terrific broth (TB) medium 
and co-expressing the chaperones, which displays a significantly higher CYP11A1 yield. The reason for 
higher expression of CYP11A1 might be due to high nutrients in TB medium, compared to LB medium 
in which the cells were capable of multiplying, leading to an increase in the number of cells and to an 
increase in the amount of enzyme [113]. 
Concerning the expression of CYP11A1 with and without molecular chaperones GroEL/GroES, the co-
expression with molecular chaperones resulted in a significantly higher expression level compared to 
the expression without chaperone (Figure 6A and B). As summarized in Figure 6B, using TB medium in 
absence of the molecular chaperone, the characteristic peak of cytochrome P450 around 450 nm was 
not significantly high; concluding that the co-expression of molecular chaperones was effective for the 
enhancement of CYP11A1 expression due to the great role of molecular chaperones in the correct 
folding of the protein [114]. These findings are in agreement with results described for human CYP19 
[115], bovine CYP21 [116], human CYP11B1 [111], human CYP11B2 [110] as well as for bovine CYP17, 
cytochrome b5 and CPR [50]. Noteworthy, previous investigations demonstrated that the co-
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expression with chaperones leads to a tight association of P450s to E. coli membranes, which results in 
the high level expression of these enzymes [117]. 
 
 
Figure 6: Effect of media and GroEL/GroES chaperones on CYP11A1 expression. A) The amount of purified 
CYP11A1 in nmol/ l culture, B) The reduced CO-difference spectrum of purified CYP11A1. 
In order to investigate the influence of metabolites of steroid hormone biosynthesis on the CYP11A1 
catalyzed pregnenolone formation, an in vitro assay was carried out in the presence of steroid 
metabolites similar to the concentration of cholesterol used. We found that only estrogens (estradiol 
and estrone) enhanced the enzyme activity and increased pregnenolone formation. Therefore, 
CYP11A1 might play a more vital role in the steroid hormones biosynthesis. However, the 
concentrations of estrone and estradiol used to investigate their influence on CYP11A1 are beyond 
physiological serum concentrations. This might also account for the CYP11A1 concentration utilized; 
although the amounts of steroids and active CYP11A1 in steroidogenic cells remain unclear. In 
contrast, other tested steroid metabolites besides estrone and estradiol did not significantly affect the 
CYP11A1 dependent pregnenolone conversion. More recently, a similar study by Neunzig and 
Bernhardt demonstrated that the CYP11A1 system might display a novel putative regulation of the 
steroid hormone biosynthesis on the cellular level. They showed that the elevation of 
dehydroepiandrosterone sulfate (DHEAS) concentrations increased the level of steroids designated for 
the production of sex hormones and this way might affect the steroid biosynthesis through an 
increased production of pregnenolone. As a result, the level of the end products of the steroid 
hormone biosynthesis might also increase [108]. 
Surprisingly, during the study of the effect of steroid metabolites on natural cholesterol conversion in 
vitro, we detected a slightly lower pregnenolone yield in the presence of DOC, androstendione, 
testosterone, and DHEA accompanied with additional products in the HPLC measurments (Figure 7). 
Therefore, in vitro conversions were performed with CYP11A1 using these steroids as the potential 
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substrates in absence of cholesterol. Successful in vitro conversion was achieved using DOC, 
androstenedione, testosterone and DHEA confirming that each of these steroids is converted by 
CYP11A1 as well as cholesterol. 
 
Figure 7: The in vitro conversion assay for cholesterol by purified CYP11A1 using cortisol (F) as an internal 
standard. A, B, C and D represent the cholesterol conversion in the presence of DOC, androstenedione, 
testosterone and DHEA respectively. 
The whole-cell system with P450 enzymes as biocatalysts has the advantage of higher stability of P450 
in a living organism and the regeneration of expensive cofactors by the host cell compared to purified 
enzymes [118]. In this study, a successful CYP11A1 whole-cell system was established for conversions 
of DOC, androstenedione, testosterone and DHEA. Our study demonstrated that the 6β-position is 
preferred by CYP11A1 in case of hydroxylation of DOC, androstenedione and testosterone. The 6β-
hydroxylase reaction in the microsomes of the liver is the major route of P450 dependent oxidation in 
the metabolism of many steroids, including testosterone, androstenedione, and progesterone 
[119,120]. In contrast, the conversion of DOC to 6β-hydroxy-DOC by CYP11A1 provides further 
evidence for a possible physiological role of this reaction in the adrenal cortex [121]. Furthermore, 
there is increasing evidence that the 6β-hydroxylation represents a significant pathway for the 
excretion of steroids in the liver of rat, mouse, rabbit, dog, hamster, guinea pig and man [122]. It has 
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been demonstrated also that the metabolism of testosterone by rat liver microsomes produced 
several metabolites including 6β-hydroxy-testosterone. Our results indicated also, that CYP11A1 has, 
in addition to the 6β-hydroxylase activity, a 2β-hydroxylase activity towards DOC and 
androstenedione, as well as a 16β-hydroxylase activity towards DHEA. The 16β-hydroxy-DHEA is 
considered as a one of the normal components of plasma and urine of adult human. It is inferred that 
16β-hydroxy-DHEA is secreted directly by the adrenal cortex and probably the gonads [123]. 
The functions of the other new products are not known and need to be investigated. The 2β-hydroxy-
androstenedione for example is a putative inhibitor for the CYP19 enzyme, which is a target in anti-
cancer therapy. Therefore the development of specific inhibitors of CYP19 is of great of interest. For 
this reason, performing more experiments concerning the in vitro characterization of CYP19 mediated 
substrate conversion in the presence of 2β-hydroxy-androstenedione will be particularly important for 
further investigations. For this purpose and in order to increase the amount of these products, further 
optimization steps of CYP11A1 will be essential for future studies like the engineering of more efficient 
CYP11A1 mutants via site-directed mutagenesis. Therefore, employing the homology modeling and 
substrate docking technology will be very helpful to identify the important amino acid residues for 
catalytic activity. 
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4.2- NOVEL AND EFFICIENT E. coli BASED BIOCATALYST FOR THE REGIOSELECTIVE 
ACETYLATION OF THE C21 HYDROXYL GROUP IN STEROIDS VIA BACTERIAL 
CHLORAMPHENICOL ACETYLTRANSFERASE I (CATI) 
The key entrance for this part of the Thesis started during the establishment of the CYP11A1 whole-
cell biocatalyst in which the system containing an expression vector (pACYC-FHH2) harboring a CAM 
resistance gene (camR) for the expression of CYP11A1 and pBar-Twin for the expression of Adx and 
AdR were used (Figure 8A and B). Interestingly, using this whole-cell system for the conversion of DOC 
resulted in the formation of unexpected acetylated DOC at the C21 position, which was not the 
expected product due to the action of P450s on steroid molecules. 
 
 
Figure 8: Plasmid maps of A) CYP11A1-containing plasmid (pACYC-FHH2), mediating CAM resistance gene, B) 
Twin Adx and AdR containing plasmid (pBar-Twin- Adx and AdR) with ampicillin as resistance marker, C) 
Tricistronic plasmid construct (pPP04) harbouring CYP11A1 gene and the redox partners, adrenodoxin (Adx) and 
ferredoxin reductase (FpR) with ampicillin as resistance gene. 
The experiments proposed that using the expressing vector pACYC-FHH2 carrying the chloramphenicol 
acetyl transferase gene (cat) is responsible for the acetylation of the hydroxyl group of DOC. An E. coli 
whole-cell system using a tricistronic expression vector (pPP04) coding for adrenodoxin (Adx), 
ferredoxin reductase (FpR) and CYP11A1 used for recombinant CYP11A1 whole-cell biotransformation 
with ampicillin instead of chloramphenicol resistance marker (Figure 8C), in contrast, did not lead to 
steroid acetylation. 
Taking this behavior of cat gene into account, it was of interest to analyze whether other biologically 
active steroids, which have structural similarities to DOC, are also capable of being acetylated by cat. 
This led us to the main idea behind further work to fully elucidate this characteristic of cat to produce 
acetylated steroids for biotechnological applications. As a consequence of the foregoing results, the 
expression vector pTG10 carrying the cat gene was used as a biocatalyst for steroid acetylation in 
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which six out of eighteen steroids: 11-deoxycorticosterone, cortisol, aldosterone, prednisolone, 
corticosterone and 11-deoxycortisol were identified as new substrates of CATI. 
It is worth mentioning that the importance of steroid hormone acetylation is shown in the preparation 
of pharmaceuticals and intermediates for the synthesis of useful steroid acetate drugs, which play a 
significant role in the treatment of endometriosis and menopausal complaints [124,125], chronic 
infections [126] and as a popular anti-inflammatory agent [127]. The acetylation of steroids for these 
purposes were carried out previously by several synthetic routes, like using microorganisms, chemical 
approaches as well as hydrolases [92,113,127,128]. However, C21 steroids acetylation was not 
reported by hydrolases or other enzymes. 
The application of biocatalysts is considered as an alternative approach for the industrial production 
of acetylated steroids. However, in this study we used the single plasmid harboring the single relevant 
gene as a tool for biocatalysis with a high selectivity. Furthermore, our biocatalyst system has not 
been identified so far as an acetylating agent for steroids and showed for the first time the ability of 
bacterial CATI as acetyltransferase to acetylate selectively the 21-hydroxl group of several steroids. On 
the other hand, it was clearly demonstrated that other hydroxyl groups as well as other functional 
groups (carbonyl and the double bond) were not modified. Therefore, this system seems to be an 
attractive approach with a new, easy and environmentally friendly technique for the production of 
acetylated steroids. It was demonstrated that biotransformation efficiency depends on the interaction 
between the whole-cell biocatalyst and bioprocess conditions [112]; therefore, the second approach 
of steroid acetylation by CATI focused on improving the whole-cell biocatalyst via optimization of 
conversion conditions to achieve a high yield of these steroids. 
In terms of the development of a whole-cell system, it is of interest to mention that in preliminary 
optimization processes, E. coli strain JM109(DE3) harboring pTG10 plasmid was grown in TB medium 
containing DOC as substrates. The results showed that the conversion of DOC to its corresponding 
acetylated product, 11-deoxycorticosterone acetate (DOCA) is a time dependent conversion (Table 2).  
Table 2: Amount of 11-deoxycorticosterone acetate (DOCA) ± SD, which was produced by E. coli JM109 (DE3) 
cells in TB medium after feeding of 300 µM DOC at different time points. 
Time (hr) DOCA ± SD (mg/L) 
3 6.5 ± 0.9 
6 24.80 ± 2.8 
24 40.73 ± 1.5 
48 - 
72 - 
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The maximum product formation using TB medium was observed after 24 hr. Interestingly, after 48 
and 72 hr there was no conversion observed (Figure 9). This might be because of the degradation of 
the protein, which demonstrates the highest protein expression after 24 hr incubation and a sharp 
decrease at 48 and 72 hr as shown by SDS-PAGE (Figure 1B, Publication 3.2). Additionally, using TB 
medium for the whole-cell conversion of steroid acetylation lead to a lower product yield compared 
with the other tested media and buffers. Another disadvantage of using TB medium is accompanied 
with the indole formation, which interferes with the product peak of some steroids and causes 
difficulties in the product separation and purification via HPLC. Therefore, subsequent experiments 
using resting cells were performed in buffer. 
 
Figure 9: HPLC chromatograms for the 11-deoxycorticosterone acetate (DOCA) formation by the whole-cell 
conversions using E. coli JM109(DE3)pTG10 in TB medium at different conversion times. 
Finally, the steroid acetylation by purified CATI was also performed. The catI gene was highly 
expressed in E. coli cells and the protein was successfully purified by IMAC. The purified protein was 
used for the in vitro conversions of 21-hydroxysteroids as well as CAM in the presence of acetyl CoA. 
The in vitro conversions of all of them were successfully achieved by purified CATI confirming that 
acetyl CoA is employed as an acyl donor in this conversion process. 
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4.3- INVESTIGATION OF STEROIDOGENIC PATHWAY FOR SULFONATED STEROIDS 
The next part of this work is the investigation of the steroidogenic pathway for sulfonated steroids, 
studying the interaction of PregS with CYP17. 
The special interest of the sufonated steroids stems from their function as prohormones, precursors 
to a great variety of steroids, both in the estrogenic and androgenic family. Previous studies have 
indicated that cholesterol sulfate (CS) is quantitatively the most important known sterol sulfate in 
human plasma [129]. It was also demonstrated, that the adrenal mitochondria of rats contains 
sulfonated cholesterol as an endogenous compound [130]. Further, cholesterol sulfate was 
metabolized efficiently by a mitochondrial side chain cleavage system producing PregS. However, 
further PregS conversion has not been studied in detail. 
In this part of work, we could demonstrate that PregS serves as a substrate for CYP17 using the 
purified enzyme as well as in a SOATHEK293 cell culture system. We found that CYP17, which is 
involved in the steroid hormone biosynthesis, can convert PregS in a similar manner as free steroids 
indicating a potential alternative steroidogenic pathway. 
Since our goal was to characterize the metabolism of PregS with CYP17 performing the in vitro 
conversion as well as the kinetic measurements, we established an efficient expression system for 
bovine CYP17, b5 and CPR in the absence of detectable amounts of other proteins. It was 
demonstrated that some P450s have been poorly investigated because of the difficulties in obtaining 
sufficient quantities of purified protein. Therefore, the expression and purification procedures for the 
recombinant proteins were improved for a high yield and purity. All three proteins (CYP17, CPR and 
b5) have been successfully expressed in bacteria, purified and used to perform the in vitro 
characterization. 
As it is well known, the heterologously expressed P450 enzymes have the potential to be used in a 
variety of industrial applications. One big advantage of P450 expression in E. coli is the abundant 
generation of the corresponding proteins [45]. Common strategies for expression of P450s in E. coli 
include N-terminal sequence modification and truncation of the N-terminal hydrophobic region 
responsible for interaction of P450s with membranes and using lower temperatures (20–28 °C) to 
achieve the maximal yield of expression of the catalytically active protein [6]. For this reason, various 
approaches have been used during the expression and purification of bovine CYP17, b5 and CPR 
proteins, including use of E. coli C43(DE3) host cells, as these cells are advisable for the over-
expression of membrane-bound P450s and other membrane bound proteins using expression vector 
pET-17b, lowering the temperature during the expression and the expression in the presence of 
molecular chaperones, which is known to assist the correct folding of proteins. In addition, it was 
demonstrated that the truncation of the membrane anchor increases the solubility of P450s and 
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facilitates the expression of protein in E. coli [116]. Therefore, the N-terminal sequence modification 
has been performed utilizing the amino acid sequence of CYP17 lacking its N-terminal hydrophobic 
anchor. As well, the CPR amino acid sequence extended at the C-terminus by three glycines and 
lacking the first 27 amino acids at the N- terminus was used. It should also be noted that the protein 
purification procedures have been improved for all three proteins by extending the amino acid 
sequences at the C-terminus by a hexa-histidine-tag to facilitate the purification process by 
immobilized-metal affinity chromatography (IMAC) using Ni–NTA agarose column. 
4.4- EFFECT OF INDOLE ON THE CYP11A1 MEDIATED BIOTRANSFORMATIONS 
This part of the work involved the improvement of the whole-cell system expressing CYP11A1 and its 
electron transfer partners and investigation of the indole effect on in vitro and in vivo conversion 
reactions catalyzed by CYP11A1. 
To perform the whole-cell conversion of the new CYP11A1 substrates (DOC, androstenedione, 
testosterone and DHEA), the complex medium Terrific Broth (TB) was chosen for cultivation. The 
whole-cell biotransformation of DOC, androstenedione, testosterone and DHEA by CYP11A1 carried 
out in TB medium did not lead to product formation for all tested substrates (Figure 10). It was 
suggested that there is a limiting factor in this process preventing the steroid conversion and we 
assumed that the indole production in TB medium might be responsible for the lack of steroid 
bioconversion. Furthermore, instead of the expected product peaks, presented in the in vitro 
conversion of the steroids, another peak was detected at ~12.2 minutes retention time, which was 
also seen in the control cultures (untransformed E. coli cells without plasmid). We expected this peak 
to belong to indole, which is produced by the tryptophanase from tryptophan as an endogenous 
metabolite in E. coli cells [131,132]. 
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Figure 10: HPLC chromatograms of the whole-cell bioconversion of 300 µM of steroids using recombinant E. coli 
whole-cell system expressing CYP11A1 using TB medium after 24 hr from substrate adding. A) 11-
deoxycorticosterone (DOC), B) Androstenedione, C) Testosterone, D) DHEA, with the indole peak present. 
As this strong indole formation could possibly inhibit the activity of CYP11A1; this side product of TB 
medium was overcome by using resting cells in potassium phosphate buffer (KPP). Applying KPP buffer 
for the biotransformation experiments exhibited a removal of indole formation and improved the 
biotransformation of the respective steroids to corresponding hydroxylated products indicating that 
the indole formation has an inhibitory effect on the CYP11A1-dependent biotransformation. 
Furthermore, CYP11A1 system is well known to efficiently convert its natural substrate, cholesterol, to 
pregnenolone. An E. coli whole-cell system expressing CYP11A1 in TB medium failed also to perform 
the cholesterol conversion; however, successful in vivo formation of pregnenolone was achieved when 
the conversion performed with resting cells in buffer (Figure 11A and B). 
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Figure 11: HPLC chromatograms of whole-cell conversion of cholesterol after 24 hr from substrate adding by 
using, A) Growing cells in TB medium, B) Resting cells in potassium phosphate buffer, C) HPLC chromatograme 
for the authentic indole injection. 
To confirm this observation and to check whether indole has, indeed, a negative influence on the 
CYP11A1 activity, we performed a CYP11A1 whole-cell conversion of cholesterol in KPP buffer 
supplemented with different concentrations of indole. As well, the in vitro cholesterol conversion by 
purified CYP11A1 in the presence of various indole concentrations was conducted (Figure 12A and B). 
 
 
Figure 12: A) Pregnenolone formation (mean ± SD) after CYP11A1-dependent in vitro conversions using 15 µM 
cholesterol as final substrate concentration in the presence of different indole concentrations after 7 min. 
conversion time, B) Pregnenolone formation (mean ± SD) of whole-cell conversions in KPP buffer supplemented 
with 300 µM cholesterol, 100 mM glucose and different indole concentrations after 24 hr conversion time. The 
standard deviation of each bar was calculated for three replicate experiments. The indole dissolved in DMSO at 
different concentrations and equal volumes were used to achieve equal DMSO concentration in all 
measurements as well as with control. 
As displayed in Figure 12B (first bar), it can clearly be seen that in the in vivo experiments performed 
with resting cells an almost complete substrate conversion took place when the suspensions 
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contained 300 µM cholesterol, resulting in a pregnenolone formation of 96 ± 1.8 %. Addition of indole, 
however, inhibited pregnenolone production. Summarizing, we demonstrated for the first time the 
ability of a CYP11A1 E. coli based whole-cell system to convert cholesterol, which has not been 
established so far. 
For further understanding, it was important to study the indole effect with other steroids rather than 
cholesterol in order to exclude the substrate dependency. Therefore, in vitro and in vivo conversion 
assays were carried out using 300 µM androstenedione (as best substrate for CYP11A1 among all 
tested substrates in this study) in the presence of increasing concentrations of indole (25-4000 µM). 
Because CYP11A1 catalyzes the conversion of androstenedione to one major and one minor product, 
the percentage of product formation was calculated for the total amount of products (Figure 13A and 
B). 
 
Figure 13: A) The effect of different indole concentrations on the conversion of androstenedione by CYP11A1 in 
vitro, which was carried out for 30 min at 37 °C employing the AdR–Adx redox system, B) The effect of different 
indole concentrations on the conversion of androstenedione by CYP11A1 using the whole-cell system after 48 hr 
conversion time using KPP buffer supplemented with 300 µM androstenedione and 100 mM glucose. The data 
expressed as a mean ± SD of three independent determinations. 
The results shown in Figure 13 together with those obtained for the in vitro and in vivo conversions of 
cholesterol confirmed the hypothesis that the indole has a negative effect on the catalytic activity of 
CYP11A1. Furthermore, increasing the indole concentration, the inhibitory effect increased and the 
conversion of cholesterol and androstenedione diminished in both cases, confirming a concentration-
dependent decrease of the CYP11A1-catalyzed conversions in the presence of indole. The reason 
might be that the indole blocks the active site of CYP11A1 and therefore it will negatively affect the 
interaction with the redox partners or the substrates. Furthermore, it was noticed that the cholesterol 
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conversion in the presence of higher concentration of indole (0.5-4 mM) was accompanied with 
formation of additional products (Figure 14), which need to be identified in further studies. 
 
Figure 14: Side product formation during the in vitro cholesterol conversion by CYP11A1 in the presence of 
different indole concentrations (0.5-4 mM). 
Our results on the inhibitory effect of indole are in agreement with a similar observation, which was 
recently reported for the in vitro conversion of myristic acid by CYP109B1 from Bacillus subtilis [133]. 
Furthermore, the negative influence of indole on the in vivo CYP11A1 conversion is consistent with the 
results of Ringle et al., which proved the inhibitory effect of indole on the in vivo conversion of 4-
methyl-3-phenylcoumarin by a whole-cell system expressing CYP264A1 from S. cellulosum Soce56 
[134]. 
Taken together, the complex TB media containing a high amount of tryptophan is not recommended 
for CYP11A1-mediated biotransformation due to the inhibitory effect of indole. Thus, effective 
methods have to be considered for the design of CYP11A1 whole-cell experiments, like using resting 
cells in buffer or using M9 minimal medium supplemented with casamino acids (M9CA), which has 
only traces of tryptophan. Furthermore, it is also of special interest for future studies to use a 
homologous recombination method to prepare a tryptophanase knockout E. coli strain to overcome 
the inhibitory effect of indole. 
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5- CONCLUSIONS AND FUTURE PROSPECTS 
The first step in the biosynthesis of steroid hormones occurs in the mitochondria, where cholesterol is 
converted to pregnenolone by CYP11A1. The main focus of this part of work was to characterize the 
influence of various metabolites of steroid hormones on the in vitro CYP11A1 mediated cholesterol 
conversion. The effect on this reaction is particularly interesting since a pro-hormone, pregnenolone, 
is the mandatory substrate for the synthesis of other steroid hormones. 
We have reported that bovine CYP11A1 can be successfully expressed in E. coli in a high yield, purity 
and catalytically active form. Furthermore, we identified a novel function and new insights into the 
regulatory effects of estrogens, estradiol and estrone, on the CYP11A1 enzyme activity in a 
reconstituted in vitro system, which give an indication on the role of metabolites of steroid 
biosynthesis as activators of the CYP11A1-dependent cholesterol conversion. For this reason, it would 
be of great interest to use a cell culture model that expresses CYP11A1 (e.g. adrenocortical NCI-H295R 
cells) and see if estrogens regulate CYP11A1 in the same manner as in the in vitro experiments and if 
the same CYP11A1 product is formed. Moreover, further examinations of these estrogens as an 
activator of pregnenolone formation should be performed, especially the determination of the binding 
affinity and kinetic parameters for CYP11A1 with cholesterol in the presence of estradiol and estrone. 
Since our in vitro experiments suggest the ability of purified CYP11A1 to convert DOC, 
androstenedione, testosterone and DHEA as new CYP11A1 substrates, it is of special interest also to 
see the influence of these steroids on CYP11A1 biochemically, focusing on the kinetics and the binding 
affinity measurements of CYP11A1 with its natural substrate, cholesterol under the influence of these 
steroid metabolites.  
Moreover, the CYP11A1 whole-cell biocatalyst was successfully applied to convert these steroids to its 
hydroxylated form. The NMR identification of the formed products showed that the C2 and C6 
positions were identified as sites of hydroxylation of DOC and androstenedione by CYP11A1 as well as 
C6 position in testosterone and C16 position in DHEA. These novel products of CYP11A1 might be 
important precursors in the synthesis of highly potent pharmaceutically interesting compounds. Thus, 
to produce these novel hydroxylated products in higher yield, it would be of interest to optimize the 
enzyme by the method of molecular evolution, thus, it is possible to generate CYP11A1 mutants to 
enhance the conversion of respective metabolites via random and site directed mutagenesis. 
Further, in this work, the negative impact of indole, produced by the host microorganism E. coli, on 
CYP11A1 activity was demonstrated. This effect has been overcome by performing the 
biotransformation assays in buffer. It is, however, necessary to investigate a potential physiological 
role of this inhibition in future studies. 
73 
 
In the past years, several studies have demonstrated that the human gut is capable of de novo 
synthesis of glucocorticoids and sex steroids. This finding is based on the detection of steroidogenic 
enzyme expression such as CYP11A1, as well as the presence of bioactive steroids in both the rodent 
and human gut. The local production of immunoregulatory glucocorticoids contributes to intestinal 
homeostasis and has been linked to the pathophysiology of inflammatory bowel diseases. Intestinal 
epithelial cells also possess the ability to metabolize sex steroids, notably estrogen. This mechanism 
may impact colorectal cancer development. It was demonstrated, that commensal E. coli strains 
produce significant amounts of indole as a result of tryptophane degradation, leading to indole 
concentrations reaching from 250 to 1,100 mM in the human feces. Thus, it is likely that intestinal 
epithelial cells are continually exposed to high concentrations of indole. 
Taking this into account, it is necessary to study the inhibitory effect of indole on CYP11A1 activity in 
more detail by determination of the inhibition constant Ki or IC50 value and the dissociation constant 
(Kd). Furthermore, these experiments should also be carried out with skatole, an important indole 
derivative in the mammalian digestive tract. As the inhibition of CYP11A1 would lead to overall 
decreased concentrations of glucocorticoids and sex hormones in the gut, an overly protein- or 
tryptohane-rich diet could have detrimental effects on steroid hormone homeostasis and potentially 
lead to chronic bowel diseases. 
Concerning the acetylation of steroid hormones, it is well known, that the development of the whole-
cell biocatalyst is of great interest for the synthesis of steroid hormone derivatives, which have several 
pharmaceutical and biotechnological applications. In this work, one of the successful applications of 
whole-cell biocatalysts has been proved to be a promising candidate for the acetylation of C21-
hydroxysteroid compounds with a high regio- and stereoselectivity. The E. coli whole-cell biocatalyst 
expressing the bacterial chloramphenicol acetyltransferase I (CATI) was investigated for acetylation of 
C21-hydroxysteroid compounds. Six steroids: 11-deoxycorticosterone, cortisol, aldosterone, 
prednisolone, corticosterone and 11-deoxycortisol were identified as new substrates of CATI. 
Furthermore, the optimization of the experimental conditions displayed an increase in the activity of 
bacterial CATI enzyme to produce the desired acetylated products. For this, the cat gene expression 
was optimized for higher expression at 24 hr, utilizing Tris-HCl buffer, pH 7.4, containing 500 mM 
glucose as a carbon source and 1 mM substrate, in which the best condition to produce acetylated 
steroids by the resting cell was obtained after 48 hr. To accomplish this goal, and since the expression 
vectors pET22b or pET17b are known as high expression vectors for protein expression, it will be of 
great benefit to utilize these vectors carrying the catI gene for efficient synthesis of acetylated 
steroids in a higher yield for biotechnological applications. In addition, the catalytic activity of CATI 
should be studied in a wider range to involve other C21-hydroxysteroids and non steroidal 
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compounds, which might also have a pharmaceutical usage if they are converted to the acetylated 
form. Moreover, since the in vitro conversions of CAM as well as C21-hydroxysteroids were achieved 
with the purified CATI, it is possible to perform further experiments concerning the comparison of the 
kinetic parameters of CATI with CAM as well as steroid substrates. 
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